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1. Introduction 
1.1 Overview of the Pakistani population 
Pakistan is inhabited by more than 170 million people ranking it at place six among the 
world’s most populated countries. Different religions are practiced in Pakistan with the 
Islam being the major religion (96.3%). The rest of 3.7% is shared by Hinduism (1.6%), 
Christianity (1.6%) and others such as Sikhs, Parsis, Buddhists, Jews, Bahais, and 
Animists (Library of Congress, http://lcweb2.loc.gov/frd/cs/profiles/Pakistan.pdf). Pakistan 
is a multilingual country with more than sixty languages being spoken. The main national 
language is Urdu but English is the official language and is used in official business and 
governmental legal issues. Other major languages spoken in Pakistan are Punjabi, 
Saraiki, Pashto, Sindhi, and Balochi along with a lot of other local languages. The 
Pakistani population is divided into six main ethnic groups, Punjabis (44.15%), Pashtuns 
(15.42%), Sindhis (14.1%), Seraikis (10.53%), Muhajirs (7.57%), and Balochs (3.57%). 
Other, smaller ethnic groups (4.66%) mainly found in the northern parts of the country are 
Kashmiris, Hindkowans, Kalash, Burusho, Brahui, Khowar, Shina, and Turwalis. 
(http://www.brookings.edu/~/media/Files/Programs/FP/pakistan%20index/index.pdf). 
The majority of the Pakistani population (~70%) lives in villages facing severe 
educational, economic, and health problems. People marry early and have many children. 
Due to the social, cultural and ethnic customs, consanguineous marriages are very 
common in the Pakistani society. Usually several members of related families marry in a 
reciprocal way. This results in large family sizes with multiple loops of consanguinity. 
Consequently, many children are born with genetic defects. Especially the frequency of 
recessive genetic diseases is dramatically increased over the usual prevalence observed 
in western countries due to homozygous mutations. The poor socio-economic conditions 
in combination with a high rate of illiteracy make the situation even worse. Birth control is 
not popular in Pakistan and not at all applied in rural areas, thus even couples having 
already a large number of afflicted children continue to reproduce in the hope for a normal 
one. Diseases that are frequently observed are beta-thalassemia, inherited deafness and 
microcephaly (Baig et al., 2008, Malik et al., 2006, Baig et al., 2011, Pattison et al., 2000, 
Roberts et al., 1999). No doubt, the high incidence of disabled children is a major political 
health issue in Pakistan and needs to be solved in the coming decades. On the other 
hand, the current situation also gives molecular geneticists good opportunities to identify 
and characterize the genes that result in the disease phenotype when mutated. This is 
well documented for autosomal recessive primary microcephaly (MCPH) in which six out 
of nine genetic loci (seven loci previously described and two from the present study) were 
identified in consanguineous families of Pakistani origin (Woods et al., 2005). 
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1.2 Microcephaly 
The term microcephaly is composed of two words, “micro” is derived from the Greek word 
“mikros”, small, and “cephaly” from a Greek word “Kephale”, head. The small head size is 
the prominent phenotype of the patients afflicted with microcephaly. 
There are two types of microcephaly; primary and secondary microcephaly. Primary 
microcephaly is a static anomaly in which the growth of the brain is reduced during 
pregnancy (develops at prenatal stages), whereas in secondary microcephaly the brain 
size is normal at birth but subsequently fails to grow normally due to progressive 
neurodegeneration. In contrast to primary microcephaly, the secondary microcephaly 
develops at postnatal stages (Woods, 2004). There are some environmental factors like; 
intrauterine infections, drugs taken during pregnancy; prenatal radiation exposure, 
maternal phenylketonuria; and birth asphyxia forming the cause of the rare secondary 
microcephaly (Jackson et al., 1998). Congenital infection with Toxoplasma, 
overconsumption of alcohol during pregnancy and Rubenstein Taybi syndrome are some 
factors that must be excluded for diagnosis of autosomal recessive primary microcephaly, 
because these factors also cause microcephaly with mental retardation (Woods et al., 
2005). The autosomal recessive primary microcephaly has only a genetic cause without 
environmental factors. 
1.2.1 Primary microcephaly 
Autosomal recessive primary microcephaly (MCPH) is defined as a neurodevelopmental 
disorder characterized by reduced head circumference (> -3SD), due to a small but 
structurally normal brain, and mild to severe intellectual disability with normal height 
(except in minor cases where the MCPH1 gene is involved), weight and neurological 
functions (Cox et al., 2006, Nicholas et al., 2009). The small head circumference (HC) is 
the result of reduced cerebral cortex size which leads to a simplified gyral pattern but the 
cortex is of normal thickness (Desir et al., 2008, Figure 1.1). 
As the patients have a significantly reduced brain growth without any affect on brain 
structure, it will be instructive to investigate the mechanism of neurogenesis in this 
disorder and MCPH can be considered a model disease for the identification of novel 
genes which have a role in prenatal neurogenesis. 
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1.2.1.1 Epidemiology and clinical features of primary microcephaly 
The incidence of MCPH is 1/250,000 in the Netherlands, 1/30,000 in Japan and 
1/2,000,000 in Scotland (Van den Bosch, 1959, Komai et al., 1955, Tolmie et al., 1987). 
But the incidence of microcephaly from genetic as well as environmental causes was 
estimated to be 1/93,000 (Van den Bosch 1959). MCPH is highly prevalent in the 
northern Pakistani population with an incidence of nearly 1 in 10,000. This shows the high 
occurrence in the Indian subcontinent as compared to the other parts of the world. The 
incidence is greater in Asian and Arab populations where a high rate of consanguineous 
marriages occurs (Woods et al., 2005).  
The inheritance pattern of MCPH is autosomal recessive. All the reported families 
afflicted with this disorder have multiple or few afflicted individuals with unafflicted 
consanguineous parents (Muhammad et al., 2009). 
Primary microcephaly is likely to be genetic in aetiology. The patients have learning 
difficulties but no environmental, metabolic, cytogenetic, developmental malformations or 
significant neurological deficits. The microcephaly which has only the genetic aetiology is 
also known as true microcephaly, microcephaly vera, recessive microcephaly or primary 
microcephaly. As MCPH is a disorder of foetal brain growth (the only significant clinical 
feature), microcephaly is apparent at birth with a sloping forehead as an obvious feature, 
The head circumference (HC) is significantly less than expected for an individual of 
similar age and sex, and the patients are mentally retarded. Brain size measurement can 
also be done with a more accurate technique like volumetric nuclear magnetic resonance 
(NMR) scanning, but HC measurement remains the most common and simple method for 
evaluating gross brain size. To determine the skull circumference reliably it is important to 
carry out the measurement from the forehead to the occipital prominence at the back of 
the head, which closely correlates with reduced brain volume. Reduced cranial size 
observed in microcephalic patients strongly correlated with mental retardation (Cox et al., 
2006). 
In MCPH, the reduced size of the skull is due to a reduced central nervous system and 
the cerebral cortex is the structure which is most strongly affected. Magnetic resonance 
imaging (MRI) and computerized tomography (CT) scans of the MCPH patient’s brain 
show a normal architecture of the brain but of reduced size, which is especially evident in 
the cerebral cortex. The structure of the cerebral cortex is simplified, and there is a slight 
reduction in the volume of the white matter, consistent with the small size of the brain 
(Barkovich et al., 2001, Bond et al., 2002).  
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Figure 1.1: A MCPH patient; front view (a) and side view (b) with typical features of 
reduced head and slopping forehead. 
 
1.2.1.2   Molecular genetics of primary microcephaly 
Although all MCPH patients reported to date have indistinguishable features, this disorder 
is genetically heterogeneous. Autozygosity mapping techniques using microsatellite 
markers or SNPs throughout the human genome in large consanguineous MCPH families 
identified seven loci, MCP1-MCP7 (Kaindl et al., 2010). Further five gene loci (MCPH8-
MCPH12) have been identified during this study. So, the number of identified MCPH loci 
increased to 12.  
The MCPH1 locus was identified on chromosome 8p22-pter, MCPH2 on 19q13.1-q13.2, 
MCPH3 on 9q34, MCPH4 on 15q15-q21, MCPH5 on 1q31, MCPH6 on 13q12.2 and 
MCPH7 on 1p32.3-p33 (Jackson et al., 1998, Roberts et al., 1999, Moynihan et al., 2000, 
Jamieson et al., 1999, Pattison et al., 2000, Leal et al., 2003, Kumar et al., 2009). Of 
these seven gene loci, three (MCPH4, MCPH6 and MCPH7) were identified in families 
from Morocco, north eastern Brazil and India respectively. MCPH1, MCPH2, MCPH3 and 
MCPH5 were mapped in Pakistani families. Studies conducted to date suggest that 
MCPH5 is the most common locus in all populations (Thornton and Woods, 2009). The 
possibility of further MCPH locus (loci) exists because 18 northern Pakistani MCPH 
families out of 56, 10 Pakistani families out of 33, 81 Iranian families out of 112 do not 
show linkage to any of the known seven MCPH loci (Roberts et al., 2002, Gul et al., 
2006b, Darvish et al., 2010). MCPH heterogeneity studies have been performed in a 
northern Pakistani population and MCPH5 was confirmed as the most common locus, 
accounting for linkage of nearly half of the amassed families (24/56 families). MCPH2 
accounted for 10 families (14%); MCPH1 and MCPH3 were each associated with two 
families (4%), whereas MCPH4 linkage has not been found in the Pakistani population 
(Roberts et al., 2002). MCPH6 and MCPH7 loci had not been identified at the time of the 
heterogeneity investigation. 
(a) (b) 
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For these loci the following genes have been identified, Microcephalin/BRIT1 was 
identified at the MCPH1 locus, WDR62 (WD repeat domain 62) at MCPH2, 
CDK5RAP2/Cep215 (Cyclin Dependent Kinase 5 Regulatory Associated Protein 2, 
Centrosomal Protein of 215 kDa) at MCPH3, CEP152 (Centrosomal Protein 152 kDa) at 
MCPH4, ASPM (Abnormal Spindle-like Microcephaly-associated) at MCPH5, CENPJ 
(Centromere Protein J) at MCPH6 and STIL/SIL (SCL/TAL1 interrupting locus) at MCPH7 
(Jackson et al., 2002, Yu et al., 2010, Nicholas et al., 2010, Bond et al., 2005, Guernsey 
et al., 2010, Bond et al., 2002, Kumar et al., 2009) (Table 1.1).  
Table 1.1: Overview of all identified MCPH loci with respect to their protein coding 
genes, ethnicity and chromosomal location. The table is reproduced from (Thornton 
and Woods 2009), only the genes functions are omitted and ethnicity is added. The data of 
MCPH2 and MCPH4 loci have been added (Yu et al., 2010 and Nicholas et al., 2010, 
Guernsey et al., 2010).   
 
Locus Chromosome Location Ethnicity Gene Protein Cellular Localization 
MCPH1 8p23 Pakistani
MCPH1/Microcep
halin/BRIT1 
(BRCT inhibitor of 
telomerase I) 
Microcephalin/
BRIT1 
Nucleus/chromatin; 
centrosome 
MCPH2 19q13.12-q13.2 Pakistani WDR62* WDR62 
cytoplasmic at 
Interphase, Spindle 
pole throughout the 
cell cycle 
MCPH3 9q33.2 Pakistani CDK5RAP2/CEP215 
CDK5RAP2/ 
Cep215 
Centrosomal 
throughout cell cycle; 
midbody at cytokinesis 
MCPH4 15q15-q21  Moroccan CEP152 CEP152 Centrosome 
MCPH5 1q31.3 Pakistani ASPM ASPM 
Pericentrosomal at 
mitotic spindle poles; 
midbody at cytokinesis; 
cytoplasmic at 
Interphase, 
MCPH6 13q12.12 Brazilian  
CENPJ/ 
CPAP 
CENPJ/ 
CPAP 
Centrosomal 
throughout cell cycle; 
midbody at cytokinesis 
MCPH7 1p33 Indian STIL/SIL SIL/STIL Pericentrosomal at mitotic spindle poles 
* The genes with HGNC name are highlighted in bold with most common alternatives.  
 
1.3 Functions of MCPH proteins  
MCPH is a genetically heterogeneous disorder with seven loci identified so far. The 
causative genes of these loci have been identified by using a positional cloning strategy. 
In this section I will briefly introduce each MCPH gene and the possible role of the 
encoded proteins in neurogenesis. 
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1.3.1 Microcephalin 
Microcephalin was the first causative gene of MCPH identified in two consanguineous 
families originating from the Mirpur area of Pakistan. A single homozygous c.74C>G 
(p.S25*) nonsense mutation was identified in the second exon of the MCPH1 gene. 
MCPH1 encodes microcephalin, a 835 amino acid protein (Jackson et al., 2002). 
Microcephalin contains three breast cancer 1(BRCA1) C-terminal (BRCT) domains. One 
BRCT domain is found at the N-terminus and the other two at the C-terminus of the 
protein. DNA repair and cell cycle checkpoint proteins also have BRCT domains (Huyton 
et al., 2000). The role of microcephalin has been elucidated in DNA damage induced 
cellular responses by the C-terminal BRCT domains in human embryonic kidney cells (Xu 
et al., 2004). This protein also plays a role in the regulation of chromosome condensation 
(Trimborn et al., 2004). The role of microcephalin in the etiology of MCPH might be due to 
defects of normal cell cycle regulation in neuronal progenitors or excessive apoptosis due 
to failure in DNA repair during neurogenesis (Jackson et al., 2002). Centrosomal location 
of microcephalin was reported in U2OS cells (Zhong et al., 2006). Previously the nuclear 
and chromatin associated distribution of microcephalin was reported (Xu et al., 2004, Lin 
et al., 2005). The centrosomal localization was confirmed in chicken DT40 cells, where it 
has been shown to localize on centrosomes by using centrosomal and pericentriolar 
markers like γ-tubulin, centrin, Aurora-A and Nedd1 (Figure 1.2). The centrosomal 
localization and cell cycle regulatory function is mediated by the N-terminal BRCT domain 
(Jeffers et al., 2008).  
 
 
 
 
 
 
 
 
 
Figure 1.2: Localization of all identified MCPH proteins. Microcephalin has a centrosomal 
as well as a nuclear and chromatin localization. CDK5RAP2, CENPJ and CEP152 are core 
centrosomal proteins, while ASPM, WDR62 and STIL have a spindle pole localization. The 
image is taken from (Cox et al., 2006) and was modified to add the localization of newly 
identified MCPH proteins.  
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1.3.2 WD repeat-containing protein 62 (WDR62) 
The MCPH2 locus was identified in two multi-afflicted consanguineous families of 
Northern Pakistani origin on chromosome 19q13.1-q13.2 (Roberts et al., 1999). Despite 
discovery of six other MCPH genes since then, the gene responsible for MCPH2 has 
escaped discovery for a long time. Recently the MCPH2 gene has been identified by 
using classical and neo-classical reverse genetics. First the WD repeat domain 62 protein 
gene (WDR62) was found to be mutated in patients afflicted with microcephaly and 
cortical abnormalities (Bilguvar et al., 2010). These afflicted patients belong to 
consanguineous Turkish families and manifested with microcephaly, moderate to severe 
mental retardation, and cortical malformation including pachygyria with cortical thickening, 
microgyria, lissencephaly, hypoplasia of the corpus callosum, schizencephaly, and in one 
instance, cerebellar hypoplasia. Later on two independent groups reported WDR62 as a 
causative gene of the MCPH2 locus (Yu et al., 2010, Nicholas et al., 2010). The WDR62 
gene consists of 32 exons and encodes a 1,523 amino acid protein containing at least 15 
WD repeats. 
Immunohistochemistry analysis and in situ hybridization in human and mice revealed 
WDR62 expression in neural progenitors within the ventricular and subventricular zones 
and predominantly in the nucleus in neuronal cells, which was confirmed by 
immunofluorescence microscopy analysis. It was also reported that this protein is not 
associated with the centrosome during mitosis (Bilguvar et al., 2010). However confocal 
microscopsy analysis in HeLa cells demonstrated a spindle pole localization of WDR62 
protein during mitosis and weak cytoplasmic staining was observed during interphase. 
Spindle pole localization of WDR62 was confirmed by overexpression of GFP-tagged 
wild-type and mutant c.1313G>A (p.Arg438His) protein in HeLa cells. The wild-type 
WDR62 protein was located at the spindle pole whereas the mutant protein was not. 
Immunohistochemistry also showed Wdr62 expression in mouse cerebral cortex 
neuroepithelium from early to late neurogenesis (Nicholas et al., 2010). An independent 
study also confirmed the spindle pole localization of WDR62 in HeLa cells during mitosis 
and perinuclear localization during interphase, suggesting a localization to the Golgi 
apparatus, which was confirmed by colocalization with the Golgi marker GM130. 
Recombinant HA-tagged WDR62 protein in HeLa cells showed a distribution closely 
matching the localization CEP170 and surrounding LIS1. This pattern of localization was 
similar to that of other identified primary microcephaly proteins (Yu et al., 2010).  
1.3.3 CDK5 regulatory subunit-associated protein 2 (CDK5RAP2) 
CDK5RAP2 which is also known as CEP215 was identified as the third causative gene of 
MCPH in a family of Pakistani origin. The CDK5RAP2/Cep215 protein localizes in HeLa 
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cells to the spindle pole. Mouse Cdk5rap2 was also reported to be expressed in the the 
neuroepithlium lining the lateral ventricles of the forebrain (Bond et al., 2005). At the 
centrosome CDK5RAP2 colocalized with γ-tubulin (Fong et al., 2008).  
Studies of the Drosophila centrosomin (cnn) that is the orthologue of human CDK5RAP2 
showed an interaction of centrosomin with the γ-tubulin ring complexes at the centrosome 
which are responsible for the formation of the microtubules that extend from the mitotic 
spindle (Li and Kaufman, 1996, Megraw et al., 1999, Terada et al., 2003). The Drosophila 
cnn mutant also exhibits reduced cell numbers in the central and peripheral nervous 
system (Li and Kaufman, 1996). Cnn is also required for the role of the centrioles in 
maintaining a stable connection both to the pericentriolar matrix (PCM) during 
centrosome maturation, and to astral microtubule arrays generated by the centrosome 
during mitosis. Without cnn, centrioles become displaced to the PCM periphery before 
losing contact and migrating randomly in the cytoplasm (Lucas and Raff, 2007). The 
depletion of either polo kinase or cnn severely affected the centrosome maturation 
(Dobbelaere et al., 2008). One of the conserved motifs of ccn (cnn motif 1) which is found 
at its N-terminus is necessary for the proper recruitment of γ-tubulin, D-TACC (the 
homolog of vertebrate transforming acidic coiled-coil proteins (TACC), and Minispindles 
(Msps) to embryonic centrosomes but is not required for assembly of other centrosome 
components including Aurora A kinase and CP60. Centrosome separation and 
centrosomal satellite formation are severely disrupted in Cnn Motif 1 mutant embryos 
(Zhang and Megraw, 2007).  
Overexpression of full length CDK5RAP2 wild-type protein leads to the formation of 
clusters of CDK5RAP2 with variable sizes both at the centrosomes and in the cytoplasm. 
This also resulted in the increased accumulation of pericentrin (PCNT), γ-tubulin and 
Cep250 and could nucleate microtubules without centrioles (Fong et al., 2008). The 
siRNA screens identified CDK5RAP2 as one of the few proteins required for centrosome 
cohesion (Graser et al., 2007), and Knockdown of CDK5RAP2 led to centrosome splitting 
and reduced PCNT localisation at the centrosome, although other proteins tested 
localized normally. CDK5RAP2 localisation to the centrosome is also partially dependent 
on PCNT (Graser et al., 2007, Haren et al., 2009). 
Thus, on the basis of investigations of CDK5RAP2 orthologues which showed that they 
regulate centrosome maturation, recruitment to and strengthening of the PCM at the 
centrioles, and might also regulate centrosome cohesion, whereas in their absence 
centrosomes fail to mature, cannot efficiently organize microtubules, and generation of 
astral microtubules is reduced, it can be speculated that similar defects in humans might 
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lead to spindle positioning defects that cannot be tolerated in neuroepithelial progenitors 
(Thornton and Woods, 2009). 
1.3.4 Centrosomal protein of 152 kDa (CEP152) 
Another primary microcephaly gene responsible for MCPH4 locus that waited 11 years for 
its discovery is the CEP152 gene. It was identified in three families of an Eastern 
Canadian subpopulation. In the first family one missense variant p.Q265P was identified 
and the second family was compound heterozygous for the missense mutation plus a 
second, premature-termination mutation (p.R987*) which resulted in the truncation of 
CEP152 protein. Expression of GFP fused wild-type and mutant (p.R987*) CEP152 
protein in human U2OS osteosarcoma-derived cells revealed a centrosomal localization 
for the wild-type protein whereas the pR987* mutant was not detected at the centrosome. 
By contrast, centrosomal localization was not disturbed in the point mutant (p.Q265P) 
CEP152 construct (Guernsey et al., 2010).  
CEP152 was originally identified as a core component of the centrosome by direct 
proteomic characterization of the human centrosome by protein correlation profiling 
(Andersen et al., 2003). CEP152 is the mammalian ortholog of the Drosophila gene 
asterless, in which mutations cause arrest of embryogenesis in the fly and male infertility. 
The protein product of asterless (Asl) directly localizes to centrioles (Varmark et al., 
2007). Polo-like-kinase 4(Plk4) plays a role in centriole assembly and duplication. The 
centriolar protein asterless (Asl; human orthologue CEP152) provides a conserved 
molecular platform, of which the amino terminus interacts with the cryptic Polo box of Plk4 
whereas the carboxy terminus interacts with the centriolar protein Sas4. So asterless is a 
scaffolding protein for the onset of centriole assembly (Dzhindzhev et al., 2010).  
Recently CEP152 was found to be a genome maintenance protein, of which disruption 
causes seckel syndrome. Immunofluorescence analysis of patient fibroblasts having 
mutations in CEP152 revealed the presence of multiple nuclei without astral microtubules. 
There were also multiple and fragmented centrosomes seen and partially depolymerized 
microtubules together with micronuclei in addition to a main nucleus (Kalay et al., 2011). 
1.3.5 Abnormal spindle-like microcephaly-associated protein (ASPM) 
The fifth gene resposible for the MCPH5 locus is ASPM. Homozygous mutations in this 
gene are the most common cause of MCPH (Bond et al., 2002, Bond et al., 2003, Pichon 
et al., 2004). The ASPM protein has been predicted to contain an N-terminal microtubule-
binding domain, two calponin homology domains (common in actin-binding proteins), 81 
Ile–Gln (IQ) repeat motifs which are predicted to undergo a conformational change when 
bound to calmodulin, and a C-terminal region of unknown function (Bond et al., 2002). 
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ASPM is also a member of a novel family of proteins that contain ASH domains (ASPM, 
SPD-2 and Hydin), which are commonly present in ciliary proteins. Based on the 
presence of ASH domains, the ciliary function of ASPM in embryogenesis has been 
uncovered, that is, it is involved in ciliary mediated movement of cerebrospinal fluid 
required for guidance of young migrating neurons (Ponting, 2006). But this function of the 
ASPM protein is not the cause of disturbed neurogenesis in MCPH because loss of ciliary 
functions of ASPM result in neuron-migration abnormalities not neuron number reduction 
(Cox et al., 2006).  
Down regulation of endogenous ASPM by siRNA has been performed which resulted in 
the decrease of endogenous BRCA1 protein levels. ASPM localizes to the centrosome 
during interphase and to the spindle poles from prophase through telophase. These 
findings indicate that ASPM may be involved in mitotic spindle function possibly through 
regulation of BRCA1 (Zhong et al., 2005). ASPM localization was also confirmed in 
mouse neuroepithelial cells at the spindle pole throughout the cell cycle with only 
decreased intensity at telophase. In this study there was no centrosomal localization of 
ASPM during interphase reported (Fish et al., 2006). Immunostaining of HT1080 cells 
revealed that ASPM is localized at the spindle poles during mitosis. This finding suggests 
that MCPH is the consequence of impairment in mitotic spindle regulation in cortical 
progenitors due to mutations in ASPM (Kouprina et al., 2005). 
The ASPM gene is the putative human ortholog of the Drosophila melanogaster 
'abnormal spindle' gene (asp). Recessive mutants of asp lead to larval lethality or 
infertility with dividing neuron progenitors unable to conclude asymmetric cell division 
(Gonzalez et al., 1990). The asp protein is required for microtubule organisation of the 
mitotic spindle poles and the central spindle in mitosis and meiosis (Gonzalez et al., 
1990, do Carmo et al., 2001). Based on the data of asp, the role of ASPM during 
neurogenesis might be to organize microtubules at the spindle pole during mitosis and at 
the central spindle during cytokinesis. 
Among all identified MCPH proteins, ASPM is the only protein for which a role in 
neurogenesis has been directly assessed. The ventricular zone (VZ) of mouse 
neuroepithelium where proliferative dividing progenitor cells are found showed a high 
Aspm mRNA expression at the onset of neurogenesis and during the early stages 
decreasing progressively as neurogenesis proceeds. Aspm protein localizes also to 
mitotic spindle poles but not overlapping with γ-tubulin. Knockdown of Aspm in the mouse 
neuroepithelium by using RNAi technique did not affect cell-cycle progression or block 
mitosis. The only feature was a detachment of the centrosome during telophase. Instead, 
loss of Aspm resulted in an increased deviation of the cleavage plane in proliferative 
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neuroepithelial progenitors, causing almost 50% of them to bypass the apical membrane 
and resulting in unequal inheritance of this domain by the daughter cells (Figure 1.3). As 
a result of this bypass, an increase in neuron-like progeny was observed. This suggests 
that loss of Aspm disrupts the alignment of the cleavage plane, causing an increase in 
non-neuroepithelial progeny and depleting the progenitor pool prematurely (Fish et al., 
2006).  
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. The developing mouse neuroepithelium. (a) Neuroepithelial cells (blue) are 
connected with apical (ventricular) and pial (basal) surfaces. The nuclei (dark blue) migrate 
basally during G1, cells (i,ii) at a basal position (iii); and migrate again apically during G2 
(iv). The centrosomes (red circles) remain at the apical membrane (green). Mitosis occurs 
at the apical surface, where the centrosomes now form the spindle poles. Symmetrical 
division leads to the production of two identical neuroepithelial cells (v,vi). By contrast, 
asymmetrical division (vii) leads to the production of one neuroepithelial cell, whereas the 
other daughter detaches from the membrane (viii) and becomes either a basal progenitor 
(ix) or a neuron. Basal progenitors (ix) lack processes and polarity and predominantly 
divide terminally to produce two neurons (x). (b) Immunofluorescence in E14 mouse 
neuroepithelium showing the apical progenitors and their processes (nestin, green), basal 
progenitors (Tbr2, red) and neurons (bIII Tubulin, purple). (c) Immunofluorescence in E12 
mouse neuroepithelium showing the apical progenitors and their processes (nestin, green), 
the nuclei of the apical progenitors (DAPI, blue) and the centrosomes (γ-tubulin, white). 
Note the arrow pointing to the cell in metaphase. The image is taken from (Thornton and 
Woods, 2009). 
Apical membraneCentrosome
Basal progenitor
Cahal Rezjus cell
Neuroepithelial cells
Symmetric division
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1.3.6 Centromere protein J  (CENPJ) 
The gene of the MCPH6 locus is CENPJ which encodes centromere-associated protein J 
(Bond et al., 2005). CENPJ was initially named centrosomal protein 4.1- associated 
protein (CPAP) and, despite its name, CENPJ is a centrosomal protein and interacts with 
the nonerythrocytes 4.1 protein 135 splice variant (4.1R-135) and is associated with the 
γ-tubulin complex (Hung et al., 2000). The centrosomal localization of this protein was 
confirmed by immunofluorescence analysis in HeLa cells (Bond et al., 2005). There are 
two main domains in CENPJ, a microtubule-binding domain (MBD) and a microtubule-
destabilising domain (MDD). The microtubule-destabilizing motif (MDD) of CENPJ inhibits 
microtubule nucleation from the centrosome and is also involved in the depolymerization 
of taxol-stabilized microtubules (Hung et al., 2004). Knockdown of CENPJ in HeLa cells 
by siRNA demonstrated a cell cycle arrest in more than 40% of the cells with multiple 
spindle poles and induced apoptosis (Cho et al., 2006). Therefore, it has been speculated 
that CENPJ might control the production of centrosomal microtubules during neurogenic 
mitosis (Bond et al., 2005). 
On the basis of data from SAS-4 of C. elegans, which is the probable homologue of 
CENPJ, the novel role of CENPJ in centriole biogenesis has been elucidated, as the 
protein product of SAS-4 is responsible for centriole duplication (Leidel and Gonczy, 
2005). Another study performed in Drosophila indicated that loss of DSas-4 resulted in 
loss of centrioles during embryonic development and slow mitotic spindle assembly and 
30% abnormal asymmetric divisions of larval neuroblasts (Basto et al., 2006). A Knockout 
study of sas4 showed abnormal spindle formation and DNA segregation defects due to 
loss of centrioles (Rodrigues-Martins et al., 2008). 
Later on the direct role of CENPJ in centriole biogenesis was also described by different 
studies. Through siRNA-mediated depletion and immunoelectron microscopy directed 
towards individual centrosomal proteins it was found that CENPJ, Plk4, hSas-6, Cep135, 
γ-tubulin, and CP110 were required at different stages of procentriole formation and were 
associated with different centriolar structures. CENPJ together with CEP135 formed a 
core structure within the proximal lumen of both parental and nascent centrioles (Kleylein-
Sohn et al., 2007). Another study showed that CENPJ is required for centrosome 
duplication in cycling human cells and its overexpression resulted in the formation of 
abnormal centrioles which were longer and in the production of more than one 
procentriole. These abnormal centrioles lead to multipolar spindle assembly and 
cytokinesis defects (Kohlmaier et al., 2009). Knockdown of CENPJ inhibited centrosome 
duplication and its overexpression induced the formation of elongated procentriole-like 
structures (Tang et al., 2009). 
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1.3.7 SCL-interrupting locus protein (SIL) 
STIL was identified as the causative gene of the MCPH7 locus in Indian MCP families. In 
mouse the expression of this protein has been shown in subventricular neuroepithelial 
cells at embryonic day 14.5 (E14.5) (Kumar et al., 2009). Antibodies generated against 
human SIL revealed its localization in HeLa cells to the poles of the mitotic spindle in 
metaphase cells, but it was not detected during anaphase. The localization of SIL to the 
spindle pole is similar to the one of ASPM. Knockdown of SIL by shRNA in HeLa cells 
showed disorganized mitotic spindles in dividing cells. Localization and knockdown of SIL 
suggested the role of SIL in organizing the mitotic spindle (Pfaff et al., 2007). Striking 
developmental anomalies like pericardial swelling, midline neural tube defects, failure of 
neural tube closure and holoprosencephaly are the main phenotypes observed in SIL 
knockout mice. These phenotypes were observed between embryonic day E7.5 to E8.5, 
and the mutant homozygote die in utero at E10.5 (Izraeli et al., 1999). 
1.4 Role of MCPH proteins in neurogenesis 
Before discussing the role of MCPH proteins in neurogenesis, a brief description of 
neurogenesis in mouse is described. During mouse brain development, apical 
neuroepithelial (NE) cells are the first progenitor cells and have centrosomes which 
remain at the apical membrane during G1, S and G2 phase of the cell cycle. These NE 
progenitor cells are attached to the apical (ventricular) and pial surfaces, have an apico-
basal polarity, and the orientation of the spindle is dependent on the positioning of the 
centrosomes. Early in neurogenesis, NE progenitor cells undergo symmetric proliferative 
division, producing the same types of NE cells, which stay attached with the apical and 
pial plasma membrane resulting in the increase of the progenitor pool. This symmetric 
division is due to the parallel alignment of spindles to the neuroepithelium within 
progenitor cells. As neurogenesis progresses, NE cells undergo asymmetric neurogenic 
division due to the alignment of the spindle perpendicular to the neuroepithelium. After 
asymmetric division one daughter cell stays attached with the apical surface and has the 
NE cell fate while the other daughter cell detaches from the apical surface and takes on 
the basal progenitor cell fate of the neuron. This basal progenitor cell is unpolarized and 
divides symmetrically to produce two neurons (Figure 1.3). Asymmetric cell division in NE 
cells maintains the progenitor pool cell numbers while producing committed precursors 
such as neuronal committed precursors. Progenitors give rise to various cell types such 
as neurons and glial cells (astrocytes, oligodendrocytes and microglia) that further 
differentiate and migrate. The cortical size depends not only on the generation, 
maturation and migration of cells, but also on the survival of generated cells. Also, the 
balance between symmetric proliferative division and asymmetric neurogenic division of 
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NE cells is considered to be important for the eventual numbers of neurons (Thornton and 
Woods, 2009, Kaindl et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: A model of MCPH protein functions during neurogenesis. Loss of MCPH1 
results in premature mitotic entry which affects centrosome maturation. Disruption of 
CDK5RAP2 or CENPJ has direct affects on centrosome maturation. Loss of CENPJ results 
in loss of the centriole. These immature centrosomes reduced PCM accumulation and can 
affect spindle orientation during division by formation of fewer astral microtubules. ASPM 
localizes to the spindle pole of the centrosomes and directly regulates spindle positioning. 
SIL and WDR62 also have spindle pole localization, suggesting a role for these proteins 
(SIL and WDR62) like ASPM. Impaired spindle alignment can result in symmetric divisions 
and reducing the progenitor pool, which ultimately results in fewer neurons. Image is taken 
from (Thornton and Woods, 2009). 
Notable features of all identified MCPH proteins are their centrosomal localization and 
expression in progenitor cells of the mouse neuroepithelium. Defects in MCPH proteins 
can be associated with a delay in centrosome maturation or disrupt spindle orientation 
directly which affects the daughter centriole and centrosome, reducing the recruitment of 
pericentriolar matrix (PCM) and accessory proteins, and deceasing microtubular 
nucleation. This can result in the production of two unequal centrosomes and also altered 
spindle positioning. A defective spindle orientation resulting from the loss of MCPH 
proteins could then lead to an increase in NE cells producing neurogenic progeny and 
reducing the proportion of symmetric divisions thereby depleting the progenitor pool and 
limiting the total number of neurons that can be generated (Figure 1.4) (Thornton and 
Woods, 2009). 
Identification of further proteins involved in MCPH will improve our knowledge of 
neurogenesis and the pathomechanism of this disorder.  
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2. Objectives of the Thesis 
The overall aim of this doctoral thesis was the exploration and molecular characterization 
of the genes responsible for autosomal recessive primary microcephaly (MCPH).  
Although seven MCPH genes have already been identified, there are still a large number 
of families which do not carry mutations in anyone of the known genes. Identifying the 
unknown genetic lesions in these families will on the one hand pave the way to a 
comprehensive diagnostic management of this highly heterogeneous disease including 
prenatal diagnosis and preconceptional carrier screening, on the other hand it will help to 
further elucidate the molecular mechanisms causing the characteristically disturbed brain 
development, i. e. to describe new signaling pathways and define essential interactions of 
various gene products in prenatal brain development especially in the cerebral cortex.  
MCPH is a disorder of neurogenic mitosis and so far all identified MCPH proteins are 
expressed in neuronal progenitors. Thus, the identification of genes responsible for 
MCPH and the understanding of their functions might have direct relevance to other 
clinical spheres such as stem-cell therapy of neurological disorders. 
The specific aims of this doctoral study were:  
1. To analyse Pakistani families afflicted with primary microcephaly.  
2. To screen for mutations in known MCPH genes to add to the mutational spectra of 
these genes.  
3. To identify novel MCPH loci and the underlying causative gene variants.   
4. To uncover the functions of the novel genes and their role in the etiology of 
MCPH. 
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3. Material and Methods 
3.1. Subjects 
Thirty families of autosomal recessive primary microcephaly (MCPH) with 1-7 afflicted 
individuals were ascertained from remote locations of Pakistan. All families were 
consanguineous and diagnosed clinically with the prominent phenotype of a sloping 
forehead which is a defining feature of this disease, normal height and weight, mild to 
moderate mental retardation without any other neurological finding, such as spasticity, 
seizures, or progressive cognitive decline. The mental functions of the patients were 
assessed by standardized questionnaires in all family members. Clinical data in terms of 
head circumference (HC) was collected which is the common and simple method for 
evaluating gross brain size (Woods et al., 2005). Head circumference (HC) of at least 
three standard deviations (SDs) below the expected mean for age and sex was observed. 
The head circumference and intelligence level of all parents of microcephaly families 
were normal. Clinical data also indicated that the disease was present at birth in all thirty 
analyzed families of microcephaly. The phenotype of this disease was documented by 
photos (Figure 3.1). 
3.2. Pedigrees construction and mode of inheritance analysis 
The family history and mode of inheritance of all MCPH families was worked out by 
pedigree analysis which was constructed in the field by standard symbols. Pedigree data 
was given by family members. Blank squares and circles represent the normal male and 
female respectively while filled squares and circles represent the afflicted family 
members. A horizontal line between a circle and square is a marriage line. Children are 
represented by drawing a vertical line down from the marriage line. Fraternal twins are 
denoted by a pair of diagonal lines connected to the parents' offspring line, so that they 
each touch the horizontal line at the same point. In addition, a horizontal line between the 
two children is used to denote identical twins. A diagonal line across a circle or square 
indicates a deceased individual. An arrow pointing at a particular afflicted individual is 
added to indicate proband (also propositus for male and proposita for female). 
In the laboratory, the pedigrees were drawn by using HaploPainter v.1.043 (Thiele and 
Nurnberg, 2005). This software is equipped with an intuitive graphical interface and is 
powerful enough to draw even complex consanguineous pedigrees. Filled symbols 
represent afflicted individuals and open symbols non-afflicted ones. Persons with an 
unknown afflicted status are shown in grey with a question mark inside. A diagonal slash 
indicates that the person is deceased. After pedigree constructions, the mode of 
inheritance of all 30 MCPH families was analyzed as autosomal recessive. 
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Figure 3.1: Clinical features of afflicted individuals of microcephaly families. 
3.3. Blood sampling 
After informed consent, the peripheral blood samples of all available afflicted individuals, 
their parents and one or two normal, healthy siblings were collected and stored in 10 ml 
BD vacutainer® (BD-Plymouth, UK) having Ethylenediaminetetraacetic acid (EDTA) as 
anticoagulant. 
3.4. DNA extraction 
DNA was extracted by using the phenol-chloroform method, a standard protocol of DNA 
extraction from blood. 0.75 ml of whole blood was mixed with same amount of solution A 
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in a 1.5 ml microcentrifuge tube (Eppendorf) and was incubated for 10 minutes at room 
temperature. The supernatant was discarded after 1 minute of centrifugation at 13,000 
rpm. The pellet was resuspended in 400 µl of Solution A and the sample was centrifuged 
for 1 minute at 13,000 rpm. The supernatant was discarded and the nuclear pellet was 
resuspended in 400µl of Solution B, 25 µl of 10% SDS (13µl of 20%SDS), and 8 µl of 
Proteinase K (20 mg/ml). Samples were incubated overnight at 37 or 65oC in a water bath 
for 3 hours. 0.5 ml of freshly prepared equal volume of solution C (250 µl) and solution D 
(250 µl) was added and the sample was centrifuged for 10 minutes at 13,000 rpm. The 
upper aqueous phase was collected in a new 1.5 ml tube and mixed with an equal 
quantity of solution D. This step of upper phase collection, solution D addition and 
centrifugation was repeated. To the collected aqueous phase, 55 µl of 3M Na-acetate (pH 
6) and an equal volume of isopropanol (500 µl, stored at –20oC) was added. The tube 
was inverted gently to precipitate the DNA. The sample was centrifuged at 13,000 rpm for 
10 minutes. The solvent phase was removed without disturbing the DNA pellet. To the 
tube containing the pelleted DNA, 350 µl of 70% ethanol (stored at –20oC) was added 
and then the tube was centrifuged at 13,000 rpm for 10 minutes. Ethanol was removed 
and the DNA pellet was dried in a vacuum dryer. DNA was dissolved in 250 µl of double 
distilled deionized water. 
3.4.1. Solutions used for DNA extraction 
Solution A (pH 7.5) 500ml 
0.32 M Sucrose   54.72 g 
10 mM Tris-HCl (pH 7.5)  5 ml (1M) 
5 mM MgCl2    2.5 ml (1M) 
The above mentioned chemicals were dissolved in 400 ml of dist. water and pH was 
adjusted to 7.5. A final volume of 495 ml was prepared by adding water. After 
autoclaving, the solution was cooled at room temperature. Finally 5 ml of Triton X-100 
(1% v/v) was added. 
Solution B, 500ml 
10 mM Tris-HCl (pH 7.5)  5 ml 
400 mM NaCl    40 ml 
2 mM EDTA (pH 8.0)   2 ml 
The volume of the solution was brought to 500 ml and autoclaved. 
Solution C (saturated phenol pH 8.0) 
Phenol (Sigma-Aldrich) was heated to 68oC in a water bath. The 100 ml of heated phenol 
were mixed with 100 mg of hydroxyquiniline (0.1%) and 100 ml of 0.5M Tris-HCl (pH 8.0). 
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Stirring was performed for 15 minutes. The upper aqueous phase was discarded. 0.1 M 
Tris-HCl (pH 8.0) of equal volume was added and stirred for 15 minutes. Again the upper 
phase was removed. This step was repeated until the pH of phenol reached 7.8. The pH 
of phenol was measured within the upper phase just above the phenolic layer. Then, 10 
ml of Tris-HCl were added containing 200 µl of β-mercaptoethanol. The solution was 
stoed at 4oC and is stable for 1 month. 
Solution D 
Isoamyl alcohol + chloroform (1:24) 
3.5. DNA Quantification 
DNA was quantified by NanoDrop ND-1000 Spectrophotometer (Theromo Scientific) and 
a 2 ng/ µl dilution of DNA was prepared for amplification with a specific set of primers. 
3.6. RNA isolation 
3.6.1. Blood 
The peripheral blood was collected in PAXgene Blood RNA Tubes to isolate cellular RNA 
from whole blood. RNA was isolated by using the PAXgene Blood RNA kit (PreAnalytiX). 
3.6.2. Human primary fibroblasts 
Total RNA was isolated from human fibroblast cells by using the RNeasy Mini kit (Qiagen) 
3.7. Polymerase chain reaction (PCR) and agarose gel electrophoresis 
Polymerase chain reaction (PCR) was performed with patient and control DNAs using 
different PCR profiles and mastermix compositions depending upon the size of nucleic 
acid to amplify and the nature of primers (sequencing oligos or microsatellites). The 
primers can be found in appendix 1 to appendix 11. Different types of DNA polymerases 
were used to get different products. For sequencing oligos and microsatellite markers 
amplification with DNA of microcephalic patients, InnuTaq DNA Polymerase 
(AnalytikJena) was used,  PfuUltra™ High-Fidelity DNA Polymerase (Stratagene) was 
employed to amplify wild-type and mutant CDK6 from whole cDNA and Takara 
PrimeSTAR™ HS DNA Polymerase (TaKaRa, USA) was used for CEP135 wild-type and 
mutant constructs. Mastermixes were run on DNA Engine Tetrad 2 Thermal Cyclers, 
Version 2.0 (Bio-Rad). Different PCR profiles and mastermix compositions are mentioned 
in each respective section. 0.7 to 2% agarose (Invitogen) was melted in TAE buffer and 
the gel was run in horizontal gel electrophoresis chambers (Horizon® 11.14) to resolve the 
nucleic acids. Quantification and size determination of the nucleic acids was done by 
HyperLadder I (BIOLINE) and 1 Kb DNA Ladder (Invitrogen). Ethidium bromide (0.1 μg/ml 
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final concentration) was used to stain the nucleic acids. Images of the gels were taken by 
Alpha Innotech Multi Image® Light Cabinet (Biozym). 
TAE buffer, pH 8.3 
40 mM Tris base 
20 mM Acetic acid 
2 mM EDTA 
Gel loading dye (Bromophenol Blue) 
For Bromophenol Blue production, 40g of sucrose and 0.25g of Bromophenol Blue 
were dissolved in 80ml of dist. H2O. Afterwards the volume was increased to 100ml. 
3.8. Reverse transcriptase PCR (RT-PCR) 
cDNA was synthesized from whole RNA by using SuperScript III reverse transcriptase 
enzyme (Invitrogen). The procedure is as follows, 9µl RNase free ddH2O was mixed with 
1µl dNTPs (10 mM), 1 µl Oligo d(T)18-Primers (50 µM) and 2µl RNA (665 ng/ µl) 
respectively in a nuclease-free microcentrifuge tube. The mixture was incubated for 5 
minutes at 65°C to get rid of secondary structures of the RNA. Then, 4 µl 5X First-Strand 
Buffer, 2µl DTT (0.1 M) and 1µl SuperScript RT (200 U/µl) were added. The samples 
were incubated at 50°C for 50 minutes and 70°C for 15 minutes in a thermal cycler. 
3.9. Genotyping with short tandem repeat (STR) markers 
For linkage analysis, PCR (Polymerase Chain Reaction) based genotyping, was 
performed using highly polymorphic fluorescently labeled microsatellite (STR) markers. 
For genotyping, the microsatellite markers were selected for each locus from the 
Marshfield (http://www.bli.uzh.ch/BLI/Projects/genetics/maps/marsh.html) genetic map, 
and were labeled with fluorescent dyes e.g. FAM, TET, HEX and NED at 5’ end of forward 
primers. Some markers of chromosome 19 were selected from Human STR Finder 
(http://portal.ccg.uni-koeln.de/cgi-bin/repfinder.pl) and designed by Primer3 v. 0.4.0 
(Rozen and Skaletsky, 2000). The mastermix composition to amplify the microsatellite 
markers is listed in table 3.1. 
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Table 3.1: Mastermix composition to amplify DNA of microcephaly patients with 
microsatellite (STR) markers 
 Final Concentartion
Mastermix for 
one reaction 
(µl) 
Mastermix for 
8 reactions 
(µl) 
DNA (2ng/µl)  4.00  
Innu Taq (5U/µl) 2.5U 0.05 0.40 
dNTP´s (10mM) 100 µM each 0.10 0.80 
Primer-F (10µM) 0.25 µM 0.25 2.00 
Primer-R (10µM) 0.25 µM 0.25 2.00 
10xPCR-Buffer II (10X) 1.5Mg 1.00 8.00 
ddH2O  4.35 34.8 
Total Volume  10.00 48.00 
.  
Table 3.2: PCR profiles to amplify the microsatellite markers of microcephaly.  
MS 
 
TDM 
1 94°C 3 min. 1 95°C 5 min. 
2 94°C 30 Sec. 2 95°C 15 Sec. 
3 61°C 45 Sec. 3 65°C 30 Sec. 
4 72°C 1 min. Decrease by 0.5°C every cycle 
Step 2-4 repeat 2 more times 4 72°C 30 Sec. 
5 94°C 30 Sec. Cycle to step 2 for 19 more times
6 59°C 45 Sec. 5 95°C 15 Sec. 
7 72°C 1 min. 6 55°C 30 Sec. 
Step 5-7 repeat 2 more times 7 72°C 30 Sec. 
8 94°C 30 Sec. Cycle to step 7 for 19 more times
9 57°C 45 Sec. 8 72°C 10 min. 
10 72°C 1 min. 9 4°C Forever 
Step 8-10 repeat 2 more times 
 
11 94°C 30Sec. 
12 55°C 45Sec. 
13 72°C 1min. 
Step 11-13 repeat 2 more times 
14 72°C 20 min. 
15 4°C Forever 
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PCR programmes 
Two different PCR profiles were used to amplify the patient and control DNAs for 
microsatellite markers. These profiles are given in table 3.2. 
Amplified markers were electrophoresed on the ABI 3730 DNA Analyzer using standard 
fragment analysis protocols according to the manufacturer’s specifications (Applied 
Biosystems, Foster City, CA). Fragment-length analysis was performed using the ABI 
GeneMapper® v.3.5 analysis packages. Haplotypes were constructed by HaploPainter 
v.1.043 (Thiele and Nurnberg, 2005) and EasyLinkage Plus v5.02 (Lindner and 
Hoffmann, 2005). If all afflicted individuals were homozygous and parents were 
heterozygous for specific markers of a region, the family was called to be linked with that 
particular locus. If all afflicted individuals and parents were heterozygous for specific 
markers of a region, the family was excluded for that particular locus. 
3.10. DNA sequencing 
3.10.1. Sanger sequencing 
Sanger sequencing was used to sequence different candidate genes. Different sets of 
primers were employed to amplify with desired DNA of microcephaly families. The 
mastermix composition is listed below in table 3.3. 
Table 3.3: Mastermix composition to amplify DNA of microcephaly patients for 
sequencing.  
 
Mastermix 
for one 
reaction (µl) 
Mastermix for 
eight 
reactions (µl) 
DNA (2 ng/µl) 3.00 -- 
Taq (5 U/µl) 0.12 0.96 
dNTP´s (10 mM) 0.30 2.40 
Primer-F (10 µM) 0.30 2.40 
Primer-R (10 µM) 0.30 2.40 
10xPCR-Buffer II (10x) 1.50 12.00 
ddH2O 9.48 75.84 
Total volume 15.00 96.00 
 
Most of the DNA was amplified with a PCR profile named TDM and 60°C. TDM profile is 
mentioned in table 3.2 and 60°C in table 3.4a. 
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Table 3.4: PCR profiles used for Sanger sequencing. (a) For patient DNA amplification 
with an annealing temperature of 60°C. (b) ExoSAP reaction to clean up the PCR product 
ultimately used for Sanger sequencing. (c) Thermal cycler profile for BigDye® Terminator 
v1.1 Cycle sequencing. 
(a) For patient DNA Amplification 
 
 (b) For ExoSAP reaction 
1 95°C 5 min. 1 37°C 30 min. 
2 95°C 30 sec. 2 85°C 15 min. 
3 60°C 30 sec. 3 4°C Hold 
4 72°C 30 sec.  
Step 2-4 repeat 44 more times (c) For Big dye reaction 
5 72°C 5 min. 1 96°C 10 sec. 
6 4°C Forever 2 55°C 5 sec. 
 
3 60°C 4 min. 
Step 1-3 repeat 44 more times 
 
3.10.1.1. Cleaning of PCR product with Exo-SAP 
Residual nucleotides from PCR products were removed with the help of the enzymes, 
Exonuclease I (20U/µl, New England Biolabs) and the Shrimp Alkaline Phosphatase 
(SAP) (1U/µl, Promega). The former enzyme removes leftover primers, while the later 
removes the unused dNTPs (Table 3.4b and Table 3.5a). 
Table 3.5: Mastermix composition used for Sanger sequencing. (a) For PCR product 
clean up by ExoSAP (b) For BigDye® Terminator v1.1 Cycle sequencing kit. 
(a) ExoSAP mastermix ( µl)  (b) BigDye mastermix ( µl) 
PCR product 8 Water 5.25 
Exonuclease I (20U/µl) 0.075 BigDye® Terminator v1.1 0.50 
SAP (1U/ µl) 0.300 5X BigDye sequencing buffer 2.00 
Water 1.625 Primer (10µM) 0.25 
Total Volume 10.00 µl PCR template (cleaned) 2.00 
 Total Volume 10.0 µl 
 
3.10.1.2. BigDye® terminator cycle sequencing  
Sequencing was performed using the BigDye® Terminator v1.1 Cycle sequencing kit 
(Applied Biosystem) together with an ABI3730/3730xl automated DNA sequencer 
(Applied Biosystem). Reaction mixture composition for BigDye® Terminator v1.1 is given 
above in table 3.5b. The thermal cycler programme was 96°C for 10 seconds 55°C for 5 
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seconds and 60°C for 4 minutes with a total of 32 cycles (Table 3.4c). Sequences were 
analysed by DNA Star (Lasergene) and Mutation Surveyor (SoftGenetics). 
3.10.2. Pyrosequencing 
The polymorphic nature of pathogenic mutations (substitutions or deletions) found in 
patient DNAs was ruled out by sequencing the control samples of the same ethnic group 
by pyrosequencing which is, widely applicable and has the advantages of accuracy, 
flexibility, parallel processing, and easy automation. This method is based on the 
sequencing by synthesis principle and relies on the detection of pyrophosphate release 
on nucleotide incorporation. 
3.10.2.1. Primer desig for pyrosequencing 
PCR primers were designed by the PSQ Assay Design program v.1.0.6 (Qiagen, Hilden, 
Germany). The forward primers used to amplify the product for pyrosequencing were 
Biotin labeled at the five prime ends (Appendix 8, Appendix 9). 
3.10.2.2. Preparation of PCR products for pyrosequencing 
10 µM of sequencing primer (0.36 µl for one reaction) was mixed with 1x annealing buffer 
(11.64 µl for one reaction). PCR products were mixed with 70 µl of streptavidin sepharose 
(GE Healthcare) and shaken for 6 minutes. The PCR product and streptavidin sepharose 
mix was added to a solution containing sequencing primer and annealing buffer with the 
help of the PyroMark Q96 Vacuum Prep Workstation. This primer-hybridization mix was 
incubated at 85°C for 2 minutes and pyrosequencing was done according to 
manufacturer’s instructions on a PSQ HS96A instrument (Qiagen, Hilden, Germany). 
Pyrosequencing was conducted using PyroMark Gold Q96 Reagents (Qiagen, Hilden, 
Germany). This kit contains enzyme (DNA Polymerase, ATP sulfurylase, luciferase and 
apyrase), dNTPs (dATP, dCTP, dGTP and dTTP) and the substrate, adenosine 5’ 
phosphosulfate (APS) and luciferin. Pyrosequencing data was analysed by Pyro Q-CpG 
V.1.0.9 analysis software (Qiagen, Hilden, Germany). 
3.10.2.3. Solutions used for pyrosequencing 
1x annealing buffer (1x AB), pH 7.6 
20mM Tris-Acetate 
2mM Mg-Acetate 
3.11. Genome-wide linkage analysis 
Excluded consanguineous MCPH families were subjected to genome-wide linkage 
analysis by using the Affymetrix GeneChip® Human Mapping 250K SNP Array. 
Genotypes were called by the GeneChip® DNA Analysis Software (GDAS v3.0, 
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Affymetrix). Sample genders were verified by counting heterozygous SNPs on the X 
chromosome. Relationship errors were evaluated with the help of the program Graphical 
Relationship Representation (Abecasis et al., 2001). The program PedCheck was applied 
to detect Mendelian errors (O'Connell and Weeks, 1998) and data for SNPs with such 
errors was removed from the data set. Non-Mendelian errors were identified by using the 
program MERLIN (Abecasis et al., 2002) and unlikely genotypes for related samples were 
deleted. Linkage analysis was performed assuming autosomal recessive inheritance, full 
penetrance, consanguinity and a disease gene frequency of 0.0001. The multipoint LOD 
score was calculated using the program ALLEGRO (Gudbjartsson et al., 2000). 
Haplotypes were reconstructed with ALLEGRO and presented graphically with 
HaploPainter (Thiele and Nurnberg, 2005). All data handling was performed using the 
graphical user interface ALOHOMORA (Ruschendorf and Nurnberg, 2005).  
3.12. Mutation detection 
All the genes residing in minimum linkage intervals of excluded families (MCP4, MCP50, 
MCP53, MCP63 and MCP67) were screened by NCBI database and prioritized by using 
Endeavour (Aerts et al., 2006) and GeneWanderer (Kohler et al., 2008). Endeavour is a 
software used to prioritize the candidate genes of a specific disease, based on a set of 
training genes while GeneWanderer is a computational method to prioritise a set of 
candidate genes by probability to be involved in a particular disease or phenotype. Highly 
ranked gene structures were searched using ENSEMBL (http://www.ensembl.org) and 
UCSC (http://genome.ucsc.edu) genome databases. All exons and the intron-exon 
boundaries of highly ranked genes were first sequenced in two afflicted individuals and 
one parent and one normal sibling. Mutations were found by analyzing the sequence 
using DNA Star (Lasergene) and Mutation Surveyor (SoftGenetics). 
3.13. Bacterial culture 
The solution of Luria Bertani (LB) media prepared with deionised water was sterilised by 
autoclaving at 120˚C. The final concentration of antibiotics used for LB media was 100 
g/ml of Ampicillin and 50 g/ml Kanamycin. 
LB medium (1L) (pH 7.0) 
Tryptone enzymatic digest from Casein (Fluka, BioChemika) 10 g 
Yeast extract (Fluka, BioChemika)      5 g 
NaCl          5 g 
LB agar plates (1L) (pH 7.0) 
Tryptone enzymatic digest from Casein (Fluka, BioChemika) 10 g 
Yeast extract (Fluka, BioChemika)        5 g 
NaCl          5 g 
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Bacto Agar (Becton, Dickinson and Company, France)  15 g 
 
3.13.1. Storing the bacterial culture 
1.0 ml overnight bacterial culture was mixed with 1.0 ml glycerol (room temperature and 
stored at -80°C. 
3.14. Mammalian cell lines and cell culture 
COS7 cell line was obtained by immortalizing a CV-1 cell line derived from kidney cells of 
the African green monkey with a version of the SV40 genome that can produce large T 
antigen but has a defect in genomic replication (Jensen et al., 1964, Gluzman, 1981). 
HaCaT is a Human skin keratinocyte cell line (Boukamp et al., 1988). 
Primary fibroblast cell lines were established from biopsies of patients carrying 
mutations in CDK6 and CEP135 and control.   
All cell lines were cultured in Dulbecco´s Modified Eagle´s Medium (DMEM, PAA 
supplemented with 10% fetal bovine serum (FBS, Biochrom), L-Glutamine (PAN Biotech) 
and antibiotics (Penicillin/Streptomycin, PAN Biotech)). Cells were cultivated at 37°C in a 
humidified incubator supplied with 5% CO2. 
Composition of media used for mammalian cell culture 
DMEM (High Glucose (4.5 g/L) with L-Glutamine)  500 ml     
FBS                  60 ml 
L-Glutamine (200 mM, 100X)         6 ml 
Penicillin/Streptomycin (10.00 IE (µl)/ml)       6 ml    
Note: For CEP135 primary fibroblasts, 15% FBS was used.  
3.15. Cell line establishment from patient biopsies 
The biopsy samples were taken from one afflicted individual of each MCP4 (individual 
MCP4-3) and MCP63 (individual MCP63-1) family and transported in DMEM with more 
additives like Amphotericin B and Gentamycin. Tissue samples were cleaned with 
antiseptic agent (Betaisodonna, Mundipharma) and incubated overnight with Dispase II 
(1.5 U/ml, Roche) diluted in PBS at 4°C to separate the epidermis from the dermis. The 
dermis was incubated in DMEM at 37°C. After one week, primary fibroblast cells were 
seen crawling from the dermis. The number of primary fibroblasts was increased by 
further culturing. Primary fibroblasts established from the MCP63 patient biopsy grew 
very slowly. To enhance growth, DMEM with 15% FBS was used. 
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3.16. Fibroblast synchronization at G0/G1 by serum starvation  
CDK6 patient and control fibroblasts (passage 4) were synchronized at G0/G1 by serum 
starvation. The medium was exchanged by two washes with PBS and then DMEM 
without FBS was added. After 48 hours, the medium was replaced by DMEM containing 
15% FBS. The cells were then processed for immunofluorescence after 24, 26, 28 and 30 
hours. 
3.17. CDK6 and CEP135 GFP constructs 
Gateway® Technology (Invitrogen) was used to clone wild-type and mutant CDK6 and 
CEP135 cDNA. 
3.17.1. CDK6 GFP constructs 
mRNA from CDK6 wild-type (NM_001145306.1) and mutant (c.589G>A) primary 
fibroblasts was isolated and converted into cDNA (procedure is described in section 3.8) 
and the CDK6 sequences cloned into the entry vector pENTR™/TEV/DTOPO® by using 
the pENTR™ Directional TOPO® Cloning Kit to get the entry clones. Expression clones 
of wild-type and mutant CDK6 were achieved by performing an LR recombination 
reaction (Gateway® LR Clonase™ II Enzyme Mix, Invitrogen) between the entry clone 
and a Gateway® destination vector pcDNA-DEST53 (Invitrogen) which has an N-terminal 
cycle 3 GFP tag.  
3.17.2.  CEP135 GFP constructs 
CEP135 wild-type transcript (NM_025009.3) isolated from wild-type primary fibroblasts 
was converted into cDNA and cloned into entry vector (procedure is the same as 
described in section 3.8). The CEP135 mutation (c.970 delC) was produced in the wild-
type entry clone by using the QuikChange® II Site-Directed Mutagenesis Kit (Stratagene). 
The QuickChange Primer Design tool (Stratagene) was used to design the mutagenesis 
primers (Table 3.6). The mutant entry vector was propagated in XL1-Blue competent E. 
coli cells instead of SURE 2 cells. Both wild-type and mutant expression clones were 
acquired as listed for the CDK6 GFP constructs. 
3.17.3. Sequencing of entry and expression clones 
Sequencing of entry clones was done by using vector specific (M13 sequencing primers) 
and internal primers, while for expression clones, the primers were designed within the 
vector and the inserts. The primers are listed in appendix 11 and the protocol for 
sequencing is described in section 3.10. 
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Table 3.6: Primers used for amplification of CDK6, CEP135 and for site directed 
mutagenesis of CEP135. 
 
 
 
 
 
 
 
 
 
 
 
 
3.18. Plasmid purification 
Correct clones identified by sequencing were cultured overnight in 100 ml LB medium 
with 100 µl Kanamycin (50 mg/ml). Plasmids were extracted by PureYield™ Plasmid 
Midiprep System (Promega). 
3.19. Transfection of GFP-tagged clones  
The plasmids (expression clones) (10 μg/μl) were used for transfection of COS7 cells 
(80% confluent and trypsinized one day before transfection) by electroporation. The 
COS7 cells were incubated on ice for 5 minutes and taken up in 189 µl normal cell culture 
medium. 200 µl (11 µl plasmid DNA plus 189 µl cells) were filled into a pre-chilled cuvette 
(0.4 mm gap) and incubated on ice for 15 minutes. Cells were electroporated using a 
GENE PULSER II (BIO-RAD) and spread in prewarmed cell culture medium. 
Immunofluorescence and protein was extracted on the third day, 72 hour after 
transfection. 
3.20. Knockdown of CDK6 
CDK6 gene silencing was performed by shRNA (short hairpin RNA) technique.  
3.20.1.  Primer design 
To knockdown CDK6, two sets of primers were designed by taking 31 nucleotides from 
each of exon 4 (5’-GATCTAAAACCACAGAACATTCTGGTGACCA-3’) and 7                     
Primers used to amplify CDK6 
CDK6-cDNA-F CACCATGGAGAAGGACGGCCTG 
CDK6-cDNA-R GCAGAGCCTGTCCAGAAGAC 
Primers used to amplify CEP135 
CEP135-cDNA-F CACCTTAGAAGACGAGATGACTACAGC 
CEP135-cDNA-R CCATGTTCATGATTTTCAGCA 
Primers for CEP135 site directed mutagenesis 
CEP135-del970-F 
ACTCTGCCAAGAATTAACTGAAA 
TAGATAGTTAGCACAGCAGT 
CEP135-del970-R 
ACTGCTGTGCTAACTATCTATTTC 
AGTTAATTCTTGGCAGAGT 
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(5’-TGAGAAGTTTGTAACAGATATCGATGAACTA-3’) of the CDK6 gene along with a 
control sequence (5’-TTAAAAGAGCTAGTTTAACTAATGGGAACTG-3’). This control 
sequence is a randomized sequence of CDK6. The Hairpin Protocol V2.1 
(http://hannonlab.cshl.edu/protocols/BseRI-BamHI_Strategy.pdf) was used to design the 
primers. The primers are listed in appendix 6. 
3.20.2. Oligonucleotides annealing 
The synthesized forward and reverse single-stranded oligonucleotides (100 μM) were 
annealed using the following conditions.  
PCR mastermix 
Primer A-F (100 µM)   4 µl 
Primer A-R (100 µM)   4 µl 
5X Annealing Buffer   2 µl 
PCR profile 
95°C for 30 second. 
72°C for 2 minutes 
37°C for 2 minutes 
25°C for 2 minutes 
4°C for Hold 
This PCR ultimately yields double stranded oligos at a concentration of 50 μM (assuming 
100% theoretical annealing) which are ready for ligation into the pSHAG-1 vector. The 
oligos are diluted with TE Buffer at the ratio of 1:100 (2 µl oligo + 198 µl TE buffer) 
5x Annealing buffer (50 ml) 
50 mM Tris/HCl, pH 8.0  2.5 ml  
250 mM NaCl    2.5 ml 
5 mM EDTA    500 µl 
3.20.3. Digestion of pSHAG-1 vector 
3 μg of pSHAG-1 vector (Paddison et al., 2002) were linearized using BseRI and BamHI 
that generate ends compatible with the target oligonucleotide sequence. Two control 
digestion, samples were digested with one enzyme each and analysed by gel 
electrophoresis (Table 3.7). 
 
 
 
 
30 
 
 
 
Table 3.7: Mastermix composition of pSHAG-1 and control sample digestion  
pSHAG-1-digestion 
 
Control digestion 
Vector (pSHAG-1) 3µl (1µg/µl)   BamHI BseRI 
BamHI 2µl (20u/µl) pSHAG-1 0.2µl (1µg/µl) 0.2µl (1µg/µl) 
BseRI 2µl (10u/µl) BamHI 0.5µl (20u/µl)  
Buffer 2 10µl BseRI   0.5µl (20u/µl) 
BSA (NeBiolabs) 1µl (100X) Buffer 2 2µl 2µl 
Water 82µl BSA 0.2µl (100X) 
0.2µl (100x 
10mg/ml) 
Total Volume 100µl Water 16.6µl 16.6µl 
   Total Volume 20µl 20µl 
 
The mixture was incubated for 4 hours at 37°C. The digested product was analyzed by 
agarose gel electrophoresis and was purified by High Pure PCR Product Purification Kit 
(Roche). 
3.20.4. Cloning procedure 
Double stranded oligonucleotides (0.5 μM) were ligated into linearized the pSHAG-1 
Vector (15ng/µl) as described below and incubated overnight at 15-17°C (Table 3.8). 
Table 3.8: Mastermix composition to clone ds shRNA oligos into to pSHAG-1 
pSHAG-1 Vector (15ng/ul) 4µl 
Insert (ds shRNA Oligos) 1.3µl 
T4 Ligase Buffer 4µl 
T4 DNA Ligase (1U/ µl) 1µl 
Nuclease Free Water 9.7µl 
Total Volume 20µl 
 
10 µl of ligation reaction was mixed with E. coli GT116. Incubation was conducted on ice 
for 15 minutes. The cells were shocked by heating for 90 seconds at 42°C. 1 ml of SOC 
medium was added followed by 1 hour shaking at 37°C. 50 and 100 µl of this mix were 
spread on LB agar plates containing Kanamycin. The plates were incubated at 37°C 
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overnight. Colonies (6-10) were picked and plasmids were extracted (PureLink™ Quick 
Plasmid Miniprep Kit) and analysed by sequencing.  
3.20.5. Plasmid purification 
Correct clones were cultured overnight in 100 ml LB medium containing 100 µl 
Kanamycin (50 mg/ml). Plasmid DNA was isolated using PureYield™ Plasmid Midiprep 
System (Promega). 
3.20.6. Transfection 
The plasmids (4 μg/μl) were used for transfection of HaCaT (80% confluent) cells by 
using the Amaxa Cell line Nucleofector (R) Kit V (LONZA). Transfection was carried out 
twice with three days interval. Immunofluorescence analysis and preparation of protein 
lysates was done on the third day after the second transfection. 
3.21. Preparation of protein lysates from eukaryotic cells 
Cells were washed twice and scraped into ice cold 1x phosphate buffered saline (PBS) 
plus protease inhibitor (DTT, Benzamidine and PMSF at 1 mM each). After centrifugation 
at 15,000 rpm at 4°C the pellet was resuspended in lysis buffer (50 mM Tris/HCl, pH 7.5, 
150 mM NaCl, 1% Nonidet P-40, 0.5% Na-desoxycholat, 0.1% SDS, Proteinase Inhibitor 
Cocktail (PIC, Sigma) and protease inhibitors DTT, Benzamidine and PMSF). The 
amount of lysis buffer should be 2-4 fold volume of the pellet. The solution was passed 
several times through 0.4x19 mm needles (27Gx3/4”, Nr.20, BD Microlane TM3) and was 
incubated on ice for 15 minutes. The sample was denatured in 5x SDS sample buffer at 
95°C for 5 minutes. 
3.22. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were resolved according to their molecular weight by using denaturing SDS-
PAGE. The MiniPROTEAN® (Biorad) system was used for gel casting and for 
electrophoresis. The composition of the resolving and stacking gel is mentioned in table 
3.9. The gel was polymerized for 30 minutes at room temperature. To smoothen the 
surface of the gel and to remove any air bubbles at the top of the resolving gel, 
Isopropanol was overlayed. The stacking gel was applied to the top of the resolving gel 
after complete removal of isopropanol, and left to polymerise for 30 minutes. The gels 
were assembled and placed into the Biorad Mini-PROTEAN® Gel Chamber and 1× SDS 
running buffer was added. The samples were loaded into the wells of the gel together 
with PageRuler™ Plus Prestained Protein Ladder (Fermentas) and Low Molecular Weight 
(LMW) marker (GE Healthcare, UK ) and were run at 80-120 V until the Bromophenol 
blue dye of the samples reached the bottom of the gel. 
32 
 
 
3.22.1. Solutions used for SDS-PAGE  
      5X SDS-sample buffer (10 ml)  1X SDS-running buffer (pH 8.3) 
0.125M Tris/HCl (pH 6.8)  2.5 ml [0.5M]  25 mM Tris-base 
4% SDS   4 ml [10%]  192 mM Glycine 
20% Glycerol   2 ml    0.1% SDS 
10% ß-mercaptoethanol 1 ml 
Bromophenol blue  0.005% (w/v) 
 
 
Table 3.9: Composition of SDS-PA gels for both the resolving and stacking gel.  
 
 Resolving gel  Stacking gel 
 10% 12% 4% 
1.5M Tris/HCl (pH 8.8) 2.5ml 2.5ml  
0.5M Tris/HCl (pH 6.8)   2.00ml 
s30% Polyacrylamide 3.34ml 4.0ml 1.33ml 
10% SDS 100µl 100µl 100µl 
Water 4.0ml 3.40ml 6.56ml 
10%APS 22µl 22µl 30µl 
TEMED 10µl 10µl 16µl 
 
3.23. Staining of polyacrylamide gels with Coomassie-Brilliant-Blue R 250 
Proteins separated on polyacrylamide gels were stained with Coomassie-Brilliant-Blue R 
250 solution for 20 minutes at room temperature. The excess staining was removed with 
destaining solution.  
Coomassie-Blue stain solution (1L) 
Brilliant-Blue R250 (Sigma)  2.5 g (Final conc. 0.25%) 
Ethanol absolute    500 ml (Final conc. 50%) 
Acetic acid    100 ml (Final conc. 10%) 
Destain solution (1L) 
Acetic acid    70 ml (Final conc. 7%) 
Ethanol absolute    200 ml (Final conc. 20%) 
3.24. Protein transfer to membranes (Western blot) 
Wet blotting was performed to transfer the proteins from gels to a nitrocellulose 
membrane (PROTRANR, Germany). The nitrocellulose membrane was soaked in blotting 
buffer together with thick blotting papers for 15 minutes. The gel and membrane were 
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sandwiched between sponge and paper and all were clamped tightly together after 
ensuring that no air bubbles had formed between the gel and the membrane. The order of 
gel and membrane from anode to cathode was blotting paper, membrane, gel and blotting 
paper. The sandwich is submerged in transfer buffer. Transfer was at 4°C overnight, and 
an electrical field of 10-15 V was applied depending on the size of protein. The 
negatively-charged proteins travel towards the positively-charged electrode, but the 
membrane stops them, binds them, and prevents them from continuing on. 
Wet blot buffer (1L) 
Glycine (193 mM)   14 g 
Tris-base (25 mM)    3 g 
Absolute ethanol (20%)   50 ml 
3.25. Immunodetection of proteins bound to the membrane 
The nitrocellulose membrane was blocked with 5% milk powder (non-fat dry milk) solution 
prepared in 1X TBS-T buffer for one hour to prevent unspecific binding of proteins. After 
blocking, the membrane was incubated with primary antibody diluted in TBS-T for 
overnight at 4°C. After washing three times each for 5 minutes with 1X TBS-T buffer, the 
membrane was incubated with an appropriate peroxidase-coupled secondary antibody 
(1:10,000 dilution) for one hour. Afterwards, the membrane was washed three times each 
for 5 minutes the blots were developed using the enhanced chemiluminescence (ECL) 
system. The membrane was exposed to an X-ray film and developed by using developer 
and fixer solutions. 
10x Tris-buffered saline (TBS) (500ml) 
1 M Tris/HCl (pH 7.4)  100 ml 
5 M NaCl   137 ml 
The volume was increased to 500 ml by adding water 
1x Tris-buffered saline-Tween 20 (TBS-T) 500 ml 
10XTBS Buffer  50 ml 
Tween 20 (Sigma)  5.0 ml 
Water    445 ml 
The solution was pipet up and down to dissolve Tween-20 
Enhanced chemiluminescence (ECL) detection solution (20ml) 
Luminol (0.25 M)  200 µl 
p-Cumaric acid (0.09 M) 89 µl 
1M Tris/HCl (pH 8.5)  2 ml 
The volume was Increased to 20 ml by adding water 
Add 6.1 µl of 30% H2O2 directly before use. 
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3.26. Immunocytochemistry  
Patients and control primary fibroblasts were cultured on 12 mm coverslips and fixed with 
3% paraformaldehyde. Permeabilization was done by 0.5% Triton X-100 in 1X PBS buffer 
for 4 minutes at room temperature. Subsequently the fixed cells were treated three times 
with 1X PBS. Blocking was done for 15 minutes with blocking buffer (1x PBG: PBS 
containing 5% BSA and 0.45% fish gelatine). Primary antibodies were diluted in blocking 
buffer and incubation was done overnight at 4°C. The following antibodies were used: 
mouse monoclonal CDK6 antibody (Abcam, ab54576) 1:200, rabbit polyclonal anti 
CEP135 (Abcam, ab75005) 1:500, rabbit polyclonal anti CEP135 (Bethyl Laboratories, 
Inc. A302-250A) 1:500, rabbit polyclonal anti Pericentrin (Abcam, ab4448) 1:300, mouse 
monoclonal anti--tubulin (Sigma, GTU-88) 1:300, rat monoclonal anti Y/L1/2 (Kilmartin et 
al., 1982) 1:20. After incubation with 1X PBS three times for 5 minutes, secondary 
antibodies (1:1,000 diluted in blocking buffer) were added for one hour at room 
temperature. As secondary antibodies, Alexa Fluor 568 goat anti-mouse IgG (Invitrogen, 
A11004), Alexa Fluor 647 donkey anti-rabbit IgG (Invitrogen, A31573), Alexa Fluor 647 
donkey anti-mouse IgG (Invitrogen, A31571), Alexa Fluor 488 goat anti-rat IgG 
(Invitrogen, A11006) and Alexa Fluor 568 goat anti-rabbit IgG (Invitrogen, A11011). DNA 
was detected with 4’,6-Diamidino-2’-phenylindole (DAPI) (Sigma, D9564). Finally the cells 
were mounted on glass slides with gelvatol. Images were taken by confocal microscopy 
(Leica, LSM TCS SP5). 
3.26.1.  Immunostaining of microtubules 
For staining microtubules, cells were fixed in 3% paraformaldehyde prepared in tubulin 
stabilization buffer for 15 minutes and permeabilized in 0.5% Triton X-100 in 1X tubulin 
stabilization buffer. All washing steps before blocking were performed with 1X tubulin 
stabilization buffer. Blocking and staining steps are as described in 
"immunocytochemistry". 
3.26.2.  Immunostaining of -tubulin  
For -tubulin detection, the cells were permeabilized with prechilled absolute methanol for 
10 minutes at -20°C. Blocking and staining steps are same as described in 
immunocytochemistry. 
3.26.3.  Solutions used for immunocytochemistry  
3% Paraformaldehyde 
3 g PFA were dissolved in 80 ml 1x PBS by heating this solution up to 50°C, while stirring 
0.4M NaOH was added drop wise until PFA was dissolved. The pH was adjusted to pH 
6.1 and the volume was filled up to 100 ml with H2O. 
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Gelvatol  
Poly(vinyl alcohol) 87-89% hydrolyzed, [-CH2CHOH-]n, MW 13-23,000 (Sigma Aldrich, 
P8136). 4.8 g gelvatol in 24 ml glycerol (50%) was added. After stirring gently for several 
hours, 24 ml Tris/HCl (0.2M), pH 8.5, was added. The solution was heated to 50°C for 10 
minutes with gentle stirring, until it was clarified. Centrifugation was conducted at 5,000 g 
for 15 minutes in 50 ml-falcon tubes, then 1.3 g of DABCO (=1,4-diazobicyclo-[2.2.2]-
octane) (Sigma Aldrich, D2522) was added. Aliquots were prepared in 2 ml-syrynges and 
stored at –20°C. 
10x Triton X-100 
2.5 ml of Triton X-100 was dissolved in 20 ml of 1x PBS. As Triton X-100 is very viscous, 
it takes some time to dissolve. After dissolving, the falcon tube was centrifuged to 
determine the exact quantity of the solution and the volume adjusted to 25 ml by adding 
more 1x PBS.  
0.5% Triton X-100  
2.5 ml of 10x Triton X-100 were dissolved in 47.5 ml of 1x PBS. Both stock and working 
dilution were stored at 4°C. 
Note: For microtubule staining, Paraformaldehyde and Triton X-100 were prepared in 1x-
tubulin stabilization buffer instead of PBS (Phosphate Buffered Saline). 
1x Tubulin-stabilisation buffer (TSB) (1L) (pH 6.1) 
Hank’s Buffer (10x)  100 ml 
1 mM MES   10 ml (0.1 M)  
2 mM EGTA   20 ml (0.1 M) 
2 mM MgCl2   2 ml (1.0 M) 
The pH was adjusted with HCl (20%). 
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Hank’s buffer  
Table 3.10: Composition of Hank’s Buffer  
 1x (g) 5x (g) 10x (g) 
137mM NaCl 4.0 20 40 
5mM KCl 0.186 0.93 1.86 
1.1mM Na2HPO4 0.078 0.93 0.78 
0.4mM KH2PO4 0.0272 0.136 0.272 
5mM Glucose 0.45 2.25 4.5 
4mM NaHCO3 0.168 0.84 1.68 
 
3.27. Immunohistochemistry of paraffin-embedded embryo sections 
Wild-type mouse embryos at E11.5 and E15.5 were fixed with 4% paraformaldehyde 
overnight. Embryos were washed with PBS (without Ca/Mg), stored in 70% ethanol and 
embedded in paraffin. Paraffin-embedded sections (6 m) were de-paraffinized and heat-
mediated antigen retrieval was performed. Sections were blocked with PBG for 2 hours at 
room temperature. Primary mouse-monoclonal CDK6 (Abcam, ab54576), rabbit-
polyclonal CEP135 (Abcam, ab75005) and chicken anti-nestin (Neuromics, CH23001) 
antibodies diluted in PBG were incubated with the sections overnight at 4°C. Sections 
were washed with PBS, and incubated with fluorescent conjugated secondary antibodies 
(Invitrogen-Molecular Probes) for 1 hour. Nuclei were visualized with 4’, 6-Diamidino-2’-
phenylindole (DAPI). After 3 washes with PBS, sections were mounted and imaged with a 
Leica confocal microscope. 
3.28. Confocal microscopy 
The images were taken by confocal laser scanning microscopy (Leica, LSM TCS SP5) 
with 60 and 100X objectives. Images were analysed by Leica-TCS-SP5/LAS-AF-
Lite_2.0.2_2038 and processed using Photoshop. 
3.29. Antibodies used for immunofluorescence and western blotting  
Antibodies         Source     Dilution 
Primary antibodies for immunofluorescence 
Mouse monoclonal CDK6 antibody (Abcam, ab54576)        1:200 
Rabbit polyclonal anti CEP135   (Abcam, ab75005)        1:500 
Rabbit polyclonal anti CEP135 (Bethyl Laboratories, Inc. A302-250A) 1:500 
Rabbit polyclonal anti Pericentrin  (Abcam, ab4448)        1:300 
Mouse monoclonal anti--tubulin   (Sigma, GTU-88)       1:300 
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Rat monoclonal anti Y/L1/2   (Kilmartin et al., 1982)      1:20  
Chicken anti-nestin    (Neuromics, CH23001)    1:200 
Secondary antibodies for immunofluorescence 
Alexa Fluor 568 goat anti-mouse IgG  (Invitrogen, A11004)       1:10,000 
Alexa Fluor 647 donkey anti-rabbit IgG  (Invitrogen, A31573)       1:10,000 
Alexa Fluor 647 donkey anti-mouse IgG  (Invitrogen, A31571)       1:10,000 
Alexa Fluor 488 goat anti-rat IgG  (Invitrogen, A11006)        1:10,000 
Alexa Fluor 568 goat anti-rabbit IgG  (Invitrogen, A11011)       1:10,000 
Primary antibodies for western blotting 
Mouse monoclonal CDK6 antibody  (Abcam, ab54576)        1:500  
Rabbit polyclonal anti CEP135   (Abcam, ab75005)        1:500 
Mouse monoclonal anti-β-Actin   (Sigma, A5316)        1:10,000   
Secondary antibodies for western blotting 
Anti-mouse IgG peroxidase conjugated  (Sigma, A4416)        1:10,000  
Anti-rabbit IgG peroxidase conjugated  (Sigma, A6154)        1:10,000 
DNA staining agent 
4’,6-Diamidino-2’-phenylindole (DAPI)  (Sigma, D9564)   
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4. Results 
4.1. Genotyping of primary microcephaly families 
PCR based genotyping of 30 autosomal recessive primary microcephaly families was 
performed by using highly polymorphic fluorescently labelled microsatellite markers of 
each known MCPH locus (Figure 4.1).  
 
Figure 4.1: Electropherograms of the M19SH2 marker analyzed within the MCP14 family 
with the ABI GeneMapper® v.3.5. MCP14-3 is the patient and shows homozygosity for the 
M19SH2 marker with allele size 324 bp, while MCP14-11 is a heterozygous normal sib 
having one mutant allele, size 324 bp and one normal allele, size 340 bp.   
Homozygosity mapping of 30 families revealed linkage of 19 families to MCPH5, of one 
family to MCPH1, of two families to MCPH2, of two to MCPH4 andof one to the MCPH6 
locus. Five families were not linked to any of the known MCPH loci (Table 4.1). MCPH 
heterogeneity clearly shows that the majority of families were linked to MCPH5 locus 
(Figure 4.1). 
 Table 4.1:  Linkage analysis of thirty primary microcephaly families. 
 
 MCPH1 MCPH2 MCPH4 MCPH5 MCPH6 Excluded Total 
No. of 
families 
1 2 2 19 1 5 30 
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Figure 4.2: A pie chart illustrating the linkage status of MCPH families. Among 30 primary 
microcephaly families, 63.3% (blue colored) were linked with MCPH5 locus, 3.33% (black) 
with MCPH1, 6.67% (red) with MCPH2, 6.67% (green) with MCPH4, 3.33% (cyan) with 
MCPH6 and 16.7% (magenta) were excluded with all known MCPH loci. 
 
4.2. MCPH1 linked family 
The MCP61 family is a large consanguineous family with four afflicted members (Figure 
4.3a). All four patients with normal parents and one normal sib were subjects of this 
study.  
Genome-wide linkage analysis was performed prior to linkage or exclusion with 
microsatellite markers in family MCP61. Genome-wide screens for regions of linkage with 
Affymetrix GeneChip(R) Human Mapping 250K SNP Array (version 2.0) show the linkage 
to the MCPH1 locus. Parametric linkage analysis showed the peak on chromosome 8 
with maximum possible LOD score of 3.13 (Figure 4.3b).  
This region maps between SNPs rs922798 (6.45cM and 3,481,618bp) and rs12898 
(23.19cM and 11,701,198bp) and results in a 8.21 Mb region (Figure 4.4). The MCPH1 
gene also resides in this region. The 14 exons of MCPH1 were sequenced in all afflicted 
members, one normal sister and both parents of the MCP61 family. One novel mutation 
(c.1178delG) was found in this family and could not be detected in 200 healthy control 
chromosomes of the same ethnic group (Figure 4.5). Deletion of a single nucleotide G 
(c.1178delG) causes a frameshift incorporating 49 amino acids before resulting in a stop 
codon (p.R393Sfs*50).  
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Figure 4.3: Pedigree and genome-wide graphical view of the MCP61 family. (a) 
Pedigree of family MCP61 with four afflicted sibs and one normal sib along with the 
parents, showing an recessive mode of inheritance. (b) Genome-wide graphical view of 
the MCPH1 locus and the result of parametric linkage analysis showing LOD scores 
(3.13) on chromosome 8. 
 
 
 
(a) 
(b) 
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Figure 4.4: The region of chromosome 8 showing the haplotype of the MCP63 family 
linked with the MCPH1 locus (MCPH1 gene).  
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Homozygous mutant c.1178delG (MCP61-1)           wild type 
G A A G G C A - G C T G C A G                      G A A G G C A G G C T G C A  
Heterozygous mutant c.1178delG (MCP61-6)     Heterozygous mutant  
 c.1178delG (MCP61-7) 
G A A G G C A - G N N N N C N                       G A A G G C A G N N N N C N C  
Figure 4.5: Sequencing chromatograms of c.1178delG. This mutation was identified in 
exon 8 of MCPH1. Black arrows indicate the position of mutations where G is deleted. 
Lower chromatograms represent the heterozygous parents (MCP61-6 and MCP61-7).                                      
 
4.3. MCPH2 linked families 
Two primary microcephaly families, MCP14 (Figure 4.6) and MCP59 (Figure 4.9), were 
linked with the MCPH2 locus which was originally mapped at chromosome 19q13.1-13.2 
between the polymorphic markers D19S416 and D19S420.  This 7.6 cM region was 
resolved in the MCP14 family. To achieve this, highly polymorphic microsatellite markers 
were selected by using the Human STR Finder (http://portal.ccg.uni-koeln.de/cgi-
bin/repfinder.pl) and by designing primers with Primer3 v. 0.4.0 (Rozen and Skaletsky, 
2000) within the region of the already described locus. The linkage interval was narrowed 
from 7.6 cM to 2.8 cM, which is 1/3 of the reported region. The previously reported region 
has its upper boundary at marker D19S416 and the lower at marker D19S420. I have 
detected heterozygosity at marker M19SH2 (61.5cM) in the MCP14-7 afflicted individual 
which defines the lower region of the MCPH2 locus at M19SH2 (61.5cM). So the new 
minimum linkage interval is defined by the markers D19S416 (58.7cM) and M19SH2 
(61.5cM) at chromosome 19q13.11-19q13.12 which is 2.8 cM (NCBI Human Genome 
Build 36.3) (Figure 4.7).  
To confirm this reduced linkage interval, homozygosity mapping was performed with the 
help of SNP marker of chromosome 19 which define the correct reduced linkage interval 
of the MCPH2 locus mapped between SNP_A-2299150 (rs3786913, physical position 
38,678,914bp) and SNP_A−2230690 (rs2271844, physical position 41,592,850bp) (NCBI 
Huamn Genome Build 36.3) (Figure 4.8). This 2.91 Mb region is the reduced linkage 
interval of the MCPH2 locus. 
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Figure 4.6: Pedigree of the MCPH2 linked family. MCP14 is a large consangineous 
family having six afflicted individuals. 
 
Figure 4.7:  Haplotype of the family MCP14 linked to the MCPH2 locus. The already 
defined locus (between markers D19S416 and D19S224 which was 7.6 cM) was narrowed 
to 2.8 cM between markers D19S416 and M19SH2. The data for the second loop of this 
family is not shown here.  
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Figure 4.8: Haplotype analysis of family MCP14 with the MCPH2 locus. Marker 
names and positions are displayed on the left side of each generation. The disease 
haplotype fragments are indicated with red boxes.  
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Figure 4.9: Pedigrees of family MCP59 with haplotypes of the MCPH2 locus. Marker 
names and positions are displayed on the left side of each generation. The disease 
haplotype fragments are indicated with red boxes. 
 
There are 89 genes in this 2.91 Mb region (NCBI Human Genome Build 36.3). Among 
these 89, the following genes were selected and sequenced: myelin associated 
glycoprotein (MAG), sodium channel, voltage-gated, type I, beta (SCN1B), amyloid beta 
(A4) precursor-like protein 1 (APLP1), carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 8 (CHST8), glucose phosphate isomerase (GPI), CAP-GLY domain 
containing linker protein 3 (CLIP3), potassium channel tetramerisation domain containing 
15 (KCTD15), and ubiquitin-like modifier activating enzyme 2 (UBA2). No mutation was 
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found in any of the above mentioned genes except for one substitution (IVS7+13C>T) in 
the intronic region of MAG in the MCP14 family. Family MCP59 was negative for any kind 
of mutation in MAG. 
Recently WDR62 (position 41,237,623 bp to 41,287,852 bp NCBI Human Genome Build 
36.3) has been identified as a causative gene of the MCPH2 locus (Yu et al., 2010; 
Nicholas et al., 2010). I  sequenced our MCPH2 linked families for WDR62 which 
comprises 32 exons. The sequencing data demonstrates the identification of two novel 
mutations in the WDR62 gene (Figure 4.10). In the MCP14 family a missense mutation 
(c.332G>C) replaces C with G which results in the change of Arginine to Threonine 
(p.R111T) in exon3 of WDR62. In MCP59, the nonsense mutation c.3503G>A introduces 
a premature stop codon p.W1168* in exon 29 of WDR62.       
Homozygous mutant c.332G>C (MCP14-7)   Wild type  
A A C A C C G C C A C G T A G G C T G A G           A A C A C C G C C A G G T A G G C T G A G  
Heterozygous mutant c.332G>GC (MCP14-1)  
A A C A C C G C C A N G T A G G C T G A G  
Homozygous mutant c.3503G>A (MCP59-1)  Wild type 
T G G A G G C C T A G C G C C C A C C        C T G G A G G C C T G G C G C C C A C C  
Figure 4.10: Sanger electropherograms for the WDR62 gene showing variants 
c.332G>C and c.3503G>A in MCP14 (upper traces) and in MCP59 (lower traces) 
respectively. Black arrows indicate the position of the mutations. 
 
4.4. MCPH4 linked families 
Two families MCP8 and MCP59 were linked with the MCPH4 locus. Both families are 
small and consanguineous (Figure 4.11). 
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Figure 4.11: Pedigrees of the MCPH4 linked families. MCP8 and MCP66 contain three 
and one afflicted individual respectively and show recessive modes of inheritance. 
 
Homozygosity mapping of the MCP8 and the MPC66 families with microsatellite markers 
supported the linkage of these families to the MCPH4 lcous which was further confirmed 
by genome-wide linkage analysis with the Affymetrix GeneChip(R) Human Mapping 250K 
SNP Array (version 2.0) (Figure 12). 
The already reported MCPH4 locus mapped on chromosome 15q15-q21 within 19 cM 
observed between markers ACTC and D15S98. Genome-wide linkage data of the MCP8 
and MPC66 families did not reduce the linkage interval. Genome-wide analysis of three 
further families from Belgium and Denmark reduced this 19 cM critical linkage interval to 
2.08 Mb mapped between rs936532 (37,585,407 bp) and rs1819454 (39,669,675 bp). 
This newly defined region of 2.08 Mb on chromosome 15q14-15q15.1 harboured 59 
genes (NCBI Human Genome Build 36.3). Candidate genes were selected for 
sequencing which have mitotic functions, centrosomal or spindle pole localization, 
embryonic brain expression or play a role in neurogenesis. Among these 59 genes, 
BUB1B, PAK6, INOC1, ITPKA, NUSAP1, OIP5 and THBS1 were sequenced. Tubulin 
gamma complex associated protein 4 (TUBGCP4) which is located in the larger 19 cM 
region was also sequenced. No mutation was found in these genes. 
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Figure 4.12: Genome-wide graphical view of the MCPH4 families. (a) Parametric 
linkage analysis (Allegro software) showing a large and wider peak (LOD = 2.6) on 
chromosome 15q13.1-15q22.2 for the MCPH4 locus. This locus in the MCP8 family is 
mapped between SNP_A-2263685 (rs768547, position: 25,774,538bp, 15.62cM) and 
SNP_A-4290104 (rs11636064 position 57,660,153bp 59.68cM). (b) The region of family 
MCP66 mapped between SNP_A-1816205 (rs11856348, position 35,979,748bp, 
37.42cM) and SNP_A-2091012 (rs17663920 position 51,954,110bp, 51.87cM) on 
chromosome 15q14-15q21.3. 
 
Only one substitution c.2437G>T was found in the leukocyte receptor tyrosine kinase 
(LTK) which results  in a missense mutation p.E813* creating a stop codon (Figure 4.13). 
(a) 
(b) 
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This substitution was only found in the MCP8 family and could not observed in the 
MCP66 and other families from Denmark and Belgium. However, c.2437G>T was not 
found in 768 Pakistani healthy control chromosomes (Figure 4.14).  
Homozygous mutant c.2437G>T         Wild type 
C A G A T C T T T G T A G T G C C T A A G       C A G A T C T T T G G A G T G C C T A A G  
Figure 4.13 Sequencing chromatograms illustrate the c.2437G>T (p.E813*) mutation in 
the MCP8 family (LTK gene). Black arrows indicate the position of mutation where G is 
replaced by T which introduces a stop codon. 
 
1300
1400
E S G A C T A G A T C
C/C
5  
Figure 4.14: Pyrogram traces obtained by Pyrosequencing analysis of the c.2437G>T 
mutation in exon 20 of Pakistani control samples which were negative for the c.2437G>T 
mutation in LTK. 
4.4.1. MCP8 family region on chromosome 1 
Homozygosity mapping of the MCP8 family by genome-wide linkage analysis with the 
Affymetrix GeneChip(R) Human Mapping 250K SNP Array (version 2.0) revealed a 
narrow peak on chromosome 1p31.3-1p31.1 (Figure 4.12). This region is mapped 
between SNP_A−1829175 (rs855325 position 63,837,368bp) and SNP_A−2270971 
(rs6658302 position 77,681,573bp). 95 genes reside within this 13.84 Mb region (NCBI 
Human Genome Build 36.3). 
4.5. MCPH5 linked families 
4.5.1. Haplotypes of MCPH5 linked families 
The pedigrees and haplotypes of 19 families linked with the MCPH5 locus (ASPM gene) 
were constructed with the help of HaploPainter v.1.043 (Thiele et al., 2004) and 
EasyLinkage Plus v5.02 (Lindner et al., 2005) respectively (Figure 4.15). For small 
pedigrees and large sets of markers, Two-/MultiPoint Para-/NonParametric Linkage 
Analysis was performed with the help of Allegro v1.2c and for larger pedigrees and small 
sets of markers, Multipoint Linkage Analysis was performed with the help of SimWalk 
v2.91.  
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Figure 4.15: Pedigrees and haplotype analysis of the MCPH5 families. 19 families 
were linked with the MCPH5 locus. Locus specific microsatellite markers were selected 
and genotyped within all microcephaly families. Marker names and positions are displayed 
on the left side of each generation. Their disease haplotype fragments are indicated with 
red boxes. 
 
4.5.2. Abnormal Spindle-like Microcephaly associated (ASPM) Sequencing 
The Abnormal Spindle-like Microcephaly associated (ASPM) gene was identified as the 
causative gene for the MCPH5 locus (Bond J et al., 2002). The ASPM gene is the human 
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ortholog of the Drosophila melanogaster 'abnormal spindle' gene (asp), which is essential 
for normal mitotic spindle function in embryonic neuroblasts. ASPM is a large gene with 
28 exons having an ORF (Open Reading Frame) of 10.4 kb. It spans 62 kb of genomic 
sequence and encodes a protein with 3,477 amino acids. The mutation in the ASPM gene 
is the major cause of primary microcephaly in the Pakistani population (Bond et al., 
2003).  
MCPH5 linked families were subjected to a screen of the ASPM gene via direct DNA 
sequencing. To sequence the ASPM gene, a set of 43 primer pairs was designed using 
Primer3 v. 0.4.0 (Rozen and Skaletsky, 2000), which covers all 28 exons and exon-intron 
boundaries of this gene. Two afflicted and one normal individual of each MCPH5 linked 
family with one normal control were sequenced using Sanger sequencing.  
Five previously reported (p.W1326*, p.Y3164*, p.R3244*, p.K1862E, and p.Y3263*) and 
eight novel mutations (p.L333fs, p.Q2890*, p.Y3163*, p.R1019*, c.3977G>A (p.W1326*), 
p.R1327*, p.N2734Lfs*16, and p. L2837Mfs*35) were identified in the ASPM gene. The 
results are summarized in table 4.2.  
Table 4.2: Novel and known mutations in the ASPM gene. 19 MCPH5 linked families 
demonstrated eight novel and five known mutations. Novel mutations in families MCP2, 13, 16 
and 19 were published with (Muhammad et al., 2009). Novel mutations are highlighted red. 
Family 
ID cDNA mutation Protein Mutation Exon Status of Mutation
MCP2 c.1002delA p.L333fs 3 Novel  
MCP13 c.9492T>G p.Y3163* 23 Novel 
MCP16 c.8668C>T p.Q2890* 18 Novel  
MCP19 c.3055C>T p.R1019* 11 Novel  
MCP31 c.3978G>A p.W1326* 17 Known 
MCP34 c.3978G>A p.W1326* 17 Known 
MCP48 c.3977G>A p.W1326* 17 Novel 
MCP52 c.3978 G>A p.W1326* 17 Known 
MCP54 c.9730C>T p.R3244* 24 Known 
MCP55 c.5584A>G p.K1862E 18 Known+ 
MCP55 c.9492T>G p.Y3164* 23 Known++  
MCP56 c.3978 G>A p.W1326* 17 Known 
MCP57 c.3978G>A p.W1326* 17 Known 
MCP58 c.3979C>T p.R1327* 17 Novel 
MCP60 c.9789T>A p.Y3263* 24 Known 
MCP62 c.8668C>T p.Q2890* 18 Novel+++ 
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MCP64 c.3978 G>A p.W1326* 17 Known 
MCP65 c.3978G>A p. W1326* 17 Known 
MCP69 c.8200-8201delAA p. N2734Lfs*16 18 Novel 
MCP70 c.8507-8508delAG p. L2837Mfs*35 18 Novel 
+This could be the rare polymorphism or might have association with the diseased variant 
(p.Y3164*).  
++The mutation c.9492T>G (p.Tyr3164*) is in cis to the missense mutation c.5584A>G 
(p.Lys1862Glu). The latter had previously been found in one MCPH family in homozygous state 
and deemed to be pathogenic (Darvish et al., 2010). 
+++ p.Q2890* mutation was identified in two differnt families, MCP16 and MCP62. 
 
A nonsense mutation (c.3977G>A, p.W1326*) was observed in family MCP48 which 
changes nucleotide G at position 3977 of the cDNA instead of position 3978 which has 
already been reported (Figure 4.16). All of these mutations (except c.5584A>G, 
p.K1862E) are truncating the protein so it is likely that they all resul in nonsense mediated 
mRNA decay. 
Homozygous mutant c.1002delA   wild type 
A A C T A G A A T T - G T A A C A T G T            A A C T A G A A T T A G T A A C A T G T  
Homozygous mutant c.9492T>G   wild type 
T T C A G A A A T A G C A T A G C A T C A          T T C A G A A A T A T C A T A G C A T C A  
Homozygous mutant c.8668C>T   wild type 
A G T G G T T T T A T A A A A T C A C T A C           A G T G G T T T T A C A A A A T C A C T  
Homozygous mutant c.3055C>T   wild type 
T C T T A A A T C A T G A G G A A T T G A A          T C T T A A A T C A C G A G G A A T T G A A  
Homozygous mutant c.3977G>A   wild type 
C A G A A A T A T T A G C G A A G A G T C           C A G A A A T A T T G G C G A A G A G T C  
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Homozygous mutant c.9730C>T   wild type 
T A G G G A G A T T T G A G A A G A A A A           T A G G G A G A T T C G A G A A G A A A A  
Homozygous mutant c.5584A>G   wild type 
C A G G G C G T A C G A G A C T C T T C A           C A G G G C G T A C A A G A C T C T T C A  
Homozygous mutant c.9492T>G   wild type  
T T C A G A A A T A G C A T A G C A T C            T T C A G A A A T A T C A T A G C A T C  
 
Homozygous mutant c.9789T>A   wild type 
T T T T G A C A T A A A A G C A C C T T           T T T T G A C A T A T A A G C A C C T T T  
Homozygous mutant c.8668C>T   wild type 
A G T G G T T T T A T A A A A T C A C T A           A G T G G T T T T A C A A A A T C A C T  
Homozygous mutant c.8200-8201delAA  wild type 
G A A A G A A A A - - C T T T T T A G C A           G A A A G A A A A A A C T T T T T A G C A  
Homozygous mutant c.8507-8508delAG  wild type 
T G G A A A C A C - - A A A T G T G C T         T G G A A A C A C A G A A A T G T G C T  
Figure 4.16: Chromatograms of ASPM mutations in MCPH5 families. Representative 
Sanger traces illustrate different novel mutations identified in ASPM. Mutant chromatograms 
are depicted on the left while wild-type chromatograms are found on the right. Black arrows 
indicate the position of the mutation. 
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4.6. MCPH6 linked family 
One family (MCP24) was linked to the MCPH6 locus (CENPJ gene) and was excluded to 
be linked to all other known MCPH loci. The family consists of four afflicted individuals 
from consanguineous parents (Figure 4.17). 
 
Figure 4.17: Haplotype analysis of the MCP24 family linked with the MCPH6 locus. 
Marker names and positions (cM) are displayed on the left side of each generation. The 
disease haplotype fragments are indicated with red boxes. 
 
The causative gene for the MCPH6 locus is the centromere associated Protein J (CENPJ; 
MIM609279), also known as centrosomal protein 4.1- associated protein (CPAP). This 
gene contains 17 exons and spans 39.8 kb on human chromosome 13q12.2 (Bond et al., 
2005). To sequence the 17 exons and exon-intron boundaries of the CENPJ gene, 
primers were designed using Primer3 v. 0.4.0 (Rozen and Skaletsky, 2000). The CENPJ 
gene was sequenced in family MCP24 (linked to the MCPH6 locus). Sequencing analysis 
identified one known homozygous deletion c.17delC (Figure 4.18). The single base 
deletion causes a frameshift that incorporates two amino acids and then introduced stops 
codon (p.T6fs*3).  
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Homozygous mutant c.17delC (MCP24-4)   wild type  
C T G A T G C C A A - C T C T T C A G A G             C T G A T G C C A A C C T C T T C A G A G  
 
Heterozygous mutant c.17delC (MCP24-5)      Heterozygous mutant c.17delC  
                                                                             (MCP24-8) 
C T G A T G C C A A - C N N N T N C A A A             C T G A T G C C A A - C N N N T N C N A A  
Figure 4.18: Sequencing chromatograms of the c.17delC mutation identified in exon 2 
of CENPJ. Black arrows indicate the position of the mutation where C is deleted. Lower 
chromatograms represent the heterozygous parents (MCP24-5 and MCP24-8). 
 
4.7. Excluded families 
PCR based Genotyping of 30 autosomal recessive primary microcephaly families 
revealed exclusion of five families. These families were not linked to any of the known 
MCPH loci and were a unique source for the identification of further genes underlying this 
disorder. These families were MCP4, MCP50, MCP53, MCP63 and MCP67. 
4.8. Excluded family MCP4 
MCP4 is a large consanguineous family with seven afflicted individuals (Figure 4.19) and 
was ascertained from remote regions of Pakistan. The patients have the typically sloping 
forehead and are mentally retarded without any other abnormalities. After exclusion of 
linkage with all known seven MCPH loci, the family was subjected to a genome-wide 
screen for regions of linkage with the Affymetrix GeneChip(R) Human Mapping 250K 
SNP Array (version 2.0) on all seven afflicted children (MCP4-1, MCP4-2, MCP4-3, 
MCP4-6, MCP4-9, MCP4-10 and MCP4-15), two unafflicted siblings (MCP4-11 and 
MCP4-12), and the parents (MCP4-13 and MCP4-14)  
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Figure 4.19: Pedigree of the MCP4 family with the MCPH8 locus. The members denoted 
with MCP were subjected to the genome screen.  
 
4.8.1. MCPH8 locus identification 
Genome-wide linkage analysis revealed the identification of one novel gene locus 
MCPH8 on chromosome 7q21.11-q21.3. The genome-wide graph shows a single clear 
peak on chromosome 7q21.11-q21.3 with a LOD score of 10.47 which reaches the 
theoretical maximum of primary microcephaly families as shown in figure 4.20. This locus 
maps between SNP_A-1844880 (rs17159934, position 84,908,672bp) and SNP_A-
1990585 (rs42511 position 92,662,815bp) and comprises a region of 7.75 Mb (Figure 
4.21).  
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Figure 4.20. Genome-wide graphical view of the MCPH8 locus. (a) Parametric linkage 
analysis (Allegro software) showing a single peak (LOD = 10.47) on chromosome 
7q21.11-q21.3 for the MCPH8 locus. The calculated LOD score (10.47) reaches the 
theoretical maximum LOD score of primary microcephaly families. (b) Results of the 
parametric linkage analysis showing LOD scores on chromosome 7. The red line shows 
the position of CDK6 (causative gene of MCPH8 locus). 
 
 
(a)
(b) 
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Figure 4.21: Haplotypes of the MCPH8 linked family. Haplotype analysis of the MCP4 
family linked to chromosome 7q21.11-q21.3. Due to large family size, the haplotype is 
divided into five parts (a to d), each part represent one loop of the family. Black symbols 
represent afflicted individuals. The critical interval was defined by the recombinations 
observed for markers from SNP_A-1844880 (rs17159934, physical position 
84,908,672bp) to SNP_A-1990585 (rs42511 physical position 92,662,815bp) comprising 
7.75 Mb region. Here only the region near CDK6 is shown. 
 
 
 
(a) (b) (c) 
(d) (e) 
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4.8.2. Candidate genes in the MCPH8 locus 
A bioinformatical analysis of the MCPH8 (7.75 Mb) region was performed to seek the 
candidate genes. 49 known and predicted genes (NCBI Human Genome Build 36.3) were 
found in this region (Figure 4.22).  
 
Figure 4.22: G-banded chromosome 7 showing the position of the MCPH8 locus 
along with the position of the genes on the long arm 7q21.11-q21.3. The locus was 
mapped between SNP_A-1844880 (rs17159934, physical position 84908672bp) and 
SNP_A-1990585 (rs42511 physical position 92662815bp) (NCBI Human Genome Build 
36.3). This 7.75 Mb region harbours 49 genes. Blue and red coloured genes were 
sequenced because they have the highest expression in human brain and have a role in 
the cell cycle.  
 
4.8.3. Candidate genes sequencing in the MCPH8 locus 
As autosomal recessive primary microcephaly is a disorder of neurogenic mitosis I 
selected those genes for sequencing which have mitotic functions, centrosomal or spindle 
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pole localization, embryonic brain expression or a role in neurogenesis. Among these 49 
genes, Cyclin D binding myb-like transcription factor 1 (DMTF1), DBF4 homolog (DBF4), 
ADAM metallopeptidase domain 22 (ADAM22), PFTAIRE protein kinase 1 (PFTK) also 
known as cyclin-dependent kinase 14 (CDK14), A kinase (PRKA) anchor protein (yotiao) 
9 (AKAP9), Hypothetical protein DKFZp564O0523 (DKFZP564O0523) also known as 
chromosome 7 open reading frame 64 (C7orf64) and cyclin-dependent kinase 6 (CDK6) 
genes were considered the strongest candidate genes. AKAP9 and Pericentrin (PCNT) 
are orthologs of the yeast Spc110 protein and a mutation in Pericentrin is the cause of 
Microcephalic osteodysplastic primordial dwarfism-type Majewski II (MOPD-II) (Rauch et 
al., 2008) which has an overlapping phenotype with MCPH. So AKAP9 was also 
considered the strongest candidate gene. Moreover, all 49 genes residing in the MCPH8 
region were prioritized by the disease gene prioritizing tools Endeavour (Aerts et al., 
2006) and GeneWanderer (Kohler et al., 2008) (Figure 4.23, Figure 4.24).                                            
 
Figure 4.23: Prioritized candidate genes of the MCPH8 locus on chromosomes 7 by 
Endeavour. CDK6 is at the highest rank. Green colour represents the CDK6 which has 
got the highest rank. 
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Figure 4.24: Prioritized genes of the MCPH8 locus on chromosome 7 by GeneWanderer. 
CDK6 is at position three. 
All selected genes were sequenced in MCP4 family members. No mutation was found in 
all of these genes except CDK6. 
4.8.4. CDK6 as the causative gene of the MCPH8 locus 
As Cyclin-dependent kinase 6 (CDK6) has got the highest rank among 49 genes, 
prioritized by Endeavour and GeneWanderer (Figure 4.23 and 4.24), this Cyclin-
dependent kinase 6 (CDK6) was sequenced within three afflicted individuals of the MCP4 
family with one control. A homozygous single base substitution c.589G>A in exon 5 was 
found. Later on the complete family was sequenced bi-directionally to confirm this 
change. This mutation was found in all afflicted individuals and segregated in a recessive 
pathogenic way. The parents were heterozygous carriers (Figure 4.25) and the mutation 
in CDK6 c.589G>A was not found in 768 Pakistani healthy control samples. The 
substitution in CDK6 (c.589G>A) was also not found in 760 German healthy control 
samples.  
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Homozygous mutant c.589G>A (MCP4-9)  Wild type  
G T C C A G C T A C A C C A C C C C C G            T C C A G C T A C G C C A C C C C C G  
Heterozygous mutant c.589G>A (MCP4-13)   Heterozygous mutant c.589G>A 
(MCP4-14) 
T C C A G C T A C N C C A C C C C C G             T C C A G C T A C G C C A C C C C C G  
Figure 4.25: Sequencing chromatograms illustrate the c.589G>A (p.Ala197Thr) 
mutation in the MCPH8 family (CDK6 gene). Black arrows indicate the position of the 
mutation where G is replaced by A which causes a change from alanine to threonine. 
Carrier status of both parents (MCP4-13 and MCP4-14) is also shown. 
 
4.8.5. Structure of CDK6 
There are five transcripts of CDK6 but only two are protein coding. The longest transcript 
(ENST00000265734) consists of 8 exons that spread over 11,612 bps length and code a 
protein of 326 residues. Exon 8 is the largest one and contains the C-terminus of the 
protein and a long non-coding region as shown in figure 4.26. 
 
Figure 4.26: Graphical representation of the CDK6 gene. Exons are drawn according 
to scale (1Kb = 1cm), while introns are just shown as artificial lines. Black boxes 
represent the non coding exons while white ones depict coding regions. The position of 
the mutation (c.589G>A) in exon five is shown. 
 
4.8.6. Evolutionary conservation of Alanine 
The missense mutation (c.589G>A) in CDK6 replaces an alanine with a threonine 
(p.A197T). Alanine in this position is highly conserved in primates and some other 
animals but is not conserved in other CDKs except CDK4 which is considered the closest 
homolog of CDK6 (Figure 4.27).  
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 Mus              VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
 Rattus           VTLWYRAPEVLLQSSYATPVDLWSVGCIFAELF 
 Homo             VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
 Macaca           VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
 Pan              VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
 Canis            VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
 Felis            VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
 Loxodonta        VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
 Monodelphis      VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
 Gallus           VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
 Xenopus          VTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMF 
                         *******************************:* 
Human CDK6       ALTSVVVTLWYRAPEVLLQSS-YATPVDLWSVGCIFAEMFRR-KPLFRGSSD  
Human CDK4       ALTPVVVTLWYRAPEVLLQST-YATPVDMWSVGCIFAEMFRR-KPLFCGNSE 
Human CDK2       TYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTR-RALFPGDSE 
Human CDK3       TYTHEVVTLWYRAPEILLGSKFYTTAVDIWSIGCIFAEMVTR-KALFPGDSE 
Human CDK5       CYSAEVVTLWYRPPDVLFGAKLYSTSIDMWSAGCIFAELANAGRPLFPGNDV 
Human CDK10      PMTPKVVTLWYRAPELLLGTTTQTTSIDMWAVGCILAELLAH-RPLLPGTSE 
Human CDK9       RYTNRVVTLWYRPPELLLGERDYGPPIDLWGAGCIMAEMWTR-SPIMQGNTE 
Human CDK8       DLDPVVVTFWYRAPELLLGARHYTKAIDIWAIGCIFAELLTS-EPIFHCRQE 
 
Figure 4.27: Cross species alignment of CDK6 sequences by ClustalW: Multiple 
Sequence Alignment (2.0.5). The amino acid Alanine (A, blue) is conserved in all species 
but is not conserved in different human CDKs (A, red).    
 
4.8.7. Sub-cellular localization of CDK6 
Endogenous and transfected CDK6 was reported to localize in the cytoplasm mainly in 
the cortical region and in cellular protrusions and in the nucleus (Kohrt et al., 2009). I 
studied the subcellular distribution of CDK6 by immunocytochemistry and confocal 
microscopy in the human keratinocyte (HaCaT) cell line during the cell cycle. This 
revealed a cytoplasimc and nuclear localization of CDK6 during interphase, while a strong 
accumulation at the spindle pole (centrosome) was observed during mitosis from 
prophase to telophase as shown in figure 4.28. 
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Figure 4.28: Subcellular localization of CDK6 in HaCaT cells. CDK6 localizes to the 
cytoplasm and nucleus during interphase and to the centrosome (spindle pole) during 
prophase to telophase. Confocal microscopy was performed in HaCaT cells stained for 
CDK6 (red), centrosomal marker Pericentrin (green) and DAPI (blue) as a DNA marker. 
Scale bar, 5 µm. The insets show centrosomes at higher magnification. 
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4.8.8. Cell cycle synchronization of CDK6 patient fibroblasts  
Fibroblasts from a CDK6 patient (MCP4-3) and control fibroblasts (passage 4) were 
synchronized at G0/G1 by serum starvation. The cells were then processed for 
immunofluorescence after 24, 26, 28 and 30 hours. Immunocytochemistry and confocal 
microscopy of synchronized mutant fibroblasts showed the following phenotypes of 
misshapen nuclei, reduced cell proliferation and increased centrosome-nucleus distance, 
which were not observed in the control primary fibroblasts. 
4.8.8.1. Misshapen nuclei  
Normally, fibroblast nuclei have an oval shape. In primary fibroblasts of the CDK6 patient 
MCP4-3, I frequently observed nuclei that were no longer oval. Instead, they had different 
shapes and were lobulated (Figure 4.29a and 4.31b). The statistical analysis revealed 
that ~12.3 % of CDK6 patient fibroblasts had misshapen nuclei as compared to controls 
where I found abnormal nuclear shapes in ~2.3% of all cells as shown in figure 4.29b. 
 
 
Figure 4.29: CDK6 patient primary fibroblasts with misshapen nuclei and statistical 
analysis. (a) Confocal microscope images of CDK6 mutant primary fibroblasts showing 
dysmorphic nuclei. The cells were stained for Pericentrin (turquoise) and DAPI (blue) 
harbouring dysmorphic nuclei. Scale bar, 5 µm. (b) Histogram showing the presence of 
dysmorphic nuclei in wild type and CDK6 mutant primary fibroblasts. 900 cells were 
analysed each. Error bars represent s.e.m. P value, 1.83477E-06 (Student’s t-test).  
 
4.8.8.2. Reduced cell proliferation 
I also noted a slower growth for mutant fibroblasts in culture. When I analysed cell 
proliferation by determining the number of dividing CDK6 mutant and control primary 
fibroblasts that had been synchronised at G0/G1, I found ~3 % of control cells in different 
stages of the cell cycle whereas this number was significantly reduced in the mutant with 
only ~0.3 % of dividing cells confirming an altered proliferation rate (Figure 4.30).  
(a)   (b)
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Figure 4.30: Statistical data of aberrant cell division in wild-ype and CDK6 mutant 
primary fibroblasts synchronized at G0/G1. ~3% of control cells were found dividing as 
compared to the mutant cells where only ~0.3% of cells were dividing confirming an 
altered proliferation rate. 900 cells were counted. Error bars represent s.e.m. P value, 
1.2968E-04 (Student’s t-test). 
 
4.8.8.3. Increased centrosome-nucleus distance 
Centrosomes detected with CDK6 as well as with pericentrin specific antibodies of 
synchronized patient primary fibroblasts were frequently detached from nuclei and 
exhibited a significantly increased distance as shown in figure 4.31a and table 4.3. In 
contrast, the control synchronized primary fibroblast cells exhibited normal nuclear shape 
and the centrosomes were not detached from the nucleus (Figure 4.31b). 
Statistical data taken from 50 cells each showed a significant difference in the nucleus-
centrosome distance measured in patient versus control fibroblasts (Table 4.3). 
 
 
                        
(a)   (b)
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Figure 4.31: Confocal microscope images of CDK6 patient and control primary 
fibroblasts showing the nucleus stained with DAPI and the centrosome. (a) Mutant 
cells were stained for Pericentrin (turquoise) and DAPI (blue). The cell exhibits an 
increased centrosome-nucleus distance. The nucleus of this cell has also the 
characteristic of misshapen nuclei. (b) Wild-type primary fibroblast stained for Pericentrin 
(green) and DAPI (blue). The centrosome-nucleus distance was determined by Lecia 
Microsystem LAS AF lite. Scale bar, 5 µm. 
  
 
Table 4.3: Centrosomes-nucleus distance measured in CDK6 patient and control 
primary fibroblast cells. Results are shown in terms of mean ± s.e.m and the P values 
(Student’s t-test) which are calculated with control versus mutant data.  
 
Centrosome-Nucleus distance (µm) (N=50) 
Wild-type primary fibroblast Mutant primary fibroblast 
3.4514 ± 0.6062 5.1646 ± 0.2661 
P value 0.008286 
 
4.8.9. CDK6 knockdown 
To obtain independent support for a role of CDK6 in cell proliferation and at the 
centrosome, I carried out Knockdown experiments in HaCaT cells using shRNA. The 
efficiency of the Knockdown was first tested by western blotting. A faint band of 37 kDa 
was detected in Knockdown cells while in control (transfected HaCaT cells with construct 
having scrambled sequence of CDK6), a strong signal was observed. To confirm equal 
protein loading, β-actin (42 kDa) was detected (Figure 4.33b). 
4.8.9.1. Normal microtubule network in control 
I first analysed the microtubule network in control HaCaT cells. These cells have a normal 
oval nucleus and the microtubule form a regular network extending into the cell periphery 
(Figure 4.32).  
 
Figure 4.32: Control HaCaT cells with normal microtubules. CDK6 expression was 
observed mostly in the cytoplasm of cells. Cells have normal microtubules and a regular 
shape of the nucleus. Cells were stained with CDK6 (red), Pericentrin (turquoise), α-
tubulin (green) and DAPI (blue). Scale bar, 5 µm. 
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In the Knockdown I observed several changes as misshapen nuclei, reduced proliferation 
rate and disorganised microtubules. 
4.8.9.2. Misshapen nuclei 
In CDK6 knockdown HaCaT cells, I found that ~21 % of all cells had dysmorphic nuclei as 
compared to 10 % in control cells (Figure 4.33a and 4.34a). 
4.8.9.3. Reduced cell proliferation 
As observed for patient fibroblasts cell proliferation was also affected by reduced levels of 
CDK6 protein. When I analysed the percentage of dividing cells in knockdown HaCaT 
cells I found that 4.45 % of the cells were dividing vs 15.3 % of control cells which were 
observed at different stages of the cell cycle (Figure 4.34b).  
 
 
                           
Figure 4.33: CDK6 mutant primary fibroblasts with western blot of CDK6 
knockdown. (a) Confocal microscope image of CDK6 knockdown HaCaT cell tained for 
DAPI (blue) harbouring dysmorphic nuclei. Scale bar, 5 µm. (b) Western blot analysis of 
CDK6 knockdown and control cells showing the reduced amount of CDK6. The blots was 
probed with β-actin (42 kDa) as loading control. 
 
 
 
Figure 4.34: Statistical Analysis. (a) Statistical data of dysmorphic nuclei in CDK6 
knockdown and control HaCaT cells. 900 cells each were analysed. Error bars represent 
CDK6 37kDa
ß-Actin 42kDa
Knockdown Control 
(a)   (b)
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s.e.m. P value, 4.72E-04 (Student’s t-test). (b) Histogram representing the statistical 
analysis of aberrant cell division in Knockdown cells. Data is taken from 900 cells. Error 
bars represent s.e.m. P value, 1.02517E-06 (Student’s t-test). 
 
4.8.9.4. Disorganised microtubules  
A prominent phenotype noticed in CDK6 knockdown HaCaT cells was the disorganised 
microtubule network (Figure 4.34). Normally microtubules extend from the centrosome 
out into the cytosol in form of long fibers. In CDK6 Knockdown cells I observed that the 
area around the nucleus was less populated by microtubules. Instead microtubules 
formed a fine filamentous meshwork near the periphery of the cells. 
 
Figure 4.35: CDK6 knockdown HaCaT cells. Cells were stained for CDK6 to 
demonstrate the efficiency of the Knockdown (red), Pericentrin (turquoise), α-tubulin 
(green) and DAPI (Blue). The cells showed disorganised microtubules. Scale bar, 5 µm. 
4.8.10. Overexpression of CDK6 
To check the ectopic expression of wild-type and mutant (c.589G>A) CDK6 protein, both 
versions were expressed with a GFP-tag in COS7 cells. I observed a reduced cell division 
rate for both wild-type and mutant transfected cells so, only few mitotic cells were 
detected. I also analysed the localization of the proteins and their effect on centrosomes 
and microtubule organisation  
4.8.10.1. Localization of GFP-tagged CDK6 
During interphase CDK6 wild-type GFP-tagged protein localizes to the cytoplasm as well 
as the nucleus and associates with centrosomes in dividing cells resembling the 
observations with primary fibroblasts (Figure 4.36). The mutant CDK6 protein also 
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localizes to cytoplasm and in the nucleus in a same fashion like wild type, but I did not 
find dividing cells in this case to observe the localization of mutant CDK6-GFP (Figure 
4.37b).   
 
Figure 4.36: Localization of GFP-tagged CDK6 in dividing cell. COS7 cells were 
transfected with GFP-tagged wild-type CDK6 (green). Staining was for Pericentrin 
(turquoise), α-tubulin (red) and DAPI (blue). Only few mitotic cells were found in these 
transfected cells. Scale bar, 10 µm.  
 
4.8.10.2. Disorganised microtubules 
Overexpression of both wild-type and mutant GFP tagged CDK6 resulted in an abnormal 
appearance of the microtubules. The pattern appeared irregular with a strong 
accumulation around the periphery in cells overexpressing wild-type CDKs whereas in the 
case of the mutant protein I observed shorter and in some cases fewer microtubules. 
Some of the transfected cells contained GFP-positive dots which appeared in the 
cytoplasm as well as in the nucleus of the cells. The size and number of these dots was 
variable (Figure 4.37). 
4.8.10.3. Multiple centrosomes 
A distinguishing feature noticed in cells expressing mutant CDK6 was the presence of 
multiple centrosomes. This was not observed in cells overexpressing wild-type protein. 
The centrosome number was increased from 3 to 5, furthermore, they appeared 
fragmented. Some were closely attached and others were found apart from each other. 
Interestingly these centrosomes frequently did not serve as microtubule organising 
centers and the cells exhibited abnormal microtubule networks (Figure 4.38). 
(a) 
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Figure 4.37: Disorganised microtubule system in CDK6 transfected cells. Confocal 
microscopy images of cells overexpressing GFP-tagged wild-type CDK6 (a) and mutant 
CDK6 (b). GFP fusion of CDK (green), Pericentrin (turquoise), α-tubulin (red) and DAPI 
(blue). Scale bar, 10 µm. 
(b) 
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Figure 4.38: Multiple numbers of centrosomes in cells expressing mutant CDK6. 
COS7 cells were transfected with GFP-tagged mutant CDK6. Confocal microscopy 
images demonstrate multiple numbers of centrosomes. Some cells have three while 
others have five centrosomes. The cells were stained for Pericentrin (turquoise), α-tubulin 
(red) and DAPI (blue). Mutant CDK6-GFP is shown in green. The cells with multiple 
centrosomes also have a disorganised microtubule network. Scale bar, 5 µm. 
 
4.9. Excluded family MCP63 
MCP63 is a consanguineous family with two afflicted individuals (Figure 4.39) and was 
ascertained from the northern region of Pakistan. The patients have a typical sloping 
forehead and are mentally retarded without any other abnormalities. After exclusion of 
linkage with all known seven MCPH loci, the family was subjected to a genome-wide 
screen for regions of linkage with the Affymetrix GeneChip(R) Human Mapping 250K 
SNP Array (version 2.0) on the two afflicted children (MCP63-1 and MCP63-2), one 
normal individual (MCP63-3), and the normal father (MCP63-4).  
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Figure 4.39: Pedigree of family MCP63 having the novel MCPH9 locus. Four individuals 
were subjected to this study. 
 
4.9.1. MCPH9 locus identification 
Genome-wide linkage analysis of the MCP63 family revealed the identification of one 
novel gene locus MCPH9 which mapped on chromosome 4p14-4q12 with LOD score 
2.53 between SNP_A-2154951 (rs12498424, position 40,326,233bp) and SNP_A-
1894332 (rs13134527 position 58,396,887bp) comprising 18.07 Mb and 12.84 cM (Figure 
4.40a and 4.41). Genome-wide analysis of the MCP63 family also revealed two narrow 
peaks on chromosome number 9 which were also taken into consideration. One peak 
maps between SNPs rs7044445, (physical position 91,463,981bp) and 
rs10993082(physical position 95,980,440 bp) on chromosome 9q22.31-9q22.32 and the 
other one maps between SNPs rs10993188 (physical position 96,201,711bp) and 
rs642771 (physical position 100,162,135bp) on chromosome 9q22.32-9q31.1. But the 
causative gene was found only in the 4p14-4q12 region which is the actual MCPH9 locus 
(Figure 4.40b). 
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Figure 4.40: Genome-wide graphical view of the MCPH9 locus. A genome-wide 
screen for regions of linkage was performed with the Affymetrix 250K SNP GeneChip. A 
marker panel of 126,000 SNPs was used (a) Parametric linkage analysis (Allegro 
software) showing the MCPH9 locus mapped in two afflicted and two normal individuals. 
The highest LOD score (2.58) was obtained on chromosome 4p14-4q12. (b) Genome-
wide view of the MCPH9 locus on chromosome 4 with the position of CEP135 which is 
shown by the red line. 
(b) 
(a) 
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Figure 4.41: Haplotype analysis of the MCP63 family linked to chromosome 4p14-
4q12. Black symbols represent afflicted individuals. The critical interval was defined by 
the recombinations observed between markers SNP_A-2154951 (rs12498424, physical 
position 40,326,233bp) and SNP_A-1894332 (rs13134527 physical position 
58,396,887bp)comprising 18.07 Mb and 12.84 cM. Here only the region near CEP135 is 
shown. 
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Figure 4.42: G-banded chromosome 4 showing the position of the MCPH9 locus, 
along with the position of CEP135 on short arm 4p14-4q12. The locus was mapped 
between SNP_A-2154951 (rs12498424, physical position 40,326,233bp) and SNP_A-
1894332 (rs13134527, physical position 58,396,887bp). This 18.07 Mb (12.84 cM) region 
harbours 116 genes (NCBI Human Genome Build 36.3). Some genes with hypothetical 
proteins are skipped. The CEP135 gene was selected for sequencing because it has the 
centrosomal localization and playsa role in the cell cycle. Deletion of a single base 
c.970delC was found which causes frameshift incorporating one amino acid and then 
causing a stop codon (p.Q324Sfs*2) This mutation was not found in 768 healthy controls 
of Pakistani origin.   
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4.9.2. Candidate genes of the MCPH9 locus 
Bioinformatic analysis of the MCPH9 (18.07 Mb) region was performed to seek the 
candidate genes. This region on chromosome 4p14-4q12 harbours 116 known and 
hypothetical genes (NCBI Human Genome Build 36.3) (Figure 4.42).  
4.9.3. Sequencing the candidate genes in the MCPH9 locus 
A role in mitosis and/or in neurogenesis, centrosomal or spindle pole localization or 
embryonic brain expression was the selection criterion to seek the candidate genes of the 
MCPH9 locus. Moreover, the genes were prioritized by tools like Endeavour (Aerts et al., 
2006) (Figure 4.43).  
 
Figure 4.43: Prioritized genes of the MCPH9 locus by Endeavour. Green color 
represents CEP135. The position of CEP135 is noticeable at the highest rank.    
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The centrosomal Protein 135 kDa (CEP135) on chromosome 4p14-4q12 and cell division 
cycle 14 homolog B (CDC14B) on chromosome 9q22.32-9q22.33 were considered the 
strongest candidates and were thus sequenced in MCP63 family members (Figure 4.43).   
4.9.4. CEP135 as the causative gene of MCPH9  
Sequence analysis showed no mutation in CDC14B but a homozygous single base 
deletion c.970delC in exon 8 of the CEP135 gene (Figure 4.44). The mutation segregates 
in a recessive pathogenic way. The parents are heterozygous carriers and this deletion 
was not found in 768 Pakistani healthy control chromosomes (Figure 4.45). Deletion of a 
single base (c.970delC) of CEP135 results in a frameshift which leads to a stop codon 
after one amino acid (p. Gln324Serfs*2). 
Homozygous mutant c.970delC (MCP63-1)       Wild type 
T G A A A T A G A T - A G T T A G C A C A           T G A A A T A G A T C A G T T A G C A C A    
Heterozygous mutant c.970delC (MCP63-4)  
T G A A A T A G A T C N T T T N C C C C N  
Figure 4.44: Sequencing chromatograms of the MCPH9 patient with wild type that 
illustrate the c.970delC (p. Gln324Serfs*2) mutation in the MCPH8 family (CEP135 
gene) by sanger sequencing. Black arrows indicate the position of the mutation where C is 
deleted which results in a frameshift that leads to a stop codon after one amino acid (p. 
Gln324Serfs*2). The mutant sequence is shown along with the wild type and one of the 
heterozygous parents. Mutation (c.970delC) was found in Pakistani family. 
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1600
E S G C T A C T G C A
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5  
Figure 4.45: Pyrogram with control samples from Pakistan. Pyrogram traces obtained 
by Pyrosequencing analysis of the c.970delC mutation in exon 8 of Pakistani control 
samples which were negative for the c.970delC mutation in CEP135. 
 
4.9.5. Structure of CEP135 
The CEP135 gene is composed of 26 exons (Figure 4.46). The 3,423-bp ORF encodes a 
1,140 amino acids protein. It gives rise to five transcripts of variable lengths (only two 
protein coding). The longest transcript (ENST00000257287) with 4,570 bps length codes 
for a protein of 1,140 amino acids.  
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Figure 4.46: The position of the CEP135 mutation in MCPH9. The human CEP135 gene 
consists of 26 exons which are drawn according to scale (1kb = 1cm), while introns are 
shown as artificial lines. Black boxes represent the non coding exons while white ones 
represent coding exons. Above exon 8 the position of mutation c.970delC is indicated. 
 
4.9.6. CEP135 in wild-type primary fibroblasts 
I first studied the CEP135 staining in control fibroblasts. For this I used antibodies that 
were generated against the C-terminal region of human CEP135. These antibodies 
recognized a single spot in non dividing cells which overlapped with the -tubulin stained 
structure defining the centrosome or microtubule organising center. Microtubules radiated 
from this structure into the cytosplasm in a regular pattern (Figure 4.47).  
 
Figure 4.47: Wild-type primary fibroblast cells. Immunofluorescence staining and 
confocal microscopy images of wild-type primary fibroblasts with a single centrosome and 
well organised microtubules. Antibodies were directed against γ-tubulin (white), CEP135 
(red), α-tubulin (green) and DAPI (blue) for DNA staining. Scale bar, 5 µm. 
 
4.9.7. CEP135 patient primary fibroblasts 
When I analysed CEP135 patient primary fibroblasts I noted various alterations with 
regard to the centrosome, microtubules, cell division and nuclear shape. Most 
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remarkably, the CEP135 antibody still recognized the -tubulin stained centrosome 
although I had assumed that the mutation would lead to a premature stop in the protein.  
4.9.7.1. Centrosome number abnormalities  
The cells harboured 3, 4 or 5 centrosomes with a frequency of 18.67 % (Table 5.4). The 
centrosomes also appeared fragmented. The abnormal centrosome number strengthens 
the role of CEP135 in centriole biogenesis. Interestingly the cells with multiple 
centrosomes also show the disorganised microtubules (Figure 4.48). 
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Figure 4.48: CEP135 mutant primary fibroblasts with centrosomal abnormalities. 
Centrosomes are variable in number (3, 4 or 5) and fragmented. The arrowheads show 
the multiple and fragmented centrosomes. Microtubules of these cells also have an 
abnormal appearance. Scale bar, 5 µm. 
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4.9.7.2. Absence of centrosomes 
Another prominent feature of CEP135 patient primary fibroblasts was the complete loss of 
centrosomes (Figure 4.49). About 22 % of mutant primary fibroblasts completely lacked 
centrosomes whereas this was never observed in WT (Table 5.4). Interestingly, the 
majority of the cells with misshapen nuclei were also deficient of centrosomes (Figure 
4.51).  
 
Figure 4.49: Absence of centrosomes in CEP135 mutant primary fibroblasts. No 
signal for CEP135 and gamma tubulin was observed in ~22 % of cells. These cells also 
show disorganised microtubules paralleled by an abnormal cell shape. Scale bar, 5 µm. 
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4.9.7.3. Disorganised microtubules 
A further feature was a disorganised microtubule system which was accompanied by cell 
shape changes and was observed in 55.33 % of the cells. (Figure 4.48, 4.49, 4.50, Table 
5.4). Disorganisation of the microtubule network points out the importance of the 
centrosome as the microtubule organising center. 
 
Figure 4.50: CEP135 mutant primary fibroblasts with disorganised microtubules. 
Confocal microscopy images of CEP135 mutant primary fibroblasts showing a 
disorganised microtubule network. Cells also lack centrosomes resulting in the absence 
of -tubulin and CEP135 staining. Antibodies were directed against γ-tubulin (white), 
CEP135 (red), α-tubulin (green) and DAPI (blue) for DNA staining. Scale bar, 5 µm. 
 
4.9.7.4. Misshapen nuclei 
Mutant cells had an increased number of misshapen and fragmented nuclei (Figure 4.51). 
Often nuclei were highly lobulated and fragmentation led to DAPI stained material in the 
cytoplasm. A statistical analysis showed that these changes were significant. About 20 % 
of mutant fibroblasts harboured misshapen nuclei whereas in control fibroblasts this 
number was only ~3% (Figure 4.52).  
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Figure 4.51: CEP135 mutant primary fibroblasts with misshapen nuclei. Dysmorphic 
nuclei often appeared like broken ones. Only few cells with dysmorphic nuclei features 
had centrosomes (arrowhead), while others did not have centrosomes and consequently 
no CEP135 staining. Another obvious feature of these cells was the occurrence of 
disorganised microtubules. Scale bar, 5 µm. 
 
Figure 4.52: Graphical representation showing the number of CEP135 mutant 
primary fibroblasts with misshapen nuclei. 300 cells were counted for wild type and 
mutant. Error bars represent s.e.m. P value, 3.44E-3 (Student’s t-test).  
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4.9.8. Overexpression of CEP135 
COS7 cells were transfected with GFP-tagged wild-type and mutant CEP135. The wild-
type exogenous CEP135 localized to the centrosome and resulted in the formation of 
spots outside of the centrosome. These spots were variable in number and size and were 
also recognized by polyclonal antibodies directed against CEP135 (Figure 4.55). But 
staining with pericentrin indicates only one spot. So the extra spots are not centrosomes 
but only exogenous CEP135 (Figure 4.53a). Furthermore I noted unusual phenotypes in 
the COS7 cells expressing GFP-CEP135. I have observed very weak mutant exogenous 
CEP135 expression (Figure 4.53b).   
4.9.8.1. Overexpression of CEP135 leads to a disorganised microtubule system. 
GFP-tagged wild-type and mutant CEP135 overexpression led to abnormal microtubule 
systems. In wild type, the immunofluorescence dots were seen but in mutant cells the 
weak expression of GFP was observed. I have noticed only one spot, stained for 
pericentrin (Figure 4.53).  
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Figure 4.53: Abnormal microtubules in CEP135 transfected cells. Confocal 
microscopy images of CEP135 wild type (a) and mutant (b) transfected COS7 cells 
showing the phenotype of disorganised microtubules. The wild-type cells also show 
several dots with variable size and number. The cells were stained with CEP135-GFP 
(green), α-tubulin (red) Pericentrin (turquiose) and DAPI (blue) for DNA staining. Scale 
bar, 10 µm. 
 
 
(b) 
(a) 
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4.9.8.2. Abnormal number of centrosomes 
GFP-tagged CEP135 mutant transfected cells also demonstrated multiple centrosomes (3 
centrosomes observed). This feature was only observed in mutant transfected cells and 
was also observed in CEP135 mutant primary fibroblast cells (Figure 4.54). 
 
Figure 4.54: Abnormal number of centrosomes in CEP135 mutant cells. COS7 cells 
were transfected with GFP-tagged mutant CEP135 (CEP135-M-GFP, green) and stained 
for α-tubulin (red) Pericentrin (turquiose) and DAPI (blue) for DNA staining. Scale bar, 10 
µm. 
 
Figure 4.55: COS7 cells with CEP135 immunofluorescence dots. These dots were 
variable in size and number. The cells were stained with CEP135-GFP (green), CEP135 
(red) and DAPI (blue) for DNA staining. Scale bar, 10 µm. 
 
4.9.9. CDK6 and CEP135 expression in mouse neuroepithelium 
It is assumed that in MCPH neurogenesis is afflicted during development. Therefore I 
examined the expression profile of CDK6 and CEP135 during mammalian cerebral 
cortical neurogenesis. Immunofluorescence studies were performed using mouse 
sections obtained at embryonal stages E11.5 and E15.5. At both stages I observed a 
strong staining for Cep135 and Cdk6 in the developing neuroepithelium of the cerebral 
cortex (Figure 4.56).  
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Figure 4.56: Confocal microscopy images of endogenous Cdk6 and Cep135 in mouse 
embryonic brain neuroepithelium. Embryos were taken from E11.5 and E15.5. Antibodies 
were used against Cdk6 (red), Cep135 (green) and Nestin (turquoise). Scale bar, 50 µm. 
 
 
Figure 4.56: Cdk6 and Cep135 expression in the neuroepithelium of the developing mouse 
brain. (a) Expression at stage E11.5 and 15.5, Cdk6 (red), Cep135 (green), Nestin (turquoise). 
Scale bar, 50 µm. (b) Localization of Cdk6 to the centrosome in the mouse neuroepithelium during 
E15.5. Cdk6 staining (red) is merged with Cep135 staining (green) which is a bona fide centrosomal 
protein. Scale bar, 5 µm. (c) Nuclear Cdk6 localization in cells of the mouse neuroepithelium at 
E15.5. Scale bar, 5 µm. 
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4.10. Excluded family MCP50 
MCP50 is a large consangineous family with three different loops. All afflicted individuals 
have consangineous parents (Figure 4.57a).               
 
 
 
Figure 4.57: Pedigree of family MCP50 and Genome-wide graphical view of the 
MCPH10 locus. (a) A family tree showing the pedigree of family MCP50 afflicted with 
primary microcephaly. (b) Parametric linkage analysis (Allegro software) showing the 
MCPH10 locus mapped in the MCP50 family. The highest LOD score (4.9) was obtained 
on chromosome 12q14.1-12q14.2. 
(a) 
(b) 
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Figure 4.58: Haplotype analysis of the MCP50 family linked to chromosome 
12q14.1-12q14.2. Black symbols represent afflicted individuals. The critical interval was 
defined by the recombinations observed for markers SNP_A-1887620 (rs17629041, 
physical position 59,900,744bp and 74.52cM) to SNP_A-2041878 (rs1463821, physical 
position 61,689,142bp and 76.28cM). 
 
PCR based genotyping of microsatellite markers resulted in the exclusion of linkage of 
this family with all known MCPH loci. So this family was subjected for genome-wide 
mapping using the 250K SNP Array (Affymetrix) and obtained a single maximum (LOD) 
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score of 4.9 for a region between rs17629041 (physical position 59,900,744bp, 74.52cM) 
and rs1463821 (physical position 61,689,142bp, 76.28cM) on chromosome 12q14.1-
12q14.2 (NCBI Human Genome Build 36.3) (Figure 4.57b, Figure 4.58). 
Bioinformatic analysis of this region revealed 13 genes (NCBI Human Genome Build 
36.3). Among these, Family with sequence similarity 19 (chemokine (C-C motif)-like), 
member A2 (FAM19A2), Ubiquitin specific peptidase 15 (USP15), MON2 homolog (S. 
cerevisiae) (MON2) and Protein phosphatase 1H (PP2C domain containing) (PPM1H) 
were selected as the strongest candidates and sequenced within MCP50 individuals. The 
MCP50 family was negative for any pathogenic change in these four selected genes. 
4.11. Excluded family MCP53 
MCP53 is small consangineous family with one afflicted individual (Figure 4.59a). After 
exclusion of linkage of the MCP53 family with microsatellite markers of all known MCPH 
loci, genome-wide linkage analysis was performed which demonstrated three different 
peaks on chromosomes 3, 4 and 6  with the maximum possible LOD score of 1.33 
(Figure 4.59b). 
On chromosome 3, the minimum linkage interval is defined by the SNP_A-1889563 
(rs832042 physical position: 99,227,425bp, 111.01cM) and SNP_A-2101206 (rs17353809 
physical position: 103,498,894bp, 113.22cM). This region of 4.27 Mb on chromosome 
3q12.1-3q12.3 harbours 60 genes (NCBI Human Genome Build 36.3). 
A wider peak which is observed on chromosome 4 is defined from SNP_A-1911424 
(rs13101536 physical position 150,514,489bp, 144.72cM) to SNP_A-2288389 (rs4690796 
physical position 166,092,275bp, 159.87cM. There are 92 genes which reside in this 
15.57 Mb region on chromosome 4q31.23-4q32.3.  
The region of the third peak on chromosome 6 (6q24.2-6q24.3) is between SNP_A-
2271440 (rs4896697 physical position 144,467,714bp, 146.69cM) and SNP_A-1782436 
(rs6570879 physical position 149,035,821bp 151.26cM) and comprises 20 genes. 
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Figure 4.59: Pedigree and Genome-wide graphical view of the MCPH11 locus. (a) 
Pedigree of family MCP53 having one afflicted individual. (b) Parametric linkage analysis 
(Allegro software) showing the MCPH11 locus mapped in MCP53 family. The highest 
three peaks can be seen on chromosomes 3, 4 and 6. 
 
 
 
(a) 
(b) 
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4.12. Excluded family MCP67 
MCP63 is a small consangineous family with three afflicted individuals (Figure 4.60). PCR 
based genotyping with microsatellite markers, specific for each MCPH loci, excluded this 
family from linkage to all known MCPH loci.  
 
Figure 4.60: Family tree of MCP67 with two afflicted individuals. Only four individuals 
were screened. The father of these patients is deceased.  
 
Genome-wide linkage analysis was performed on the MCP67 family with a reduced 
marker panel of 20K, which shows a  peak on chromosome 6 which maps between 
SNP_A-4282597 (rs12206695 position 126,297,240bp 126.69cM) and SNP_A-2181427 
(rs9388518 position 127,145,478bp 127.27cM) along with 6q22.32 (Figure 4.60a, Figure 
4.62a). Eight genes were found in this small 0.84 Mb (0.58cM) linkage interval (NCBI 
Human Genome Build 36.3). 
Analysis with an increased marker panel of 32K and 50K was conducted, which resulted 
in a peak on chromosome 11 with a LOD score of approximately 2.2 and a region on 
chromosome 2 with a LOD score of approximately 2.4(Figure 4.60b, Figure 4.61). These 
three regions on chromosomes 2, 6 and 11 were further confirmed by linkage analysis 
with the Affymetrix GeneChip(R) Human Mapping 250K SNP Array (version 2.0). The 
region on chromosome 11p15.4 mapped between SNP_A-4286081 (rs4929918 position 
8,795,236bp 15:14cM) and SNP_A-2048279 (rs7931872 position 9,098,638bp and 
15.98cM) (Figure 4.62b). The region on chromosome 2q14.2 mapped between SNP_A-
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2164389 (rs6541729 position 121,096,831bp and 130.91cM) and SNP_A-4253620 
(rs12616919 position 121,627,677bp and 132.91cM) (Figure 4.63). Eight genes were 
found in the 0.30 Mb (0.84 cM) region on chromosome 11p15.4 and one gene was found 
on chromosome 2q14.2 in the 0.53 Mb (2cM) region (NCBI Human Genome Build 36.3). 
 
 
 
Figure 4.60: Genome-wide graphical view of the MCPH12 locus. (a) Parametric 
linkage analysis (Allegro software) with a marker panel of 20K, showing the MCPH12 
locus on chromosome 6q22.32 which was mapped in the MCP67 family. (b) Parametric 
linkage analysis (Allegro software) with a marker panel of 32K, showing the MCPH12 
locus mapped on chromosome 11p15.4 in the MCP67 family.  
(a) 
(b) 
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Figure 4.61: Genome-wide graphical view of the MCPH12 locus. Parametric linkage 
analysis (Allegro software) with a marker panel of 50K, showing the MCPH12 locus 
mapped on chromosome 2q14.2 in the MCP67 family.  
 
 
Figure 4.62: Haplotype analysis of MCP67 family. (a) On left the haplotype on 
chromosome 6q22.32 is described which maps between SNP_A-4282597 (rs12206695 
position 126,297,240bp 126.69cM) and SNP_A-2181427 (rs9388518 position 
127,145,478bp 127.27cM) with a small linkage interval of 0.84 Mb (0.58 cM). (b) On the 
right the haplotype on chromosome 11p15.4. is depicted. The critical interval (0.30 Mb, 
0.84 cM) is mapped between SNP_A-4286081 (rs4929918 position 8,795,236bp 
15:14cM) and SNP_A-2048279 (rs7931872 position 9,098,638bp and 15.98cM). 
 
(b) (a)
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Figure 4.63: Haplotype analysis of the MCP67 family linked to chromosome 2q14.2. 
The linkage interval (0.53 Mb, 2 cM) is mapped between SNP_A-2164389 (rs6541729 
position 121,096,831bp and 130.91cM) and SNP_A-4253620 (rs12616919 position 
121,627,677bp and 132.91cM).  
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5. Discussion  
Autosomal recessive primary microcephaly (MCPH) is a rare congenital, genetically and 
clinically heterogeneous disease. Patients with MCPH typically exhibit reduced head size 
and mental retardation, but usually there are no further neurological findings or 
malformations. Also, the macroscopic organization of the brain is preserved. MCPH 
therefore is considered a consequence of a reduced brain volume, which is evident 
particularly within the cerebral cortex and thus results to a large part from a reduction of 
grey matter (Kaindl et al., 2010). Although the MCPH brain is small, it exhibits the normal 
six-layer neuronal architecture, suggesting that MCPH results from a decrease in neural 
progenitor cell number (Bond and Woods, 2006). 
There has been a dramatic expansion in brain size during mammalian evolution with a 
thousand fold increase in cortical surface area between mouse and man (Rakic, 1995). 
Morphometric studies have revealed a scaling of the brain relative to body size during 
mammalian evolution with disproportionate enlargement of the cerebral cortex (Northcutt 
and Kaas, 1995), (Clark et al., 2001). In primates, this might have been driven by 
increased social rather than environmental complexity and their ability to execute 
complex cognitive functions such as speach (Finlay and Darlington, 1995). Expansion 
progressed through an increase in surface area rather than an increase in cortical 
thickness (Rakic, 1995), (Northcutt and Kaas, 1995). This has been accommodated 
topologically by folding of the cerebral cortex to form convolutions, so that there is a 
transition from the smooth cortical surface seen in rodents to one with multiple folds in 
humans (Ponting and Jackson, 2005).  
The genes responsible for MCPH are specific regulators of brain size and have evolved 
under strong positive selection in the lineage leading to Homo sapiens. One genetic 
variant of Microcephalin in modern humans, which arose ∼37,000 years ago, increased in 
frequency too rapidly to be compatible with neutral drift. This indicates that it has spread 
under strong positive selection, although the exact nature of the selection is unknown. 
The finding that an important brain gene has continued to evolve adaptively in 
anatomically modern humans suggests the ongoing evolutionary plasticity of the human 
brain. It also makes Microcephalin an attractive candidate locus for studying the genetics 
of human variation in brain-related phenotypes (Evans et al., 2005). One genetic variant 
of ASPM in humans arose merely about 5800 years ago and has since swept to high 
frequency under strong positive selection. These findings, especially the remarkably 
young age of the positively selected variant, suggest that the human brain is still 
undergoing rapid adaptive evolution (Mekel-Bobrov et al., 2005). 
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MCPH is a primary disorder of neurogenic mitosis and not due to neural migration, neural 
apoptosis, or neural function. This is the case because all known MCPH genes are 
expressed in the neuroepithelium, and phenotypic features and brain scans suggest that 
MCPH patients have a small brain that functions normally for its size (Woods et al., 
2005). The functions of MCPH genes during neurogenic mitosis are unknown except for 
ASPM, so elucidation of the genes responsible for MCPH and understanding the 
pathomechanisms leading to MCPH is of high importance not only for our understanding 
of physiologic brain development (particularly of cortex formation), but also for both 
genetic counseling and prenatal diagnosis. So I aimed to identify novel genes responsible 
for causing the phenotype of MCPH and to explore their role during cell division. 
5.1. Mutational spectra of known MCPH genes 
Molecular genetic analysis of thirty primary microcephaly families ascertained from 
different regions of Pakistan resulted in the linkage of 19 (63.3 %) families to the MCPH5 
locus, one (3.33 %) was found mutated at the MCPH1 gene, one (3.33 %) in CENPJ 
(MCPH6), two (6.67 %) in WDR62 (MCPH2), two (6.67 %) were linked to the MCPH4 
locus and five were excluded from any linkage with MCPH loci which accounts for 16.7 % 
of all families (Figure 4.2). Our data is in line with previous results which reported the 
MCPH5 (ASPM) mutations as the major common cause of MCPH in the Pakistani and 
other populations of the world (Bond et al., 2002, Roberts et al., 2002, Gul et al., 2006b, 
Kumar et al., 2004, Nicholas et al., 2009, Muhammad et al., 2009, Kousar et al., 2010). 
Recently a study carried out in 112 Iranian MCP families detected homozygosity of 8 
families at MCPH1, 13 at MCPH5, 3 at MCPH2, five at MCPH6 and two at MCPH7, while 
the remaining 81 families were not linked to any of the seven known loci (Darvish et al., 
2010). The ASPM linked families in this study account for 13.3 % which is considerably 
lower prevalence than within the Pakistani’s population, where frequencies between 43 % 
and 55 % were reported (Gul et al., 2006b, Roberts et al., 2002).  In the Indian population 
however, 33 % ASPM linked families were reported (Kumar et al., 2004). As already 
reported in the study carried out in Iranian population (Darvish et al., 2010), there is a 
high prevalence of ASPM linked families in the Pakistani population as compared to other 
parts of the world. 
To date, 95 different mutations have been reported in ASPM (Bond et al., 2002, Bond et 
al., 2003, Kumar et al., 2004, Shen et al., 2005, Gul et al., 2006b, Gul et al., 2007, 
Nicholas et al., 2009, Muhammad et al., 2009, Kousar et al., 2010, Passemard et al., 
2009, Darvish et al., 2010, Halsall et al., 2010). This study has increased the number to 
99, by identifying eight further novel mutations in ASPM (Table 4.2). Among these eight 
novel mutations are, four (c.1002delA, c.9492T>G, c.3055C>T and c.8668C>T) that I 
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have already contributed to an earlier publication (Muhammad et al., 2009). One of our 
novel mutations (c.3977G>A) is interesting in the sense that it introduced a change of 
nucleotide G into A at position 3977, but an already reported variant (c.3978G>A) 
constitutes a change at nucleotide position 3978. Both variants result in the introduction 
of a stop codon (p.W1326*). In family MCP55 I have found one missense variant 
c.5584A>G which is not reported as a SNP in the database. This variant introduces 
glutamic acid instead of lysine (p.K1862E) in exon 18 of ASPM. On completion of the 
ASPM screening in the MCP55 family, I observed a further already reported nonsense 
mutation (p.Y3164*) in exon 23 of ASPM. The mutation c.9492T>G (p.Tyr3164*) is in cis 
to the missense mutation c.5584A>G (p.Lys1862Glu). The latter had previously been 
found in one MCPH family in homozygous state and deemed to be pathogenic (Darvish et 
al., 2010). This suggests that the missense variant (p.K1862E) is infact a rare variant that 
is not associated with the phenotype of primary microcephaly. Except for one missense 
mutation (c.9539A>C, p.Q3180P) which still has to be tested functionally, all of the other 
mutations identified so far in ASPM result in premature stop codons leading to truncated 
protein products due to resistance of the mRNA to nonsense mediated mRNA decay 
(NMD) (Gul et al., 2006b, Kouprina et al., 2005).  
Microcephalin/MCPH1 was identified as the first causative gene of MCPH (Jackson et al., 
2002). To date twelve mutations are reported in MCPH1 (Jackson et al., 2002, Trimborn 
et al., 2004, Trimborn et al., 2005, Garshasbi et al., 2006, Farooq et al., 2010, Darvish et 
al., 2010). All reported variants in MCPH1 result in a premature truncation except three 
missense variants p.Thr27Arg, p.His49>Gln and p.Ser72>Leu which may have an affect 
on the protein structure by changing the amino acids (Trimborn et al., 2005, Darvish et 
al., 2010). I identified the variant c.1178delG which causes a frameshift incorporating 49 
amino acids before introducing a stop codon (p.R393Sfs*50). This increases the number 
of MCPH1 mutations to 13 (Table 5.1). Mutations in MCPH1 are the rare cause of primary 
microcephaly in the Pakistani population, because out of twelve already identified MCPH1 
mutations, only one (c.74C>G) was reported in the Pakistani population (Jackson et al., 
2002). Other populations screened for mutations in MCPH1 are Caucasians, Lebaneses 
and Iranians. Out of twelve known MCPH1 mutations, eight were identified in the Iranian 
population (Garshasbi et al., 2006, Darvish et al., 2010).  
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Table 5.1: Summary of reported MCPH1 mutations 
No. cDNA Protein Affected Exon References 
1 c.74C>G p.S25* 2 Jackson et al., 2002 
2 427insA Thr143Asnfs*5+ 5 Trimborn et al., 2004 
3 c.80C>G p.T27R 2 Trimborn et al., 2005 
4 150-200Kb deletion++ Truncated protein 1 to 6 Garshasbi et al., 2005 
5 c.302C>G S101* 4 Farooq et al., 2010 
6 del exon 4 Truncated protein 4 Darvish et al., 2010 
7 c.566_567insA p.Asn189fs 6 Darvish et al., 2010 
8 del exon 2&3 Truncated protein 2 and 3 Darvish et al., 2010 
9 c.436+1G>T Truncated protein 5 Darvish et al., 2010 
10 c.147C>G p.His49>Gln 3 Darvish et al., 2010 
11 del exon 3 Truncated protein 3 Darvish et al., 2010 
12 c.215C>T p.Ser72>Leu 3 Darvish et al., 2010 
13 c.1178delG p.R393Sfs*50+++ 8 This study 
+ Insertion resulted in a frameshift incorporating 4 amino acids followed by a stop codon  
++ Deletion of approximately 150-200 kb, encompassing the promoter and first 6 exons 
+++ Deletion of a single nucleotide G causes a frameshift incorporating 49 amino acids followed 
by a stop codon (p.R393Sfs*50).  
 
In CENPJ, the causative gene of the MCPH6 locus, four mutations have been reported in 
families from Iran, Brazil and Pakistan (Bond et al., 2005, Darvish et al., 2010, Gul et al., 
2006a). I have identified one already reported mutation (p.Thr6fs*3) in CENPJ increasing 
its prevalence in the Pakistani society (Table 5.2). 
Table 5.2: Summary of reported CENPJ mutations 
No. cDNA Protein 
Affected 
Exon 
References 
1 c.17delC p.Thr6fs*3 1 Bond et al., 2005, present study
2 c.2462C>T p.Thr821Met 7 Darvish et al., 2010 
3 c.3243delTCAG p.S1081fs 11 Gul et al., 2006a 
4 c.3704A>T p.E1235V 16 Bond et al., 2005 
 
The MCPH2 locus was identified in 1999 but the causative gene of this locus (WDR62) 
was only recently reported by two independent groups (Yu et al., 2010, Nicholas et al., 
2010). They have reported 10 novel pathogenic variants in WDR62. Among these are, 
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three missense mutations, while the other seven are truncating the WDR62 protein. I 
have identified two novel variants in WDR62 which increased the total number of different 
mutations to 12 (Table 5.3).   
Mutations in the WDR62 gene have also been reported in patients afflicted with 
microcephaly and cortical abnormalities. One missense (W224S) and four nonsense 
(Q470*, E526*, G1280Afs*21, V1402Gfs*12) mutations were identified (Bilguvar et al., 
2010). 
Table 5.3: Summary of reported WDR62 mutations 
 
5.2. WDR62, the causative gene of the MCPH2 locus  
Among 30 MCP families analyzed during this study, two (MCP14 and MCP59) were 
linked to the MCPH2 locus. The linkage interval was reduced from the originally reported 
7.6cM to 2.8cM by using highly polymorphic microsatellite markers. Sequencing analysis 
of 8 candidate genes residing in this small region did not show any pathogenic mutation. 
Later on one group reported WDR62 as causative gene of the MCPH2 locus. The 
position of the WDR62 gene (41,237,623bp to 41,287,852bp according to NCBI Human 
Genome Build 36.3) is however outside of the linkage interval defined by family MCP14 
(38,760,490 to 41,220,124bp) (Figure 4.7). Unfortunately, I have observed 
heterozygosity of two different markers (D19S224 and M19SH2) adjacent to this region. 
Interestingly homozygosity mapping based exclusively on the SNP markers of 
chromosome 19 defined the correct linkage interval of the MCPH2 locus between 
No. cDNA mutation Protein mutation Affected Exon References 
1 c.193G>A p.Val65Met 2 Yu et al., 2010 
2 c.363delT p.Asp112Mfs*5 4 Yu et al., 2010 
3 c.1043+1G>A p.Ser348Rfs*63 8 Yu et al., 2010 
4 c.2867+4_c.2867+7delGGTG p.Ser956Cfs*38 23 Yu et al., 2010 
5 c.3839_3855delGCCAAGAGCCTGCCCTG p.Gly1280Afs*21 30 Yu et al., 2010 
6 c.1313G>A p.Arg438His 10 Nicholas et al., 2010 
7 c.1531G>A p.Asp511Asn 11 Nicholas et al., 2010 
8 c.3232G>A p.Ala1078Thr 27 Nicholas et al., 2010 
9 c.3936dupC p.Val1314Rfs*18 30 Nicholas et al., 2010 
10 c.4241dup p.Leu1414Lfs*41 31 Nicholas et al., 2010
11 c.332G>C p.R111T 3 This study 
12 c.3503G>A p.W1168* 29 This study 
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rs3786913 (physical position 38,678,914bp) and rs2271844 (physical position 
41,592,850 bp) with WDR62 included (Figure 4.8). Sequencing analysis of MCP14 and 
59 revealed two novel homozygous mutations in the WDR62 gene (Table 5.3). Obviously 
the homozygosity analysis via STR markers did not provide reliable data and should be 
avoided in future studies as a method for reducing any linkage interval defined by SNP 
data. 
5.3. CEP152 and the MCPH4 locus 
The MCPH4 locus was originally identified on chromosome 15q15-q21 with a 19 cM 
minimal critical region mapped between markers ACTC and D15S98 (Jamieson et al., 
1999). Homozygosity mapping of five MCP families (further three families from Denmark 
and Belgium) reduced the linkage interval to 2.08 Mb between rs936532 (37,585,407 bp) 
and rs1819454 (39,669,675 bp). I have identified one missense variant (c.2437G>T, 
p.E813*) in the leukocyte receptor tyrosine kinase (LTK) gene residing in a newly defined 
region. I was however unable to find any further pathogenic variant in any one of the four 
other MCPH4 linked families. Recently one group from Canada claimed to have identified 
CEP152 as the causative gene of the MCPH4 locus (Guernsey et al., 2010). Sequencing 
results of the CEP152 gene excluded any pathogenic variant in our MCPH4 linked 
families which is in line with the fact that CEP152 is not located in the reduced 2.08 Mb 
critical interval. These results indicate that either CEP152 is not the causative gene of the 
MCPH4 locus, so there might be the possibility of another causative gene at the MCPH4 
locus, or in our MCPH4 linked families the mutation might be located in the regulatory 
elements of CEP152. It also might be the case that the leukocyte receptor tyrosine kinase 
(LTK) gene is the MCPH4 causative gene because the variant c.2437G>T was not found 
in 768 Pakistani healthy control chromosomes and mutations in further MCPH4 linked 
families might be located in the regulatory elements of LTK. However, the mutation in 
LTK might also represent a non-pathogenic nonsense variant which seem to be quite 
common in human genomes (Yngvadottir et al., 2009). 
5.4. Identification of novel loci 
Five families could not be linked to any of the known MCPH loci and subsequently lead to 
the discovery of 5 new gene loci, MCPH8-MCPH12, situated on different chromosomes. 
For two of the five new loci, namely MCPH8 on chromosome 7q21-q22 (LOD score 
10.47) and MCPH9 on chromosome 4p14-4q12 (LOD score 2.53), the causative genes 
could be identified in families MCP4 and MCP63, respectively. The MCPH10 locus was 
mapped on chromosome 12q14.1-12q14.2 in family MCP50 (LOD score 4.9). The 
MCPH11 locus is less precisely defined so far. It should be situated in one of the 
following three chromosomal regions, 3q12.1-3q12.3, 4q31.23-4q32.3, and 6q24.2-
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6q24.3. The 15.57 Mb region mapped on chromosome 4q31.23-4q32.3 would be most 
interesting to focus on in future whole-exome sequencing of MCP53. Nevertheless, the 
regions on chromosomes 3 and 6 should also be taken into account when scrutinizing the 
whole-exome sequencing data for pathogenic variants. The mapping data of the MCPH12 
locus are also still ambiguous. Three chromosomal regions will have to be considered, 
2q14.2, 6q22.32, or 11p15.4. The region on chromosome 6q22.32 seems to be most 
promising because it is the largest homozygous region found in family MCP67. 
5.5. CDK6 as novel MCPH gene 
In family MCP4, cyclin-dependent kinase 6 (CDK6) was identified as the causative gene 
of the MCPH8 locus, where a homozygous single base substitution c.589G>A was found 
in exon 5. The missense mutation (c.589G>A) in CDK6 changes an alanine with a 
threonine (p.A197T). Alanine is strictly conserved in this position in vertebrates and even 
up to the sea urchin homolog but is not conserved in other human CDKs except for CDK4 
which is considered the closest homolog of CDK6 (Figure 4.27). 
The cyclin-dependent kinase CDK6, a protein of 326 amino acids, together with CDK4 
and cyclin D act in concert with CDK2 and cyclin E to regulate the G1 phase and the 
G1/S transition of the cell cycle. Active CDK4/6 phosphorylate the retinoblastoma tumor 
suppressor protein (pRb), releasing the transcription factor E2F which induces the 
transcription of genes including Cyclins A, Cyclin E, DNA polymerase and Thymidine 
kinase ultimately allowing the cells to enter S-Phase, whereas the INK4 family of 
inhibitors prevent CDK4/6 activity (Meyerson and Harlow, 1994). CDK6 also plays a role 
in the differentiation of a variety of cell types. CDK6-null mice are viable, develop 
normally, display normal organogenesis and cell proliferation in most tissues; however 
hematopoiesis was impaired (Malumbres et al., 2004).  
In non-dividing cells CDK6 was reported to localize in the nucleus and to the cytoplasm 
with particular enrichment in cytoplasmic protrusions (Kohrt et al., 2009). I found that 
CDK6 is not only present in the cytosol and in the nucleus but localises also to the spindle 
poles (centrosome) during mitosis from prophase to telophase as exemplary shown for 
HaCaT cells (Figure 4.28). Spindle pole localization of CDK6 is similar to the localization 
of other MCPH proteins like ASPM, STIL and WDR62 (Bond et al., 2005, Pfaff et al., 
2007, Bond and Woods, 2006, Nicholas et al., 2010).  
Analysis of CDK6 patient primary fibroblasts revealed defects in the growth rate of the 
cells, aberrant nuclear shape as well as an increased centrosome-nucleus distance as 
compared to control primary fibroblasts. Suppression of CDK6 by shRNA resulted in 
similar defects, with regard to nuclear shape and growth rate. Furthermore the 
microtubule system was disorganised. Overexpression of mutant CDK6 produced 
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multiple centrosomes and also resulted in disorganised microtubules which confirmed its 
role in microtubule dynamics (see Table 5.4 for statistical analysis).  
A disorganised microtubule system was also reported for other MCPH proteins, where 
depletion of known MCPH proteins or their homologs led to the production of abnormal 
microtubules (Thornton and Woods, 2009). Furthermore, the centrosome abnormalities of 
CDK6 patient fibroblasts might also be the result of perturbed centrosome duplication as 
the Rb/E2F pathway regulates centrosome duplication (Meraldi et al., 1999) and the 
phosphorylation of Rb protein is mediated by CDK6-Cyclin D. Cyclin D1 and D2 are 
regulatory subunits of CDK6 and are expressed in the neural progenitor cells of the 
ventricular zone (VZ) and subventricular zone (SVZ), respectively (Meyerson and Harlow, 
1994), (Glickstein et al., 2009). Mice lacking Cyclin D2 show reduced proliferation and 
enhanced cell cycle exit in embryonic cortical progenitors and were microcephalic. It was 
also demonstrated that Cyclin D2 is used for radial glial cells (RGCs) transition to 
intermediate progenitor cells (IPCs) and is important for expansion of the IPC number 
(Glickstein et al., 2009). CDK6 activity is observed at the mid G1 phase of the cell cycle 
and is responsible for G1 progression and G1 to S phase transition. These are the stages 
where centrosomes and subsequently genomic DNA are duplicated. 
Table 5.4: Statistical analysis of CDK6 mutant and control primary fibroblasts and 
HaCaT control and CDK6 knockdown cells.  
Phenotype 
Mutant/ 
Knockdown 
Control P Value N 
Dividing primary 
fibroblasts after 
synchronization at G0/G1 
0.34 ± 0.17 3.11 ± 0.42 3.32E-04 900 
Misshapen nuclei in 
primary fibroblasts after 
synchronization at G0/G1 
12.34 ± 0.71 2.34 ± 0.24 1.83477E-06 900 
Dividing cells after CDK6 
knockdown 4.45 ± 0.5 15.3 ± 0.69 1.02517E-06 900 
Cells with misshapen 
nuclei after CDK6 
knockdown 
21.34 ± 2.02 10 ± 0.5 4.72E-04 900 
Centrosome-nucleus 
distance (µm) measured 
in control and mutant 
primary fibroblasts 
5.1646 ± 
0.2661 
3.4514 ± 
0.6062  8.286E-03  50 
Results are shown in terms of mean ± s.e.m and the corresponding P values (Student’s t-
test) which are calculated with control versus mutant data. N is the number of cells 
analysed. 
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An interaction between known MCPH proteins and transcription factor E2F has already 
been reported. Microcephalin promotes the expression of CHK1 and BRCA1 through 
interaction with transcription factor E2F1 and enhancement of their transcription as well 
as other E2F targeted genes involved in DNA repair and apoptosis such as RAD51, 
DDB2, TOPBP1, p73 and caspases (Yang et al., 2008). STIL expression is also regulated 
by transcription factor E2F, and it is required for E2F induced transition through mitosis 
(Erez et al., 2008). Based on these results I speculate that the expression of STIL is 
regulated by CDK6, because active CDK6 protein complex regulates transcription factor 
E2F and there might be a common pathway between microcephalin and CDK6 to 
regulate the expression of E2F. 
 
Figure 5.1: Three-dimensional structure of CDK6 with its activator cyclin K and 
inhibitor INK4. Red balls (Ala 197) indicate the position of the mutation (p.A197T). 
Phosphorylation of Thr177 activates the enzyme, phosphorylation of Tyr24 leads to 
inactivation. 
The consequences of the A197T mutation in the patient are currently unclear as this 
region is not directly implicated in cyclin or INK binding nor is the ATP-binding site or the 
catalytic center directly affected (Figure 5.1). Based on the data obtained with the 
patient’s fibroblasts, CDK6 knockdown, and overexpression of wild-type and mutant 
CDK6, I propose that the A197T mutation may lead to reduced cell proliferation and also 
affects the correct functioning of the centrosome in microtubule organisation and its 
positioning near the nucleus. 
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5.6. CEP135 as novel MCPH gene 
The gene on chromosome 4p14-4q12 encoding the centrosomal protein 135 kDa 
(CEP135) was mutated in family MCP63, where a homozygous single base deletion 
c.970delC in exon 8 of this gene was found. The CEP135 gene is composed of 26 exons 
(Fig. 2d). The 3,423-bp ORF encodes a 1,140 amino acids protein. CEP135 was 
previously identified as a centrosomal component by proteomic analysis and localizes 
around the centriolar surface as well as within the proximal lumen of the centrioles 
(Andersen et al., 2003, Kleylein-Sohn et al., 2007). Knockdown of CEP135 caused 
premature centrosome splitting and disorganized interphase and mitotic spindle 
microtubules (Kim et al., 2008, Ohta et al., 2002). A role in procentriole formation has 
been uncovered where CEP135 and CENPJ (MCPH6 protein) form a core structure 
within the proximal lumen of both parental and nascent centrioles (Kleylein-Sohn et al., 
2007). 
I observed in CEP135 patient primary fibroblasts alterations with regard to the 
centrosome, microtubules, cell division and nuclear shape (Table 5.5). The centrosomes 
were either multiple in number or completely missing in the patient cells which is 
consistent with its proposed scaffolding role during centriole biogenesis (Kleylein-Sohn et 
al., 2007) and the premature centrosome splitting and disorganized interphase and 
mitotic spindle microtubules after CEP135 (Kim et al., 2008, Ohta et al., 2002) and 
confirm CEP135´s role in centriole biogenesis. CEP135 patient’s fibroblasts also exhibit 
slow growth rate and I was unable to detect any single dividing cell, even though the 
disorganised microtubule network was only observed during interphase. Overexpression 
of wild-type and mutant CEP135 also leads to disorganised microtubules and the mutant 
protein led to the production of multiple centrosomes. Similar results have been reported 
previously where ectopic expression of the CEP135 mutants (one mutant coding only 1-
658 and other coding 648 to 1141 amino acids) proteins also caused centrosome splitting 
in association with a reduction of the levels of centrosomal C-NAP1 (Kim et al., 2008). 
The abnormal centrosome number strengthens the role of CEP135 in centriole 
biogenesis, whereas a disorganisation of the microtubule network points out its role at the 
centrosome as microtubule organising center.  
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Table 5.5: Statistical analysis of CEP135 mutant and control primary fibroblasts.  
Phenotype Mutant Control P Value N 
Primary fibroblasts having 
misshapen nuclei 20 ± 1.15 3 ± 0.58 3.44E-03 300 
Primary fibroblasts with 
multiple centrosomes 18.67 ± 2.73 0 0.0207 300 
Primary fibroblasts without 
centrosomes 22 ± 2.31 0 0.0441 300 
Primary fibroblasts with 
disorganised microtubules 55.33 ± 2.60 0 0.0022 300 
Results are shown in terms of mean ± s.e.m with corresponding P values (Student’s t-
test). N is the number of cells analysed. 
 
5.7. Cdk6 and Cep135 expression in the neuroepithelium of the mouse 
cerebral cortex 
Most known MCPH proteins are expressed in the ventricular zone (VZ) of the mouse 
neuroepithelium, particularly in progenitors undergoing proliferative divisions (Thornton 
and Woods, 2009). Our study also shows a strong staining for CEP135 and CDK6 in the 
developing neuroepithelium of the cerebral cortex. Detection of CEP135 and CDK6 at 
E11.5 and E15.5 shows that both proteins are expressed in the neuroepithelium of the 
developing cortex during neurogenesis. This localization is reminiscent of that of WDR62, 
a spindle pole protein expressed in neuronal precursor cells undergoing mitosis in the 
mammalian embryonic neuroepithelium. Mutations in this protein presumably decrease 
the number of neuronal precursor cells giving rise to microcephaly (Nicholas et al., 2010, 
Yu et al., 2010). Our studies suggest that CEP135 and CDK6 are important components 
of the spindle pole and might be involved in controling the position of the central spindle 
and regulation of cytokinesis. 
5.8. Final conclusions and outlook 
Brain size is largely determined by the relative rates of proliferation and cell death, and 
proteins encoded by MCPH genes have been shown to play a prominent role in several 
key steps of developmental processes that could be responsible for a marked reduction 
of the cortical area, such as cell cycle progression, DNA and spindle checkpoints as well 
as centrosome and spindle apparatus integrity. Some common pathways have been 
identified for MCPH proteins such as the interaction of MCPH1 and STIL with 
transcription factor E2F (Kaindl et al., 2010).  
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In this work I propose a novel role for CDK6 at the centrosome during particular cell cycle 
phases. Together with the implication of the centrosomal component CEP135 in MCPH 
this strengthens the role of centrosomes and spindle poles in the etiology of MCPH. In 
line with previous suggestions I speculate that mutations in these proteins can affect 
proliferation of apical neuronal precursor cells and/or can create an imbalance of 
symmetric and asymmetric cell division resulting in depletion of the progenitor pool which 
may be the cause of reduced neuron production.  
 
Figure 5.2: A model of CDK6 and CEP135 functions during neurogenesis. Loss of 
CDK6 might cause premature mitotic entry which affects centrosome maturation. Loss of 
CEP135 is suggested to results in immature centrosomes or a loss of the centriole. The 
immature centrosomes have a reduced PCM accumulation and can affect spindle 
orientation during division due to formation of fewer astral microtubules. CDK6 like ASPM 
localizes to the spindle pole of the centrosome and directly regulates spindle positioning. 
Impaired spindle alignment can result in asymmetric divisions and reduction of the 
progenitor pool, which ultimately results in fewer neurons. The idea was expanded from 
Thornton and Woods, 2009.  
 
Elucidation of further MCPH genes and their pathomechanisms will not only increase our 
knowledge of this Mendelian disease but also enhance our understanding of the normal 
brain development and of the evolution of the brain development. Moreover, the 
identification of novel loci, genes and their pathogenic variants in Pakistani families as 
analyzed in this study will help to design improved strategies of genetic counseling in 
Pakistan and will also be of great importance to establish prenatal diagnosis and carrier 
screening in this country.  
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6. Abstract 
Autosomal recessive primary microcephaly (MCPH) is a rare genetic disorder in which 
the afflicted individuals have head circumference more than 3 SDs below the age- and 
sex-related mean. The reduced head circumference is due to a small but architecturally 
normal cerebral cortex. MCPH is characterized by a pronounced heterogeneity with 
seven loci, designated MCPH1-7, have already been identified. The underlying genetic 
defects were found in the following seven genes, MCPH1, WDR62, CDK5RAP2, 
CEP152, ASPM, CENPJ, and STIL/SIL. The incidence of this disorder is highest in 
Pakistan (Woods et al., 2005).  
Here, I ascertained thirty families with MCPH from various regions of Pakistan. 
Homozygosity mapping revealed linkage in 19 families to the MCPH5 locus, in 2 to 
MCPH2, in 2 to MCPH4, in 1 to MCPH1, in 1 to MCPH6, and in 5 families linkage to all 
known MCPH loci was excluded. Families linked to the MCPH1, MCPH2, MCPH5, and 
MCPH6 loci were also subjected to direct genomic sequencing of the corresponding 
genes, i.e. MCPH1, WDR62, ASPM, and CENPJ, respectively. This revealed one, two, 
and nine novel mutations in MCPH1, WDR62, and ASPM, respectively. Genome-wide 
linkage analysis in the 5 families previously excluded to be linked to any of the known loci 
resulted in 5 different new gene loci, MCPH8-MCPH12, situated on different 
chromosomes. For two of the five new loci, namely MCPH8 on chromosome 7q21-q22 
(LOD score 10.47) and MCPH9 on chromosome 4p14-4q12 (LOD score 2.53), the 
causative genes could be identified. Positional candidate gene sequencing revealed 
mutations in CDK6 (c.589G>A, p.A197T) at the MCPH8 locus and in CEP135 (c.970delC, 
p.Gln324Serfs*2) at the MCPH9 locus as the most likely pathogenic variants. These 
variants were not found in 768 chromosomes from healthy Pakistani controls.  
These two novel MCPH proteins cyclin-dependent kinase 6 (CDK6) and a centrosomal 
protein of 135kDa (CEP135) presented as transient or permanent components of the 
centrosome. Cdk6 and Cep135 showed a high expression level in the developing 
neuroepithelium of the mouse cerebral cortex of E11.5 and E15.5 embryos. In human cell 
lines, the localization of CDK6 at the spindle pole was observed. Primary fibroblasts of 
the patient with the CDK6 mutation failed to grow normally and showed an aberrant 
nuclear shape as well as centrosome-nucleus distance. CDK6 suppression by shRNA 
mimicked the defects in cell proliferation, nuclear shape, and microtubule organization. 
Likewise, overexpression of mutant CDK6 resulted in the production of multiple 
centrosomes and disorganised microtubules. Primary fibroblasts of the patient with the 
CEP135 mutation showed multiple and fragmented centrosomes, a disorganised 
microtubule system, misshapen and fragmented nuclei, and sometimes a complete loss 
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of centrosomes. Altered levels of wild-type and mutant CEP135 protein by 
overexpression caused disorganization of microtubules, while overexpression of mutant 
CEP135 showed also multiple centrosomes observed before in the patient’s primary 
fibroblasts. 
Based on the data on CDK6, I propose that mutation p.A197T may lead to a reduced cell 
proliferation and may also affect the correct functioning of the centrosome in microtubule 
organisation and its positioning near the nucleus. The abnormal centrosome number 
associated with mutant CEP135 strengthens its role in centriole biogenesis, whereas a 
disorganisation of the microtubule network points to its role at the centrosome as a 
microtubule organising center. The data obtained lend further support to the hypothesis 
that the exquisite control of the cleavage furrow orientation in mammalian neural 
precursor cell mitosis, controlled in great part by the centrosomes and spindle poles, is 
critical in the etiology of MCPH (Fish et al., 2006, Thornton and Woods, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
119 
 
7. Zusammenfassung 
Autosomal rezessive primäre Mikrozephalie (MCPH) ist eine seltene, genetisch bedingte 
Erkrankung, bei der die Betroffenen einen verringerten Kopfumfang von mindestens drei 
Standardabweichungen unter dem für das Alter und Geschlecht durchschnittlichen 
Normalwert haben. Der reduzierte Kopfumfang ist auf eine kleinere, aber architektonisch 
normale Hirnrinde zurückzuführen. MCPH ist durch eine ausgeprägte genetische 
Heterogenität gekennzeichnet. Bisher sind sieben Loci bekannt, die als MCPH1-7 
bezeichnet werden. Die zugrundeliegenden genetischen Defekte wurden in den 
folgenden sieben Genen gefunden: MCPH1, WDR62, CDK5RAP2, CEP152, ASPM, 
CENPJ und STIL/SIL. Die Inzidenz dieser Erkrankung ist in Pakistan am höchsten 
(Woods et al., 2005).  
In der vorliegenden Arbeit wurden dreißig Familien mit MCPH aus verschiedenen 
Regionen Pakistans untersucht. Homozygotie-Kartierungen ergaben, dass die 
Erkrankung in 19 Familien mit dem MCPH5-Lokus, in zwei Familien mit dem MCPH2-
Lokus, in zwei weiteren Familien mit dem MCPH4-Lokus, in einer Familie mit dem 
MCPH1-Lokus und in einer anderen Familie mit dem MCPH6 gekoppelt ist. In fünf 
Familen wurden alle bekannten MCPH-Loci ausgeschlossen. In den Familien, bei denen 
eine Kopplung mit dem MCPH1-, MCPH2-, MCPH5- oder MCPH6-Lokus vorlag, wurden 
die entsprechenden Gene, d. h. MCPH1 WDR62, ASPM und CENPJ, genomisch 
sequenziert. Dabei konnten in den Genen MCPH1, WDR62 und ASPM eine, zwei bzw. 
neun neue Mutationen gefunden werden. Eine genomweite Kopplungsanalyse in den 5 
Familien, in denen zuvor eine Kopplung zu bekannten Loci ausgeschlossen worden war, 
resultierte in 5 verschiedenen neuen Loci, MCPH8-MCPH12, die sich auf verschiedenen 
Chromosomen befinden. Für zwei der fünf neuen Loci, MCPH8 auf Chromosom 7q21-
q22 (LOD-Score 10,47) und MCPH9 auf Chromosom 4p14-4q12 (LOD-Score 2,53), 
konnten die ursächlichen Gene identifiziert werden. Positionelle 
Kandidatengensequenzierungen offenbarten Mutationen in CDK6 (c.589G> A, p.A197T, 
MCPH8-Lokus) und in CEP135 (c.970delC, p.Gln324Serfs*2, MCPH9-Lokus) als die 
jeweils wahrscheinlichsten pathogenen Varianten. Diese Varianten waren in 768 
Chromosomen gesunder pakistanischer Kontrollen nicht nachweisbar. 
Die zu den neuen MCPH-Genen korrespondierenden Proteine, die Cyclin-abhängige 
Kinase 6 (CDK6) und das Zentrosomale Protein 135 kDa (CEP135), stellen 
vorübergehende oder dauerhafte Komponenten des Zentrosoms dar. In Mausembryonen 
(Stadien E11.5 und E15.5) zeigen die Proteine Cdk6 und Cep135 eine hohe Expression 
im sich entwickelnden Neuroepithel der Großhirnrinde. In humanen Zelllinien konnte 
erstmalig die Lokalisation von CDK6 am Spindelpol beobachtet werden. Primäre 
120 
 
Fibroblasten des Patienten mit der CDK6-Mutation wuchsen sehr schlecht und zeigten 
eine abweichende Kernform sowie einen extremen Zentrosom-Kern-Abstand. Die CDK6-
Inhibierung durch shRNA ahmte die Proliferationschwäche der Zellen, die veränderte 
Kernform und die gestörte Mikrotubuli-Organisation nach. Ebenso führte die 
Überexpression von mutiertem CDK6 zur Bildung von multiplen Zentrosomen und 
desorganisierten Mikrotubuli. Primäre Fibroblasten des Patienten mit der CEP135-
Mutation zeigten multiple und fragmentierte Zentrosomen, ein desorganisiertes 
Mikrotubuli-System, deformierte und fragmentierte Kerne sowie manchmal einen 
vollständigen Verlust der Zentrosomen. Eine Überexpression von Wild-typ und mutiertem 
CEP135-Protein führte zu einer Desorganisation der Mikrotubuli, während bei der 
Überexpression von mutiertem CEP135 zusätzlich multiple Zentrosomen wie zuvor in den 
primären Fibroblasten des Patienten zu beobachten waren.  
Basierend auf den CDK6-Daten kann vermutet werden, dass die Mutation p.A197T zu 
einer verringerten Zellproliferation führt und auch die korrekte Funktion der Zentrosomen 
für die Mikrotubuli-Organisation und ihre Positionierung in der Nähe des Kerns 
beeinträchtigt ist. Die abnorme Zentrosomenzahl, die mit dem mutierten CEP135 
assoziiert ist, weist auf die Rolle dieses Proteins in der Zentriol-Biogenese hin, während 
die Desorganisation der Mikrotubuli auf seine Rolle am Zentrosom als Mikrotubuli-
organisierendes Zentrum hindeutet.  
Die gewonnenen Daten bestätigen erneut die Hypothese, dass die exquisite Kontrolle der 
Teilungsfurchenorientierung während der Mitose der neuralen Vorläuferzellen, die in 
starkem Maße von den Zentrosomen und den Spindelpolen kontrolliert wird, für die 
Ätiologie der MCPH entscheidend ist (Fish et al., 2006, Thornton and Woods, 2009). 
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9. Abbreviations 
 
Asp   Abnormal spindle gene 
ASPM    Abnormal Spindle-like Microcephaly-associated 
Asl   Asterless 
APS   Adenosine 5’ Phosphosulfate  
BRCT   Breast cancer 1(BRCA1) C-terminal 
CDK5RAP2  Cyclin Dependent Kinase 5 Regulatory Associated Protein 2 
CDK6   Cyclin-dependent Kinase 6 
CEP135  Centrosomal protein 135 kDa  
CENPJ   Centromere Protein J 
CEP152  Centrosomal Protein of 152 kDa 
CPAP   Centrosomal protein 4.1- associated protein  
Cnn   Centrosomin 
CT   Computerized tomography  
DAPI   4’, 6-Diamidino-2’-phenylindole 
DMEM   Dulbecco´s Modified Eagle´s Medium 
ECL    Enhanced chemiluminescence 
FBS   Fetal bovine serum  
HC   Head circumference 
IPCs   Intermediate progenitor cells 
IQ   Isoleucine-Glutamine  
LB   Luria Bertani  
LMW   Low Molecular Weight 
LOD   Logarithm of the odds 
LTK   Leukocyte receptor tyrosine kinase 
MCPH   Autosomal recessive primary microcephaly 
MBD   Microtubule-binding domain 
MRI   Magnetic resonance imaging 
MCPH1  Autosomal recessive primary microcephaly locus 1 
MCPH2  Autosomal recessive primary microcephaly locus 2 
MCPH3  Autosomal recessive primary microcephaly locus 3 
MCPH4  Autosomal recessive primary microcephaly locus 4 
MCPH5  Autosomal recessive primary microcephaly locus 5 
MCPH6  Autosomal recessive primary microcephaly locus 6 
MCPH7  Autosomal recessive primary microcephaly locus 7 
MCPH8  Autosomal recessive primary microcephaly locus 8 
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MCPH9  Autosomal recessive primary microcephaly locus 9 
MCPH10  Autosomal recessive primary microcephaly locus 10 
MCPH11  Autosomal recessive primary microcephaly locus 11 
MCPH12  Autosomal recessive primary microcephaly locus 12 
MDD   Microtubule-destabilising domain  
NCBI   National Center for Biotechnology Information 
NE   Neuroepithelial 
NMR    Nuclear magnetic resonance 
ORF    Open Reading Frame 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PCM   Pericentriolar matrix 
PCNT   Pericentrin 
PIC   Proteinase Inhibitor Cocktail 
Plk4   Polo-like-kinase 4 
pRB   Retinoblastoma tumor suppressor protein  
RT-PCR  Reverse transcriptase PCR  
SAP   Shrimp Alkaline Phosphatase  
SD   Standard deviation 
SDS-PAGE   SDS-polyacrylamide gel electrophoresis  
shRNA   short hairpin RNA 
STR    Short tandem repeat 
SVZ   Subventricular zone 
STIL/SIL   SCL/TAL1 interrupting locus 
TBS   Tris-buffered saline 
VZ   Ventricular zone 
WDR62   WD repeat domain 62 
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Appendices 
Appendix 1 
Microsatellite markers spanning the identified interval of six MCPH loci with additional 
information of amplification condition, fluorescent dyes, repeat unit size and physical 
positions. Physical positions in term of base pair is taken from NCBI Human Genome 
Build 36.3 and in term of Centimorgan (cM) are taken from Marshfield genetic map. In 
marker M19SH1, M stands for microsatellite, 19 is chromosome number, SH is the name 
of marker developer (in this case SH means Sajid Hussain) and 1 stands for 1st primer of 
this region. 
 
Locus Marker PCR 
Prog
. 
Dye Repe-
at unit 
PCR 
product 
size (bp) 
Posit
ion 
(cM) 
Physical position (bp) 
MCPH1 D8S518 MS Fam Di 229-253 5.6 4475013-4475263 
 D8S1798 MS Tet Di 145-165 6.7 5090694-5091016 
 D8S1742 MS Fam Di 130-150 7.7 6201415-6201550  
 D8S277 MS Fam Di 148-180 8.34 6504133-6504278 
 D8S1819 MS Fam Di 207-223 10.0 6737377-6737597 
 D8S1825 MS Hex Di 127-143 15.4 8962276-8962408  
MCPH2  D19S226 MS Ned Di 191-233 42.3 14494401-14494643 
 D19S917 MS Tet Di 216-240 43.3 16222045-16222265 
 D19S49 MS Hex Di 102-126 50.8 26783346-26783462 
 D19S414 MS Hex Di 125-171 54.0 36606611-36606773 
 D19S416 MS Fam Di 165-185 58.7 38760490-38760654 
 D19S425 MS Fam Di 252-280 59.4 40185772-40186036 
 M19SH1 TDM Fam Di   464 60.0 41038399-41038449 
 M19SH12 MS Fam Di   295 61.0 41130340-41130382 
 M19SH14 MS Hex Di   293 61.0 41166101-41166127 
 D19S224 MS Tet Di 240-262 61.5 41219912-41220169 
 M19SH2 MS Hex Di   337 61.5 41220086-41220124 
 D19S896 MS Fam Di 194-220 62.0 42170482-42170679  
 M19SH9 MS Fam Di   237 62.0 42195509-42195555  
 D19S570 MS Fam Di 186-210 62.0 42419583-42419782 
 D19S420 MS Fam Di 251-267 66.3 48500639-48500901 
MCPH3 D9S302 TDM Fam Tetra 232-316 123.3 116120936-116121193 
 D9S934 MS Hex Tetra 206-230 128 120135575-120135798 
 D9S1872 TDM Fam Di 111-135 129.7 120829322-120829427 
 D9S1850 MS Ned Di 218-230 132.1 122490084-122490307 
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 D9S1682 MS Hex Di 200-208 132.1 124033006-124033207 
 D9S1881 MS Fam Di 220-236 135.9 126019300-126019529 
 D9S1825 MS Ned Di 127-145 136.5 126927953-126928083 
 D9S1821 TDM Hex Di 168-174 137.4 128369402-128369573 
 D9S1819 TDM  Di 228-236 136.5 129241188-129241414 
MCPH4 D15S1042 MS Ned Di 177-202 32.6 34050903-34051090 
 D15S1012 MS Fam Di 160-174 36.0 36794835-36795008 
 D15S1044   MS Fam Di 183-195 39.7 37456267-37456453 
 D15S146   MS Tet Di 217-227 39.7 37911344-37911564 
 D15S968 MS Tet Di 204-235 40.3 38432560-38432785 
 D15S641 MS Fam Tri 90-114 39.7 39631223-39631327 
 D15S537 MS Hex Tetra   185 40.3 42602780-42602964 
 D15S659 MS Hex Tetra 166-210 43.5 44161300-44161483 
 D15S1006 MS Fam Di 208-228 44.9 45334255-45334468 
 D15S126 TDM Fam Di 188-218 45.6 47089563-47089750 
 D15S1016 MS Hex Di 239-267 47.3 51320121-51320369 
 D15S962 MS Fam Di 282-294 47.9 54362360-54362643 
 D15S648 MS Hex Tri 242-260 47.9 55165601-55165839 
MCPH5 D1S2816 MS Fam Di 248-252 211.1 194917168-194917415 
 D1S1660 MS Fam Tetra 248-252 212.4 196877970-196878197 
 D1S1660 MS Fam Di 165-189 214.8 198381195-198381375 
 D1S373 MS Hex Tetra 283-330 214.0 198521109-198521419 
 D1S1723 MS Hex Di 167-181 215.1 199657511-199657681 
 D1S2655 MS Fam Di 224-260 216.8 200831893-200832140 
MCPH6 D13S1275 MS Ned Di 198-214 7cM  
 D13S787 MS Hex Tetra 231-271 8.87 23278738-23278989 
 D13S742 MS Hex Tetra   364  10.7 24180814-24181171 
 D13S283 MS Fam Di 128-153 11.5 24498985-24499113 
 D13S1294 MS Hex Di 247-273 12.9 25374909-25375159 
 D13S221 MS Ned Di 318-366 12.91 25474866-25475100 
 D13S1304 MS Hex Di 149-165 13.45 26268064-26268222 
 D13S1244 MS Fam Di 92-108 15.19 27144977-27145072 
 
 
 
 
 
134 
 
Appendix 2 
MCPH1 Sequencing Oligo used to sequence MCPH1 gene in MCP61 microcephaly 
family. 
 
MCPH1 Sequencing Oligo 
MCPH1-Ex1F CTCCCGCCTCACCTACAGAG 
MCPH1-Ex1R AGCAGTACGGGGGAGGAAG 
MCPH1-Ex2F GTCTCAAACCCCTGACTTCG 
MCPH1-Ex2R TCCTCCTCCTCACTCAATGC 
MCPH1-Ex3F TTCACCGTTGTAACTGGAACAG 
MCPH1-Ex3R TCCCCCTAGGCAGAGTTAGG 
MCPH1-Ex4F GGGAAGTTTGATTTATACTGACTTTTG 
MCPH1-Ex4R ACCACAGGCTTTTCCATTTC 
MCPH1-Ex5F TTGCCAGTTCACATACAGTGC 
MCPH1-Ex5R TATTATGGCTCCCAGCCAAG 
MCPH1-Ex6F CAACATCACTGCCTGTGGAG 
MCPH1-Ex6R CAAAGCCAGCCATGAAATAAG 
MCPH1-Ex7F CAGGCAAGTTGACTTTAAGATCC 
MCPH1-Ex7R GAGCAATGGATTCTGTAGCAAG 
MCPH1-Ex8-1F CCCTTAAGTGGAAATGAGAAGAAC 
MCPH1-Ex8-1R CAAACGATACTTCTCTTCAAACG 
MCPH1-Ex8-2F TCATCACCATCTTTCACTCACC 
MCPH1-Ex8-2R AACTGAGCAGGGCTTGATG 
MCPH1-Ex8-3F CTGGAGGCTCTTAGCTGTGG 
MCPH1-Ex8-3R CTTTTCAGACCAACCGCTTC 
MCPH1-Ex8-4F TTCGAGTTGCGTGACTTCTG 
MCPH1-Ex8-4R TCATTGGAATGATCAAATGCAC 
MCPH1-Ex9F TTTATTTAAAAGGCCTATAACTTCCTG 
MCPH1-Ex9R GCAAACAACGCTTTCAGTTTC 
MCPH1-Ex10F GCTTTGGGGACAGTATCTGAG 
MCPH1-Ex10R CTGCCTAAACAACCCCAGAG 
MCPH1-Ex11F TTTATTTCCCCAGGTTTCAAAG 
MCPH1-Ex11R GACCAACAGGAGGAAAGACG 
MCPH1-Ex12F TTCATAACATTTATGCAACATGAAG 
MCPH1-Ex12R AAAAGGTGTTAAGTTCTGTGAATGTC 
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MCPH1-Ex13F TGTCATCATCTTCTCTGGATTCTC 
MCPH1-Ex13R CGTCTGCTAACAGCAAGGAG 
MCPH1-Ex14F TTGTATTGAATTTCGTTTCACG 
MCPH1-Ex14R TCTTAAGAACCACAACACATGG 
 
Appendix 3 
Sequencing oligonucleotides used to find pathogenic variant in MCPH5 (ASPM) linked 
families. 
 
ASPM Sequencing Oligos 
ASPM-Ex1-1-F GATTCCGCTACCGTTCTCAC 
ASPM-Ex1-1-R AAGGAGACCTGCAGAAGTGG 
ASPM-Ex1-2-F GAATTCACTCCCACGACCTC 
ASPM-Ex1-2-R AAGAGCCACCCACAGTTATTG 
ASPM-Ex2-F TTCTTATAATTAAGCAGATAGGGTAGG 
ASPM-Ex2-R GCAATATTACTTCAAGCCTGTTATC 
ASPM-Ex3-1-F ATGTTTTAACCATTCTGTGATTTACTC 
ASPM-Ex3-1-R ACGTACAGAGAGTGGCAAGC 
ASPM-Ex3-2-F CCCCCAACAGAAAACAATTC 
ASPM-Ex3-2-R GGGGATAAAATAGGATTAACTGACTC 
ASPM-Ex3-3-F AGCCTGTGCATTTGGAATC 
ASPM-Ex3-3-R ACCCACTGCACTGTTGAGAC 
ASPM-Ex3-4-F GAAGGCCACCTGTACCAGAG 
ASPM-Ex3-4-R AGGAAATGTACCCAGCAAATAAG 
ASPM-Ex4-F TCATAGCATTAGTGCGTGGAG 
ASPM-Ex4-R TTCTTCCAGGCTGTTATTCAAC 
ASPM-Ex5-F TTCAGTGTTTTAAAGATGGTATTGC 
ASPM-Ex5-R GCTAATGAACAGGGAATTATGC 
ASPM-Ex6-F TGAAATTGCATTTTATTGCTG 
ASPM-Ex6-R AAAAACACAAAATCTCTTGAATG 
ASPM-Ex7-F TTTCCCACTGATATACTCTCCTTG 
ASPM-Ex7-R AAAAGATGAATCAAGCTAACCTAATG 
ASPM-Ex8-F TTATGGTCTGCCATTCCTCAG 
ASPM-Ex8-R GGAATGAGGGTGGAGGAAG 
ASPM-Ex9-F TTGCTACCCTACACTTTTTGTTTTAC 
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ASPM-Ex9-R GATGGGACTCACCAGACAGG 
ASPM-Ex10-F CAGAATGATTTGGAGGATTTG 
ASPM-Ex10-R GACATAACATTGATGTACCACTTCC 
ASPM-Ex11-F ATGGAGCAACAGAGTTTTGAG 
ASPM-Ex11-R AAAAGAAAAGGTTGTCCATTAGC 
ASPM-Ex12-F AGAGGTAAAACTTATTCTCCTCACTG 
ASPM-Ex12-R GTTACTGGGGCAAAATAAACC 
ASPM-Ex13-F TCCATTTCAGGCACTTTATTTTC 
ASPM-Ex13-R AAGAAATTCAAGAAAAGACTTCAGG 
ASPM-Ex14-F CTGCCTTTATTATTCACAGGTATTC 
ASPM-Ex14-R CTATTATGCAGGAGGAAAGGAG 
ASPM-Ex15-F TCCCTTTTGGTTACTTTTCC 
ASPM-Ex15-R AAAAACCCACAAAAGATAAAAAC 
ASPM-Ex16-F AATTCAATAATAAAGTCTCAGAAGATG 
ASPM-Ex16-R ATACTCATACCTCCCCAACC 
ASPM-Ex17-F TTCCAAAGATGAACACAAGAAG 
ASPM-Ex17-R ACCATAACGAGCTTTTCAGG 
ASPM-Ex18-1-F TGAATTGGCTACAGGTATATCAATG 
ASPM-Ex18-1-R CTTGTGATTGCATTTTACGTTG 
ASPM-Ex18-2-F GTTACAATTCAGAGGCATTGG 
ASPM-Ex18-2-R CGCTCAATCTTTCCTTTCAG 
ASPM-Ex18-3-F AGAAAAGATTTCGGTGCTTTC 
ASPM-Ex18-3-R AGACTGCAGCACAATGACAG 
ASPM-Ex18-4-F TCATTTCCGAGCTTATATTTTTG 
ASPM-Ex18-4-R AATACTGCCGAGCCTTTCTC 
ASPM-Ex18-5-F AGGATACCTTGTCCGAAAGC 
ASPM-Ex18-5-R AAATCACAGCTGCCTTTGTC 
ASPM-Ex18-6-F ACGCCAGCTAATCAAACAAC 
ASPM-Ex18-6-R CTTTTGTTGCACATGCATTC 
ASPM-Ex18-7-F TGTGGAAGGGAAAAACACTGAG 
ASPM-Ex18-7-R ATAAAAGTGGCTGCCCTGTG 
ASPM-Ex18-8-F AAGACAGCAATTAAAATCCAATCTG 
ASPM-Ex18-8-R GAATGAGAGTTGCGGCTATATG 
ASPM-Ex18-9-F CAGCAAAGATACTGGGCAATG 
ASPM-Ex18-9-R ATGCTGCCTCTGCAGTTTTG 
ASPM-Ex18-10-F GGGCTGCTACTTTCATCCAG 
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ASPM-Ex18-10-R GCATGTTTCCAAGTCTGAAATG 
ASPM-Ex18-11-F AAGGGCTGCAGTTCTCATTC 
ASPM-Ex18-11-R AATAATAATGGCAGCCTGGTG 
ASPM-Ex18-12-F CTTGTGTTCAGGCAGGTTTTC 
ASPM-Ex18-12-R GGCTGCCATCTTTTCCTCTG 
ASPM-Ex18-13-F GCTGCTTTTAGAGGCATGAAAG 
ASPM-Ex18-13-R TTGGTCAAAAGAAAGACTCACAG 
ASPM-Ex19-F ATGCAATTTATTTTTGTCTGCAC 
ASPM-Ex19-R CAGTACGAGAGATGTATTTTGTTTCC 
ASPM-Ex20-F ACTTCTTTCGTGTGCGTGTG 
ASPM-Ex20-R TGTGTGAAATAAATGCATACTTAGGTC 
ASPM-Ex21-F TGAAACATGGCATTCTTAGAC 
ASPM-Ex21-R TCAGTGCTCTTGTCACTTACC 
ASPM-Ex22-F TGATTAACTTAGGAGGCAGATACTTG 
ASPM-Ex22-R AACCCTCAAATCATTGTAACAGC 
ASPM-Ex23-F TGGACTGGAAAGGTTTTTGC 
ASPM-Ex23-R TGAGTTATTCTACCGGCTAATGC 
ASPM-Ex24-25-F GATGTAGATATAAATAGAAAACATTGG 
ASPM-Ex24-25-R CAGGGGCATATTTGTTGAC 
ASPM-Ex26-F AAAGTCCTTTGCACTTGCTG 
ASPM-Ex26-R TTTATCCGTGCAAAAAGCAG 
ASPM-Ex27-F GCGACAGAGCAAGAGAGACC 
ASPM-Ex27-R TGTTGTTTCTCCACTGAAAAGC 
ASPM-Ex28-F AAGGTGAAGGTAACTCTAAAGAGAAG 
ASPM-Ex28-R TTTTATGAAAATTCCTCAACTTACC 
 
Appendix 4 
Sequencing oligonucleotides used to find pathogenic variant in MCPH6 (CENPJ) linked 
family. 
CENPJ Sequencing Oligos 
CENPJ-Ex1-F CGCCTACGTCGACCACTG 
CENPJ-Ex1-R GAACGAAGCCACTGAACTGC 
CENPJ-Ex2-F GCCCAATTGCTTTGCTAGTT 
CENPJ-Ex2-R TTTCAGAGTGAAGGGGAAAAA 
CENPJ-Ex3-F TTTTAGATTTTCGGTGGCTGA 
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CENPJ-Ex3-R GCAGCTCCTTCTTGTTCCAG 
CENPJ-Ex4-F TGGTTTTGTTAAACACCATTTCC 
CENPJ-Ex4-R AACACGGCAACACTCCATCT 
CENPJ-Ex5-F CCGGCCTCAAGTGTCTTAAT 
CENPJ-Ex5-R GGCAGCTTGACATATCTCCTC 
CENPJ-Ex6-7F AGGTGTGGAGAGGGATTGTG 
CENPJ-Ex6-7R CCGCTGGAGTTGCTGTCTAT 
CENPJ-Ex7b-F AACAACCATTTTTAAAACGAGGAG 
CENPJ-Ex7b-R TCCTTTTCCTTTTCTCGTTCC 
CENPJ-Ex7c-F AAGAGCCCCATAAGGGAGAC 
CENPJ-Ex7c-R TGTGGGCTATCCTCTCTGCT 
CENPJ-Ex7d-F GCACTGACTCTGAGGAACAGC 
CENPJ-Ex7d-R TTGAGCAATAAGGAAAGTTAGGATTT 
CENPJ-Ex8-F AAATTCCCACTGATTTCCTCA 
CENPJ-Ex8-R TTGACTACCCTGGGTCATTTT 
CENPJ-Ex9-F GTAGGCACCCAATGAATGCT 
CENPJ-Ex9-R TTGCTGAATGAATGAATAATGGA 
CENPJ-Ex10-F TCGTCTTAAATGTCGTCTGTTGA 
CENPJ-Ex10-R TTCACAGTCACTCCCCACTG 
CENPJ-Ex11-F CTTGTTTGCTTTGGCCTGTT 
CENPJ-Ex11-R GGCGGAATAAGATGATGCAC 
CENPJ-Ex12-13-F CCTGTGTCGGAGAACTACAAA 
CENPJ-Ex12-13-R TCTGAACGAGAAATGGCAAC 
CENPJ-Ex14-15-16-F CGAGTTTGCTACTCCTCACG 
CENPJ-Ex14-15-16-R AATATGGGTGTCACATATCATCAG 
CENPJ-Ex17a-F GCAGAAACACTGTAGAAAGTTACAA 
CENPJ-Ex17a-R AAAAATGAAGATGCCACAGG 
CENPJ-Ex17b-F TGTACATTTACTGTGGATTCTGTTTA 
CENPJ-Ex17b-R CCATGATTACTACCTGTTGTGTG 
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Appendix 5 
Sequencing oligonucleotides used to find pathogenic variant in MCPH8 (CDK6) linked 
family. 
CDK6 Sequencing Oligos 
CDK6-Ex1F GCACACTCTGGGCTGCTC 
CDK6-Ex1R TACGAAGCCTCCATCGCTAC 
CDK6-Ex2-1F AAAGGAGGAGGAGGGGAGTC 
CDK6-Ex2-1R GGGGTGCGCTCAACTAGC 
CDK6-Ex2-2F GGGGAGCAAGTAAAGCTAGACC 
CDK6-Ex2-2R TTTCTGGGCCTGAGGATTC 
CDK6-Ex3F TTTTCTATTATGAGACCAAATTGAGC 
CDK6-Ex3R GGCAATTTTCATAAGGAAAGAAAG 
CDK6-Ex4F GCAGCCACAAAATGCTAAGG 
CDK6-Ex4R GAGACATGGAAGAGGGACAGAC 
CDK6-Ex5F GGAGTTCTTTCTGAACTACATCTTGTC 
CDK6-Ex5R AATGCCATGCTGCCACTC 
CDK6-Ex6F TTTTGCTTCCTGTGAAACAATG 
CDK6-Ex6R GCATGTCAGAGGAAAGTCACTG 
CDK6-Ex7F TTTGCCTTTCTCTGGAAATTG 
CDK6-Ex7R ACTGATATTTGTGCCCACCAC 
CDK6-Ex8F CCCACTGTAGATGCGCTTAAC 
CDK6-Ex8R TGAACATAAAGCTGCAATCACTC 
CDK6-EX8-2F CCTTCCAGCTGCTGTCTTC 
CDK6-EX8-2R TTCTTGTCGTTTACAAAAAGTAACAC 
CDK6-EX8-3F AGTGGGTAATCCAGGCACAG 
CDK6-EX8-3R GGGAAGAAAGGAATTTCAAACC 
CDK6-EX8-4F TCTTTTGGAAAATAGCCTGTAAGC 
CDK6-EX8-4R CCTGTTAGGTTTGCAGAATCG 
CDK6-EX8-5F TGTCTATCTCCCGGCACTTC 
CDK6-EX8-5R GCCAACTGAGCACTAAACCAC 
CDK6-EX8-6F GCCTGGGCATTGTAAACAG 
CDK6-EX8-6R ACCTGACCTTGAATGCTGTG 
CDK6-EX8-7F GGAGATGGGCCATACAAATG 
CDK6-EX8-7R TTCACTCAAATGCAACAACTACAC 
CDK6-EX8-8F GCACAAACATTCTGGCATTC 
CDK6-EX8-8R CCTTTGCCATGGGATTTC 
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CDK6-EX8-9F TGTTTGAATTTCATAGTAGGACCAG 
CDK6-EX8-9R TCAAGATGGATAGTACATTCTGGAG 
CDK6-EX8-10F TGAAAGCTTTAGAAGGCATGAG 
CDK6-EX8-10R TTTCTTTCCAGGGTAAATATTCTGTAG 
CDK6-EX8-11F TCCAAAAGCAGGCTTTAATTG 
CDK6-EX8-11R GTGGCATAGGAAACACATGC 
CDK6-EX8-12F AGAAGCTGTCCCAAGCAAAC 
CDK6-EX8-12R AAACATTTTGAAAAGCTGATTGG 
CDK6-EX8-13F CCAAAAATAATCCTTTGGTCTCTC 
CDK6-EX8-13R GCGCAGAAAAATAAAGTTAGAATG 
CDK6-EX8-14F AGGCTCTTTTCGAGCATCTG 
CDK6-EX8-14R AGGGAATTTGAAAGCAGCAG 
CDK6-EX8-15F AAAATTTTTGAAGTACCCAGTTACC 
CDK6-EX8-15R AAAATACTGCAATATCCTTCCCTAC 
CDK6-EX8-16F TGAGCATAACAACTTAGGAGTGTG 
CDK6-EX8-16R GTTTTGAGCACGAGCAAATG 
CDK6-EX8-17F TCCAGTTAAAGCCCCTATGC 
CDK6-EX8-17R CCAGGCATATCTTTCACCATC 
CDK6-EX8-18F CTGTCTACCCCGCATCTCTC 
CDK6-EX8-18R CGGAATTTTTCTAGGGACCAC 
CDK6-EX8-19F TCAAATGTAGGTTTTTCTCAAAGG 
CDK6-EX8-19R TTTCACAGGACTAGTGTGATTCAG 
CDK6-EX8-20F CTACCCCCAGGAACAGCAC 
CDK6-EX8-20R TACGAGGGCACTACATCACG 
CDK6-EX8-21F CTTAATTTAGAAACTGTGCCAGGTG 
CDK6-EX8-21R CCCTATGGCAATGCAGAAAC 
CDK6-EX8-22F GGTTAAAGGGCAAGTGTTTGG 
CDK6-EX8-22R CCAGCATCAGGAACCATCTC 
CDK6-EX8-23F TGCTCTCCATCTTCCTCCAC 
CDK6-EX8-23R CAGGCCACTGTGGTAACTCTC 
CDK6-EX8-24F GTTCTGCAGACCCAAGAAGC 
CDK6-EX8-24R AAACCCTGGGTCACAAAGC 
CDK6-EX8-25F CCTTCCTATCTGAGGAGGAGAATAG 
CDK6-EX8-25R AAAAGAAAATAGCCAGGAGAGTAATTC 
CDK6-EX8-26F TTGGTGTTGAAATATCACTGTCC 
CDK6-EX8-26R CATGCCCGGCTAGTTTTC 
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Appendix 6 
Oligonucleotide sequences used to knockdown the expression of CDK6. 
CDK6-shRNA-1-F 
TCACCAGAATGTTCTGTGGTTTTAGATCGAAGCTTGGATTTAAAACCATAGAACATTC
TGGTGGCCATTTTTT  
CDK6-shRNA-1-R 
GATCAAAAAATGGCCACCAGAATGTTCTATGGTTTTAAATCCAAGCTTCGATCTAAAA
CCACAGAACATTCTGGTGACG 
CDK6-shRNA-2-F 
TTCATCGATATCTGTTACAAACTTCTCAGAAGCTTGTGAGAAGTTTGTGACAGATATT
GATGAGCTATTTTTT 
CDK6-shRNA-2-R 
GATCAAAAAATAGCTCATCAATATCTGTCACAAACTTCTCACAAGCTTCTGAGAAGTT
TGTAACAGATATCGATGAACG 
CDK6-shRNA-C-F 
TTCCCATTAGTTAAACTAGCTCTTTTAAGAAGCTTGTTAGAAGAGTTAGTTTAATTAAT
GGGAACTGTTTTTT 
CDK6-shRNA-C-R 
GATCAAAAAACAGTTCCCATTAATTAAACTAACTCTTCTAACAAGCTTCTTAAAAGAG
CTAGTTTAACTAATGGGAACG 
 
Appendix 7 
Sequencing oligonucleotides used to find pathogenic variant in MCPH9 (CEP135) linked 
family. 
CEP135 sequencing Oligos 
CEP135-Ex1F CTGAGGTTTGGCATTTGCTG 
CEP135-Ex1R GCCTGGCCTCACTTCCTC 
CEP135-Ex2F CCAGAAGGCTACCTACCTGAAG 
CEP135-Ex2R AGAGTTCTGCCGTGTGGAAG 
CEP135-Ex3F CAGCTGCCCCCATTATAAATC 
CEP135-Ex3R CACACCATCCAGCTGTAGGAC 
CEP135-Ex4F TGAAGATTCTCTTTTGTGCTTAGTG 
CEP135-Ex4R GCATGAAAATCCAATCCAAAG 
CEP135-Ex5F TTGATAACCATGTCTTGTTGAGG 
CEP135-Ex5R AGTGCCGGTGCAAAGTTC 
CEP135-Ex6F ATTGATTTGGGGACCCTTTG 
CEP135-Ex6R AAAGCCACCTAAGCCATTCC 
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CEP135-Ex7F TGAATGTTAATCTCTTGCATACATTG 
CEP135-Ex7R TTCTATCAAATTTTTCCCATTGC 
CEP135-Ex8F CACTGCACATGGTCAGTTTTG 
CEP135-Ex8R CACTTCAGAAAACCCTGAATTACC 
CEP135-Ex9F TCACTGGTAAGAGGGAACGTG 
CEP135-Ex9R CATGTTGATGTGGCTGGATG 
CEP135-Ex10F CCACCCTCAAAGAAGCATTG 
CEP135-Ex10R TGGTTTTTGACTAATGGTAAGCAC 
CEP135-Ex11F CCTCTTCAATAGATTTGGTACCTACAG 
CEP135-Ex11R CAGGATTTTTCAAAGCAAGTACG 
CEP135-Ex12F AAAGGCACTTGTGTTCTTTTTG 
CEP135-Ex12R CATAGATAGGCTAGAAAAGGGAAAG 
CEP135-Ex13F GCGAAGAGAGTGACGGTAGC 
CEP135-Ex13R GGCCATACATAAACAAAGTGGTC 
CEP135-Ex14F TGTAAAAGATGAGAACGTATTGTGC 
CEP135-Ex14R GCTTGAAGCTGGAGTTGGAG 
CEP135-Ex15F CACCCATTCTGACTCTTAGAACC 
CEP135-Ex15R CAAAAGCTCCCAGGTGAGTC 
CEP135-Ex16F AGATGGAACCATTTTGGAGAAG 
CEP135-Ex16R ATGAGCCTCCTCATCCTGTG 
CEP135-Ex17F GAACTTGAATCAGCCCAAGC 
CEP135-Ex17R CCAAGAGATAGGGGTTGCAG 
CEP135-Ex18F AAGGGTTGGTCAAAACATGC 
CEP135-Ex18R CAAGCTGGAGACTGAGAAAATG 
CEP135-Ex19F TTAATAGGTCTCTTAATGCAGCAG 
CEP135-Ex19R AATACCCTGATAAACACCATTGTC 
CEP135-Ex20F GCTGTGATCACGCCATTG 
CEP135-Ex20R TGCAGGTACCACACTAAAATCTATG 
CEP135-Ex21F TGCCTTTTTCTATTTTTCCCATAG 
CEP135-Ex21R AATTGGCCAGGTGTGGTG 
CEP135-Ex22F AAATAGTAGGCAGCTTCCTGAGAG 
CEP135-Ex22R AGATGCCTGAGGGAGAATTG 
CEP135-Ex23F CCCAAAATGAAACAAGTGATAGG 
CEP135-Ex23R TGAGCTCAGGCAATCTACCC 
CEP135-Ex24F GAGAATTCTTGTTGAAAGGTCTTG 
CEP135-Ex24R GCTATTATCTTCCCCAACACTTG 
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CEP135-Ex25F AGAAGCAAGATGCTCCTCAC 
CEP135-Ex25R TATACCCACATAACTACTATCACCAAG 
 
Appendix 8 
Oligonucleotide sequences used to screen the control individuals of Pakistani population 
for variant (c.970delC p.Gln324Serfs*2) in CEP135 with pyrosequencing. 
 
CEP135-Ex8-DelC-F  BIOTIN-TGGAAACCAAGGAAACAGTGACAT 
CEP135-Ex8-DelC-R  TTTGCTTCCCCAAGCTCTTTATC 
CEP135-Ex8-DelC-S  CTTTCCAACTGCTGTG 
 
Appendix 9 
Oligonucleotide sequences used to screen the control individuals of Pakistani population 
for variant (c.2437G>T p.E813*) in LTK with pyrosequencing. 
 
LTK-ex20.GT-F        BIOTIN-CTGGGCTGGGGAACAGAT 
LTK-ex20.GT-R        ACTCAGTTCCTGGGGCTGTG 
LTK-ex20.GT-S      GGGGTCTTAGGCACT   
 
Appendix 10 
Sequencing oligonucleotides used to find pathogenic variants in MCPH2 (WDR62) linked 
families. 
 
WDR62-AMP.1-F GCCCCCATTGGTTCTAAGC 
WDR62-AMP.2-F GGGTGTTGAATGTAGCAGGAC 
WDR62-AMP.3-F ATTTGTGGGCTTTTCTGGTG 
WDR62-AMP.4-F AGGCAGAAGAGGGCAGAGTC 
WDR62-AMP.5-F GACTTGGAGTGGGGACGAG 
WDR62-AMP.6-F CCATTTGGAAGAGCTTCTTAGAG 
WDR62-AMP.7-F TGGGTGTCTTAGACCCAAGG 
WDR62-AMP.8-F GATGGATGGCCACAAATACC 
WDR62-AMP.9-F TTGCACGATACCTGTTTATCTTTAAC 
WDR62-AMP.10-F CTCTGCATCACTGCCTCTTG 
WDR62-AMP.11-F ATTGGTGAAACTCCCAGCTC 
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WDR62-AMP.12-F TTCAACACGGCTCCCTTTAC 
WDR62-AMP.13-F GAACCAAAGACCCCTTCTCC 
WDR62-AMP.14-F TTGATTGATGGCTCTTGCAG 
WDR62-AMP.15-F TCAGCTTGAGATGGGGTTTC 
WDR62-AMP.16-F AGAGTCCCATGTGCTGTGC 
WDR62-AMP.17-F CAGGAGCATCTGGAGAATGG 
WDR62-AMP.18-F CACATGGAGCTTAGCACAGG 
WDR62-AMP.19-F CTTCTGACTTCTGGGTTGTGG 
WDR62-AMP.20-F CAGATGGGCTGTGTGAAATG 
WDR62-AMP.21-F CTGCTGGCATGGTTCCTG 
WDR62-AMP.22-F AGGGGGCATTTGGAGGAG 
WDR62-AMP.23-F TACCATCCCTCCTCCAGATG 
WDR62-AMP.24-F CCCACTGAGCCTGGAAGAC 
WDR62-AMP.25-F CTGCTCGTACCCTGTGTCTG 
WDR62-AMP.26-F CCGGATGTCCAGCCTAGC 
WDR62-AMP.27-F GGGACCCAGAGAAGTGTTCC 
WDR62-AMP.1-R GAACAACCTGAGGGGACTGG 
WDR62-AMP.2-R GAGCTGGGACACAAATCCAG 
WDR62-AMP.3-R CGTCTCCTCTGGTCACTGC 
WDR62-AMP.4-R TGCGTCCTCTCATGTAGCTC 
WDR62-AMP.5-R GAGAGTAGGCCCAGAAGCAG 
WDR62-AMP.6-R AACCTGTGTGGTCAATGCTG 
WDR62-AMP.7-R TGGGTATTTGTGGGATGGAC 
WDR62-AMP.8-R AGAGGGTTACTGCTGCTTGG 
WDR62-AMP.9-R TTGCCCTCATGGAACCTAAC 
WDR62-AMP.10-R CTCAGCTCCCCAGAGACG 
WDR62-AMP.11-R TATTCACAGCCCCTCATTCC 
WDR62-AMP.12-R AACTCCCAGCTGTCATCCAC 
WDR62-AMP.13-R CGGCCCCAGTCATTATTCTG 
WDR62-AMP.14-R ATTCCTTCCCAGCTTCTTGG 
WDR62-AMP.15-R GGCACAGGTCTCAGGTGTG 
WDR62-AMP.16-R ACTCCCACAATCCAAACTGG 
WDR62-AMP.17-R TCAGCTGTGAGTGTGCTAAGG 
WDR62-AMP.18-R GCTGGGATTACAGGTATCAGC 
WDR62-AMP.19-R ACTGAGCCTGGAAGGATGAC 
WDR62-AMP.20-R GGAGTGGGAGTCAGCCTAAG 
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WDR62-AMP.21-R CCACTGGGAAGGCAGAGAG 
WDR62-AMP.22-R CAGAATCCTCAGGCAGCAG 
WDR62-AMP.23-R CGTCTTCCAGGCTCAGTGG 
WDR62-AMP.24-R CTCTCCACTCACCCTCCTG 
WDR62-AMP.25-R CACAGAACTGATGGCTAGGG 
WDR62-AMP.26-R CGAATGAATGAATGGCACAG 
WDR62-AMP.27-R TCTGGGCATCACCTTCTACC 
 
Appendix 11 
Sequencing oligonucleotides used to confirm the sequences of CDK6 (a) and CEP135 (b) 
constructs with entry vector (pENTR™ Directional TOPO® Cloning Kits, Invitrogen) (c) 
and destination vector (d). 
(a) 
CDK6-Seq-F1     CGTGGTCAGGTTGTTTGATG 
CDK6-Seq-R1 AATTGGTTGGGCAGATTTTG 
(b) 
CEP135-Seq-F1 TTGGAGAAAGAGAGCAAAGC 
CEP135-Seq-R1 AATTCCACCACAACCCTCTC 
CEP135-Seq-F2 CAAAAATGAAAAACTCTGCCAAG 
CEP135-Seq-R2  TCTTCTTTTTCTTGCACTGCTG 
CEP135-Seq-F3 GACTCCAACATATAATACAGCGAAG 
CEP135-Seq-R3 TTTTATGGAAAGTCGGTGCTG 
 
(c) 
M13 Forward  GTAAAACGACGGCCAG 
M13 Reverse CAGGAAACAGCTATGAC
 
(d) 
DEST53-F GATGGAAACATTCTCGGACAC 
DEST53-R GCTTAATGCGCCGCTACAG 
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